var title_f26_8_26752="CDC modifications to WHO eligibility for contraceptive use";
var content_f26_8_26752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64282&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of",
"    <span class=\"red\">",
"     changes",
"    </span>",
"    to the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th Edition, to create the US Medical Eligibility Criteria for Contraceptive Use, 2010",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td colspan=\"8\">",
"        The classification additions, deletions, and modifications from the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use, 4th Edition, are summarized below. For conditions for which classification changed for &ge;1 methods or the condition description underwent a major modification, WHO conditions and recommendations appear in",
"        <span class=\"red\">",
"         curly",
"        </span>",
"        brackets.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Categories for classifying hormonal contraceptives and intrauterine devices:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        1 = A condition for which there is no restriction for the use of the contraceptive method.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"8\">",
"        4 = A condition that represents an unacceptable health risk if the contraceptive method is used.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"8\">",
"        Summary of",
"        <span class=\"red\">",
"         changes",
"        </span>",
"        in classifications from WHO Medical Eligibility Criteria for Contraceptive Use, 4th edition*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle2\">",
"        COC/P/R",
"       </td>",
"       <td class=\"subtitle2\">",
"        POP",
"       </td>",
"       <td class=\"subtitle2\">",
"        DMPA",
"       </td>",
"       <td class=\"subtitle2\">",
"        Implants",
"       </td>",
"       <td class=\"subtitle2\">",
"        LNG-IUD",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clarification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Breastfeeding",
"       </td>",
"       <td rowspan=\"3\">",
"        The US Department of Health and Human Services recommends that infants be exclusively breastfed during the first 4-6 months of life, preferably for a full 6 months. Ideally, breastfeeding should continue through the first year of life. {Not included in WHO MEC}",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;1 mo postpartum {WHO: &lt;6 wks postpartum}",
"       </td>",
"       <td>",
"        3",
"        <sup>",
"         &bull;",
"        </sup>",
"        {4}",
"       </td>",
"       <td>",
"        2",
"        <sup>",
"         &bull;",
"        </sup>",
"        {3}",
"       </td>",
"       <td>",
"        2",
"        <sup>",
"         &bull;",
"        </sup>",
"        {3}",
"       </td>",
"       <td>",
"        2",
"        <sup>",
"         &bull;",
"        </sup>",
"        {3}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 mo to &lt;6 mos {WHO: &ge;6 wks to &gt;6 mos postpartum}",
"       </td>",
"       <td>",
"        2",
"        <sup>",
"         &bull;",
"        </sup>",
"        {3}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Postpartum (in breastfeeding or nonbreastfeeding women), including post caesarean section",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;10 min after delivery of the placenta {WHO: &lt;48 hrs, including insertion immediately after delivery of the placenta}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 {1 if not breastfeeding and 3 if breastfeeding}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        10 min after delivery of the placenta to &lt;4 wks {WHO: &ge;48 hrs to &lt;4 wks}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 {3}",
"       </td>",
"       <td>",
"        2 {3}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Deep venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        DVT/pulmonary embolism (PE)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. History of DVT/PE, not on anticoagulant therapy",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        ii. Lower risk for recurrent DVT/PE (no risk factors)",
"       </td>",
"       <td>",
"        3 {4}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Acute DVT/PE",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 {3}",
"       </td>",
"       <td>",
"        2 {3}",
"       </td>",
"       <td>",
"        2 {3}",
"       </td>",
"       <td>",
"        2 {3}",
"       </td>",
"       <td>",
"        2 {1}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        c. DVT/PE and established on anticoagulant therapy for at least 3 mos",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Higher risk for recurrent DVT/PE (&ge;1 risk factors)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 {1}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Known thrombophilia, including antiphospholipid syndrome",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Active cancer (metastatic, on therapy, or within 6 mos after clinical remission), excluding non-melanoma skin cancer",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        History of recurrent DVT/PE",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lower risk for recurrent DVT/PE (no risk factors)",
"       </td>",
"       <td>",
"        3",
"        <sup>",
"         &bull;",
"        </sup>",
"        {4}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 {1}",
"       </td>",
"       <td>",
"        Women on anticoagulant therapy are at risk for gynecologic complications of therapy such as hemorrhagic ovarian cysts and severe menorrhagia. Hormonal contraceptive methods can be of benefit in preventing or treating these complications. When a contraceptive method is used as a therapy, rather than solely to prevent pregnancy, the risk/benefit ratio may be different and should be considered on a case-by-case basis. {Not included in WHO MEC}",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complicated",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (pulmonary hypertension, risk for atrial fibrillation, history of subacute bacterial endocarditis)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 {2}",
"       </td>",
"       <td>",
"        1 {2}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Ovarian cancer",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        1 {Initiation = 3, Continuation = 2}",
"       </td>",
"       <td>",
"        1 {Initiation = 3, Continuation = 2}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Uterine fibroids",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 {1 if no uterine distortion and 4 if uterine distortion is present}",
"       </td>",
"       <td>",
"        2 {1 if no uterine distortion and 4 if uterine distortion is present}",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"8\">",
"        Summary of recommendations for medical conditions",
"        <span class=\"red\">",
"         added",
"        </span>",
"        to the US Medical Eligibility Criteria for Contraceptive Use*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle2\">",
"        COC/P/R",
"       </td>",
"       <td class=\"subtitle2\">",
"        POP",
"       </td>",
"       <td class=\"subtitle2\">",
"        DMPA",
"       </td>",
"       <td class=\"subtitle2\">",
"        Implants",
"       </td>",
"       <td class=\"subtitle2\">",
"        LNG-IUD",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cu-IUD",
"       </td>",
"       <td class=\"subtitle2\">",
"        Clarification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        History of bariatric surgery",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Restrictive procedures: decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, laparoscopic sleeve gastrectomy)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Malabsorptive procedures: decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass, biliopancreatic diversion)",
"       </td>",
"       <td>",
"        <p>",
"         COCs: 3",
"        </p>",
"        <p>",
"         P/R: 1",
"        </p>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Peripartum cardiomyopathy",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"8\">",
"        Normal or mildly impaired cardiac function (New York Heart Association Functional Class I or II: patients with no limitation of activities or patients with slight, mild limitation of activity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &lt;6 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &ge;6 mos",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td class=\"sublist_other\">",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moderately or severely impaired cardiac function (New York Heart Association Functional Class III or IV: patients with marked limitation of activity or patients who should be at complete rest)",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        On immunosuppressive therapy",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2/3",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 2",
"        </p>",
"        <p>",
"         Continuation: 1",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 2",
"        </p>",
"        <p>",
"         Continuation: 1",
"        </p>",
"       </td>",
"       <td>",
"        DMPA use among women on long-term corticosteroid therapy with a history of, or risk factors for, nontraumatic fractures is classified as Category 3. Otherwise, DMPA use for women with rheumatoid arthritis is classified as Category 2.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not on immunosuppressive therapy",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Endometrial hyperplasia",
"        </strong>",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Inflammatory bowel disease (IBD)",
"        </strong>",
"        (ulcerative colitis, Crohn disease)",
"       </td>",
"       <td>",
"        2/3",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        For women with mild IBD, with no other risk factors for VTE, the benefits of COC/P/R use generally outweigh the risks (Category 2). However, for women with IBD with increased risk for VTE (eg, those with active or extensive disease, surgery, immobilization, corticosteroid use, vitamin deficiencies, fluid depletion), the risks for COC/P/R use generally outweigh the benefits (Category 3).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Solid organ transplantation",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complicated: graft failure (acute or chronic), rejection, cardiac allograft vasculopathy",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 3",
"        </p>",
"        <p>",
"         Continuation: 2",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Initiation: 3",
"        </p>",
"        <p>",
"         Continuation: 2",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uncomplicated",
"       </td>",
"       <td>",
"        2",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Women with Budd-Chiari syndrome should not use COC/P/R because of the increased risk for thrombosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"8\">",
"        Summary of",
"        <span class=\"red\">",
"         additional changes",
"        </span>",
"        to the US Medical Eligibility Criteria for Contraceptive Use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Condition/contraceptive method",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"7\">",
"        Change",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency contraceptive pills",
"       </td>",
"       <td colspan=\"7\">",
"        History of bariatric surgery, rheumatoid arthritis, inflammatory bowel disease, and solid organ transplantation were added to Appendix D (Classifications for Emergency Contraceptive Pills) and given a Category 1.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barrier methods",
"       </td>",
"       <td colspan=\"7\">",
"        For 6 conditions - history of bariatric surgery, peripartum cardiomyopathy, rheumatoid arthritis, endometrial hyperplasia, inflammatory bowel disease, and solid organ transplantation - the barrier methods are classified as Category 1.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterilization",
"       </td>",
"       <td colspan=\"7\">",
"        In general, no medical conditions would absolutely restrict a person's eligibility for sterilization. Recommendations from the World Health Organization (WHO) Medical Eligibility Criteria for Contraceptive Use about specific settings and surgical procedures for sterilization are not included here. The guidance has been replaced with general text on sterilization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other deleted items",
"       </td>",
"       <td colspan=\"7\">",
"        <p>",
"         Guidance for combined injectables, levonorgestrel implants, and norethisterone enanthate has been removed because these methods are not currently available in the United States.",
"        </p>",
"        <p>",
"         Guidance for \"blood pressure measurement unavailable\" and \"history of hypertension, where blood pressure CANNOT be evaluated (including hypertension in pregnancy)\" has been removed.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unintended pregnancy and increased health risk",
"       </td>",
"       <td colspan=\"7\">",
"        The following conditions have been added to the WHO list of conditions that expose a woman to increased risk as a result of unintended pregnancy: history of bariatric surgery within the past 2 years, peripartum cardiomyopathy, and receiving a solid organ transplant within 2 years.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WHO: World Health Organization; COC: combined oral contraceptive; P: combined hormonal contraceptive patch; R: combined hormonal vaginal ring; POP: progestin-only pill; DMPA: depot medroxyprogesterone acetate; LNG-IUD: levonorgestrel-releasing intrauterine device; Cu-IUD: copper intrauterine device; DVT: deep venous thrombosis; PE: pulmonary embolism; VTE: venous thromboembolism; IBD: inflammatory bowel disease.",
"     <br>",
"      * For conditions for which classification changed for &ge;1 methods or the condition description underwent a major modification, WHO conditions and recommendations appear in curly brackets.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Consult the clarification column for this classification.",
"       <br>",
"        &Delta; Condition that exposes a women to increased risk as a result of unintended pregnancy.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: US Medical Eligibility Criteria for Contraceptive Use, 2010. Available at:",
"     <a href=\"file://www.cdc.gov/Mmwr/preview/mmwrhtml/rr59e0528a1.htm\" target=\"_blank\">",
"      file://www.cdc.gov/Mmwr/preview/mmwrhtml/rr59e0528a1.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26752=[""].join("\n");
var outline_f26_8_26752=null;
var title_f26_8_26753="Polyp forceps-Kevorkian curette";
var content_f26_8_26753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine polyp forceps and Kevorkian curette",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Kevorkian-Younge curette. (B) Randall-Stone polyp forceps.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26753=[""].join("\n");
var outline_f26_8_26753=null;
var title_f26_8_26754="Morquio syndrome";
var content_f26_8_26754=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mucopolysaccharidosis type IV A (MPS IV A, Morquio syndrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Children with Morquio syndrome, showing typical bony features including a protuberant chest (pectus carinatum), deformed and misshapen long bones, extreme short stature, and knock-knee deformity (genu valgum).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Neufeld, E, Muenzer, J. The Mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver, CR, Beaudet, AL, Valle, D, et al (Eds), McGraw-Hill, New York 2001. Copyright &copy; 2001 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26754=[""].join("\n");
var outline_f26_8_26754=null;
var title_f26_8_26755="Thoracolumbar fracture-dislocation radiograph";
var content_f26_8_26755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Thoracolumbar fracture-dislocation radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 387px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGDAgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6G8c+LbXwhY2Vzd2V9em8uhaRQ2Yj3l/LeTJ8x0UDbG3f0rlx8W4CMjwn4l/Oy/8AkmmfHfH2Dwpnp/bX/tndVyPgzw1F4hsvEupan4i1XTbXTbwwhbVbby0iW1hlZj5kLsTmRz16Y4oA7RfitEw48JeJD/wKy/8Akmnj4oqenhDxJ/31Y/8AyTXD/Cyx8P8AxH0y8vdA8VeMIBaTCGWG7isEkGVBVsLAw2nnHPY8UeDLifUPCujXl3JvubmyhmlfaBudowScDjqe1AHdD4nZPHg/xL/31Y//ACTUi/El26eDvEp/4HY//JNYtvCpPXnvV1ItrDjigDQHxDnPTwZ4l/7+WP8A8k0f8LDn/wChM8S/9/LD/wCSabDHuKkLn1q9HbL1bkHtQBXTx9dOcL4K8Sn/ALaWH/yTTx45vT08E+Jf+/th/wDJVXxEAoCjilZQEzigDPPjm9B/5EnxJ/39sP8A5Kpv/Cd3mcf8IV4kz/11sP8A5Kq0zc89KqzMd2RzQA0+ProHnwX4k/7+WH/yVSf8LAuM4/4QvxJ/38sP/kml2ng0ir7UAJ/wsK4zj/hC/Ev/AH8sP/kmmH4jSjOfBviXjr89j/8AJNPKnJ461F9lLuQBwe9AD4/iJNJ9zwZ4lP8A20sP/kmrKeN75yAvgnxISen72w/+SqIbVY1UBcY/Wtazi5U7ST/OgCl/wlOrf9CJ4k/7/wCnf/JVH/CU6t/0IniT/v8A6d/8lV1CnKgng0tIRy3/AAlOrf8AQieJP+/+nf8AyVR/wlOrf9CJ4k/7/wCnf/JVdTRRcDlv+Ep1b/oRPEn/AH/07/5Ko/4SnVv+hE8Sf9/9O/8AkqupoouByreKtWAyfAviQf8AbfTv/kqs/UviHPpoU3vgzxLEG6fvLA5/K5rs7skIAAOe9cV49gM9lbYPzKfzpjKifFeJ/u+EvEp/Gy/+SanHxMJ248H+Jfm6fPY//JNclYx43DHI961EO2BmboBke1AFrUfjHZabKY73wv4jicDJGbI/yuKpx/HbR5JRGnhzxIXPQYtB/wC3FeReL7trrUZn6845rmbi4MZjZCN6nORQB77P8f8AQoJHSXw94lVl6jZa/wDx+q7/ALRnhpM7tB8S8f8ATK2/+P14brwFykN3HjLDDkDpWFJCowc84wRQB9Dt+0x4TU4Oi+JR/wBsbf8A+PUL+0v4Tb7ui+JP+/Nv/wDH6+Yrqz4Py5rPks5Il3AnFAH1iP2kvCxOP7D8Sf8Afq2/+P0v/DSHhf8A6AfiT/v1bf8Ax+vlCOYkKTwR61OJN47HvQB9UH9pDwwBk6H4kx/1ytv/AI/UZ/aW8KA/8gTxL/35t/8A4/Xy6HMi7eAKjCb32qORzQB9UJ+0n4WkOE0PxKT/ANcbb/4/ViL9obw7K4VPD/iUse3l23/x+vly2IiYNsDdua27d2LoyKPqB0oA+l7f436XcJui8M+JCucZItB/O4rXtPiYbxc2/g/xG46532I/nc18yi8kPyJuAHoK9R+HuqzR6fJHeHMZBwTwaAPXfA/jq08W6hqtlBpupafdaasLTJeiHkSGQLtMcjg/6ts5x2rz7xD+0r4O0HX9T0i803xA9zp91LaStFBCULxuVJUmUHGQcZAqT4DSCXxx45ZTkGGwwf8AgV1XzD4h0OPXv2gNT027aVLTUPFMtpK8RAdUkvChKkgjOCcZBoA+iv8AhqvwP/0CvEn/AIDwf/HqP+Gq/A//AECvEn/gPB/8erznxR8Lvhl4d1nXdPuF8e3I0OKGe/ubeax8uJJQNp+YKzdcEBSa5X9oT4Y6B8PrTwvc+GrvVLmLV455HN86MQqCIrgKi4/1hznPbpQB7h/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH2r/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH2r/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH2r/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH2r/w1X4H/wCgV4k/8B4P/j1H/DVfgf8A6BXiT/wHg/8Aj1fFVFAH2r/w1X4H/wCgV4k/8B4P/j1Oi/an8FSyKkek+JC7HAH2eD/49XxUBkgDqa1NOtTDcwzMGIRgSAM0AfbUH7QGgz2ouY/D3iUwltu4x2o5+hnzWhpnxosNUuPJsfC3iWWXGcYs1/ncCvlTSdRN9pot4yyoshJ55616r4M3W95ZsrfKBj3PFAHtI+JjHdjwd4l+Xr89j/8AJNUm+L9qpIPhTxJke9l/8kVkw3Cm3l4OWQk5rlLqJ0k8yB9wPUGgDvZPjLYxAl/C3iQAf9ef/wAkV1fgDxlZeNtMvL2ws76zW0ujaSRXgjD7xGj5Gx2BGJF7+tfPetTOkZzlc9Qeor0v9mYlvDHiQnvrTf8ApLbUAaPx5UPp3hVScA6z1/7c7quO8P6BrPif4Y+PNC8OXNpbXd/rCwST3LMqrCbS08zG1SSSuVx7nmux+PRxp3hU/wDUa/8AbO6ry59C0XUJ5J7zSdPuLl8bpJbZHZsDHJIz0AoA9L8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXJ/D5iPAnh09v7Ntv/RS1l23hLw4cZ8P6QT0/48o//ia7HTrNIbeOGONIYI1CJHGoVVUDAAA4AAoAuW7M5GwfjWraRH+M8VVttq/dHQdfWrkbktzQBoqVA2p2qQMRzmqTNgZzSrIBjmgDRWTI4pryHbVPzjjg8e1BcEAc0ATmRGOKiKZPAOO9PjQdRSkEfd/WgBDjgDn2ob0Xk0/dgc05I954oAZFEXO09KuCAIoAqeCAIvvSXEghQufyoArSyRW4yxBYjgYqxZGebDPgZ4wO1UYYfOlLycjtWhbSrDJ7dKANgDAApajhlEoyKkpCCmlvnC4696dR70AFFFIzBepoAZcIrx7XOBnr71yfiJfNMcTH7ucGuku5iDhelctqEnm3BJOMUxnK6hYyRspjOP7wFZuq3kltp0nzYLfKB611zRCV/mArjPGUDLIPL6KASKAPN9VyyyA4LHniuXukwN3Jwea6y9iElwzt0Pasp7cAuHGVbtQBnaXcI5mspSNsv3T71Skj8mR0cgleKfdWclvdq6DlTkVY1i3LpDdrwrDDj3oAy2xg5IyaryxAgYHXvU6oI2wpyKsCLeuOPWgDCvLBS2cc461nmJoD6rXVSwHuPas66tw/y4+poAyDNggrwKmtjv3FWAPrTbiyZOVqqCY5QADzwaAN5WT7OADyeK3tGsyxQmQhR74zXK27uJVG39371v6Xcnhh8xB2gelAHd6bZLJcrGvlMO/c13FrpKpYAZG7GcVyngC0L35yqs6gsc11+oXcoTZGqjFAE/7PAI8XeNwwxiGwH/j11XhZx/w0KOP+Zz6/9xCva/2aJGk8VeOi5yQliP8Ax66rwjxpZR3HjzxS0sQkU61fcMMg/wCkyUAfQXjv4UaxrvjLxfqtvY+G7yLWrOC2tLi/mkWfT3SMKZUAhb5s8jDr0GT2rhv2qdKlsdH+HWm3l1Jfz2dldQyXMn3pmUWqlz7k89+teRro1p0NnBn3iH+FH9mwwbmhtoo2IxlUAyPwoA4K/syhLouFHUVn1297Z53A/l61g3Gmq83ygr64oAyEjZ8kA8DNNxW69iFdBAzfJyCe5p8ttDdRZYKsq9QO9AHP0VotprEExN/wHvVGWJ4m2upBoAjopaMUAJRRRQA+MEuoXqTxWxphuY714t5bAGc9MVjKdpDDtzXeaElre2kbgATqMPz1oA2vDNsnnmaIAxucvH3B9a9N8PTRC/hCvjDcD0ryPTWNvdl4WO1WwV9RXpegfvdQhnhGFK52+mKAPR1mdYWHYqVz2FUpGHmbdvOOoqpbXpjxubzEz0FSTTbrzK/dPpQBma4gnjbI+b1PevQP2ZlKeGPEik5I1tv/AEltq4HWtylzjnFeg/s1nPhzxKf+o03/AKS21AFv4/MF0vwsT0/tr/2zuq8/s2aRsR4rvP2hhnRvC49daH/pJdVxGmbI0A70AdFpkJXBbANaydayLV1JB/rWiLhR3oAuJweTU4bnoDWObtQT35qWKbnBPXtQBqs7FRwBSBznnGKrGXgUCTJBzQBoI/HH6VIH+UVURgBzzU6uMjjAoAuq3T6VJkZBPWq6HOMVaijB65zQBJGm8jI4q4gCAbfxpsYVY8c0FwmcmgB7y7cl+3SqMs3mtn3ptzPvGOoHaoogvUHmgCwrEcA8U5WZ2AzUG7nHep7UgSgHuaANbT43UZB496vUABQAOgpaQgpjbjxgYpxqESEuB2zTAnFZt1JKkjErgdq0qZMnmRle/akBhXFy8iYxg84rno9zSOshz81b84eJD5vGP1rBXb50uepNMZHDJ/pRST8PpWL4ihMszZHJGK1rohbpXH3vWqup/vgGxzQB5prGmiMEqpz3rnpY18whu1ekapAroQcEnrXHalYohYgAH1oA5m7HzOB0pbGNbu3uLJ+hHmR/71PuEKlt2N392orcGK5ikRiCrdRQBhyWjxuQRhgcE1KhVVyV+YV0mvWQWVLiNB5Uw3ADpWPNa8ZPBxxQBnSS7sk4+lUZGIYnAxUl7FIjEjOKoPPg/PnFAD5DvPtWZd2zNIHTG4VpwyBvlxVmGFTINwoAzYWdoxC6At64rW0yxuUbOQwOM/StC3SFM4iyD/ERWvp9sjbS6bEz1FAHXeAUdZmlRTuA6Guj1CScrIwgBk6VR8NAWGmSFn+V2+Xjk1qrdsyBo0Dlgc8UAVv2ZN//AAlHjrzBtbZY8f8AArmvHfFQP/CZ+Jjj/mNX/wD6VSV7P+zYSfF3jzcMHZY/+hXVeQ+JbcyeMPEhH/Qa1D/0qloAzwf7hB/CmyBgf3ijBq3BbHyvmGKY8G4gA7Sv60AYOo2wD5UZBrPjtEd/nGB7V0F3EGJVe1VIbRg44oApNplvJnBYDFVn0NADtk2E/drf+yHdwpqzFC+MMKAOSNk9tlZFOFHGwcGs+W0RhgovPQiu9NiWGSCF9KrzaFFdDKqRQB5je6ZMjtIpVlz0qiVQow+ZJB/D2Nen3Xh2VIzsG5R1rktT8M3m55Ej6evFAHL0lSzRPDIY5VKsPWkWN35VSRQBPbWjTkAH5iMgURzXNjONrFXXjGa2/DtvkL5qqQTkCsvW2zfyrsChTxigDpPD+qpO6u65lB+6K9W8FyyPqUMucxsjBk9q8J8MyGLWIWzgc5Ne5eDEKXyHbmNoiQ1AHVylreV42jPPIqS0uXiuzuGUYd+1P1nDiNs9Ris6eYm4WONyeBQBY8Qkpp7yg98A16J+zP8A8ix4jz/0GmP/AJK21eb62WbRYgTlwTmvSP2Z/wDkWPEmf+g03/pLbUAWv2hDjR/C5/6jQ/8ASO6rz+zkAAPBNd9+0ScaH4Yzx/xOh/6SXVeSi78s43flQB16Xij0B9qk+17xx09a5S3uSW5b3rUinOMjHNAG5BPyc4P1q7HLlh0rCgl6HPNXoZPnGTQBtoxbqcYqeNvmAzVBHXGcgVKsgHJNAGqCMDk1KpyRt6VQikDADnNaNrHuAIwMetAGlbRdCTxV1H2niqEbEf1pZbvYBkgH2oAvyz4Byapz3G48Gs+S8ZzwDioZbgjrQBoqx7gfnTWuRE2AuSazpJ32DFRRSSF85z60AasV5ISWIAxV+ymM8yhsYz2rDRtqHJPWuk8N26kmV+wGKAOi7UjcYPvS1HOR5bAnkikIkHIyKp3N3DDJgkFvQVmy3cluD82QOorBlu2lnMgHPemM7Kzuxck4GMU+WbDFF+92rG0WdlGWPFWZZz9pVh0H60AZuqXX7ku5B2vgisndHMjSJ1zzV3UY1kjnUnqd23vmsLS2bdND3HNAE83Lg4qO5iLxfL1qeVgOSDmq5kC9Dx6UAcveH/SGRiRisq7hWdXGOlaviHHzMhXdz0rBiuTt2nOaAMK704szfKc54JquNPK/I4+brxXa6akeoT+XIAoxwcVQ1mya1kKjn3FAFIWjXWivG+PNg6Y9K5uS3GDzn0rpNLeRL3EgYRSfLzTb+wWG5ljA+QHK0AcDfRlS2fpXPXsGR6Y6V32p2O+NvkPHPNcrPYTSPgABQeeaAOWmllt5lIPSt7SHM5LE/wC77mq99YqoO4ZI9KisHKyCMNsUdKAOugtzPyxAZRyueKuxxlNoGSh6DNYNjAz7nllctn7oPJrp9JRftMXmKdmMYzzQB1WmXrWmlKJwTGTkFh0og19LNS6zBhzwwp2pRxLpSwzMoHX5TkiuOk8oxyoqlsZ5NAHpH7Md0LzxP46mXGClj0/3rmvNNZ58U+JcD5hrWoc/9vUtdx+yGc6x465zxY8/jcVy1zb+Z4o8SnA/5DOoH/ybloAoCFjFwc1QuEKqQ3BU1uykKNseBWZfRNjrnPegDKMQ27u9WbO2+be3IxVqC1MjoBWoLAgDGc+g6UAUFt15OBn1pptzuPP6Vpx25yAVxzT2tDnOeaAMw2/qenpRsK8CtBoj/dwKjaFgc8YoAq7WIOe1U7mDzVKkc44rVA2kjFRMmW7UAcVq+ixToy+Spf1IrmJ9FlhKxKM7jjp2r1qeCNgCBk+gqG402ORIiiEOOeRQB5dpeyC/jtSCFQgO3ofSql/pyz3l0q5DMxIz6VreJNCng1OSWHdhm3NjufWpdNt3mnBlxkcFqAKmiaMfK5C5CHB75r1HwvDIlrY+blXjjIPvWfpekxrIjorZ211EMRWWR+iptyB2zQBoai6stuoHO3P41BYRiS+MuPlFRSF55oyo+VRtrRt4zFuVRjjrQBn65cNh0I4C5r0r9mNt3hXxGTznWm/9JbavJdbnI80kDOMV6p+yyxfwd4hY/wDQaf8A9JregCx+0xJ5Xhjw447ayv8A6SXNeGwXBlfca9r/AGpDjwf4fP8A1Gk/9JbmvBbWTnNAHS2Tgv1rbi5Qc1y9tL8wrZt58d6ANm3Yq3tV+OVSwJrDjuQKuQzgketAG9HKCAOwq3Htcgdc1jwsSQa1LNhz60Aa9shG3b0rRWTywBxWbazKo5pZrselAGlc3hVMIwqh5ruwLk+1V1bzCSTgVMrqFwOTQBJ5pUZ6iovOaQ9KdFE8jfMMJjrU2wKQEHNAFuKL9wCckihvLjGTjPpT1kCQ4/iqoxBJY8mgBjy+ZLmPsK3NP1WWKFFdBtHQisdSigtjBPNAZmTIzj2oA6WTxBIqAqVyTjB6irs2oebED0JHWuOs7KSa5jyGK55rXaFllOCSoGCKAEuLoPKytGSPrWfM0aFQqsuavG2y5ODVC7twpZ9xBz0JoAngvzHII8ZBGck/pVafxmlu7xm2+ZehPrWZczPEPNkcAgHH5V55qVzcEtI8hw7EjFAHb3/iRmuPtDyKD1ZQajXVka+juIWIVhkgV5nLcM2MsSM9DWlpF6YJPmJdD+lAHqs13FJGJEOB1NY2oamI422qRx36mqVje7lG074j+lR65GJ4FaPO7uB6UAZ0lw9wrNk5PaqX2eSYjYcGrUCbVYAEHHGa0dMtPLg8yT1oAbpcJtSELAsec1NdQyT3J3cimlSZAydBWhHtaX94cUAZU9lsZWKk7eRjtVjVdPSaKC5XgFcceta1wtuISVfLdOtV52E2lvGv/LNqAOXvrOMKAvzE8EGsi80WEx7ohhyOma15WKElzVCW4JJC9KAOWvtBeQMCgB9jWBdaBLbOHQZ5713NxdYNZ9xciQH7p280ActDDdJKvlqeeNxHSuw0Yxw/PcktP2qCyge8icLGu0d6WSzmidQUIzxmgDfjkkud6uqkfyrE1YBVlKxGNue2M1sabdLE2zcrcfN61U1e3luoJfNI+QHAXqBQBvfsgOr6r44KggbbEYP1ua5m+uPK8Q+IgOCdZ1Hn/t7lrpP2Pl2at47XOcfYv53FcjqqE+JPEp/6jWoY/wDAuWgBHfc2RSyR+cECAnHWmwRF2AxWnbRrGRuJyf1oAgWz8tBk4Pap4rmSIBGwV9auskTLySzdj6VQv4HXmMA/WgDRikgcA7gH9aHh3H5SPxrCilYEhl5HIqRL2ZPut+dAF5kZTyCDTWUEZNLBfeZgXABPrVgxqxJVgRjigCoIFwCDkH1qKWBBnOMHtmpLiQqmB2rMeV2kySaALiWoyNjYPpWrawrKhMgyyjpVKxbJG4ZFaMcot8sR1PSgDmdQsl+0OSgKMfmz1FZsehxrcgwg7WOfpXU3xFw+YlAJPIqS1CRIQU3NnOaAGwWqxoicAAck1rWtrHMtwsbZVsdfas+Rw7jgHnvW3oW3bIwQZx1oArWtr5UrRuBu6ip7khVLjjcMVdvIQJSw4yKydWlMcCAEUAcb4il2o3PU16/+yjn/AIQnX89f7ak/9JrevDfEEgbcMjJNe3/slknwLrxPP/E6k/8ASe3oAk/asIXwVoBPT+2k/wDSa4r58tZOmOlfQP7WPPgbQv8AsMp/6TXFfNthMdu3IyDQB1NpNyRWnE545rnLaQ8EGtW3nHHt0oA3Im5q5aufMA7ZrHtpAzjnrWzbAYDA85oA37fG1etaCMAODgmsaCQtgDjFWJJ1jQkmgDZNwIlBBBquLlmfnBrFN5ufAPFSpKzEYOT7UAdFFN0C9au20eSWzWNZZXk/rWnHPtAx3oA1VYYC5prEJknrVRbhSMng9qo3+pBExjLdOKANMSMTyOPrUU0+0Y5Ga52C/mjn8w7jH1xW5vW8tzIg+bGaAG+YWI+Y/nXQ6ZB5iAgbuKxtLsDOoaTruwBXb2sC20YiSPL+vtQAmkWMiTM2MDZx7VKLMq2ZpAFJpwupLckMMHGBWfd3DykHGMe9AGk1rE7p5T5Td96s3UrRMlkkDqT2oiuCkRCnBHQVnQM/mkRnILc80AY/iSxAsC5BHp6V5rqkCxpkk5zwK9k1n94scFxGRE3f0ry7xwn9n3UdvwzupOewFAHKoAMlh14FXLeIZCjkHrUaRcBce5q3aEIeRQB0GnSx20e0DMZFXoh9oZQp4J7VnaTtllMfGccZrVsofKmJHAzQBYuNNAiXaRuFQuGVFRxjA7VpSXCmPrg1nyncGVf4u5oAqouXIHFQSzfO+eOantkIkk9ulZF5OAZMnnNAGktypG0kcdKnsJgJ5IuodTjPrXLzTkglcjHTFWNO1LZOgJGRzQBLeoEZ4+6msO7Plg9ea2tUYC9lwchsEisS+YngDigDA1DUFjdgeoFYsWpvJKV2jBq1rUDm43r0qhZwp5rFmwwoA3bS8mtghRjtY9BW1HcSTsiMcL3z3rGtdmxIWAaQnKn0rWhZFkRZFJYkDjtQBotZqE3DbEw+6/8AjWHrNxBDZ3EqSusoyCdx5qtrOqNbSyqxfCn5QT1rlb7VldZY+quMhSOlAHrn7GTmS/8AHLMcn/Qv53Fc9fRmTxN4jGOP7Z1D/wBK5a2/2KG3XXjnnvZfzuKyL2RovEfiNsZB1rUB/wCTctAE9uEhj5OTSIzS3O4dAOPpVUy7W55TvVuCQGPdF3HU9xQBOzFFUg8GopZSSSemKjmulcKvcDtUYJduM4I70AWV8pyB5ecjBNVTZRSEYYjmp4yy+o7cU9M5GKAK/wDZkyH5cEfWlMdxD1XaB6VcRyDxU3+sABNAGRITKcHJFQeSGkGzPFaxsRvyWwKfAkaB+AWFABpto4GXPH0qxNDvkGOFq7YfOADjA/KhYwsrgZx9elAGUkQjuXB6Z4qNVb7Vx92rV3jzDt5AHBog+dRgfUjvQBXk+W6Xjg10Hh9cRsc/xdKxLtNiggYINa3h+QBR1yTQBqao+2Hfg8Vy+vyYhQ+tdHqb7rZgOcVzHiAgWee4H5UAee647FWKgHnjNe9/skHPgLXc/wDQak/9J7evnzWWJ3ehr6B/ZGOfAGuH/qNSf+k9vQBJ+1mceBNCP/UaT/0muK+YYGKynHQ19L/tfsU+HmisOo1qP/0nuK+XLe5+dSTnPSgDpLWTIA3c1r27ZwAeTXO2j5xt6mt20+Ujn5vSgDbtcKcnOa1rRhnkkc1j2hDcscGrZuPKGBjNAHQi6VV5xVWadpG44A7Vhtds5GT3qwlydpwcmgDSV2LhRWxYRszjdxisKxbOSfv+lalrO0R+9kHvQBvmZEzjmnLNjjOc1kJOWOSOPWrCTgjt+dAGn53zAbsg1maldJDI29+OwqdJOmRWPfxr5zGY5yfloAUasmCnpWloWrDzmTkKe/WuXuLUMGZBzWl4acqXRgpagD1TTcSCNlOMYP1rtbOLeVk65HNcF4dmDryeFA4rvbC5SWFEzjA6jigA1GxWYiTOMdRWXNYxKcMxH41uXZ/dFBncRXOzl1ZgeWzxQA2OyQM29vlp+nWcJuGKA5zTFd2KjBBPrWrZW5iXzM5J7AUAV7y3Nx5keFIbgE9q8h8d2zm9keVeE+VWx0r2i8mSAb1T58c815l4vmRlLOhcEkFcdDQB5ojndjIJxg1oWMXmPilkggL5RSMjt2qfSoWUu3OB3oA2LKz8rkEBvXFX95VM7TVSAS7wzcgVPI5J9FxQAkr7lzg5+tVJJWjIO7Ap084AABrOvZ/3ZB5FAGppz+eJcHFY1/GJJ3CDn+VWfDX7x5RzyeK07m3gsWkklIDH+9QBxN/IVO1f4ePrWaskgmRs7RmtbX5op0/cALg8t61z3mbZYyWyB1oA6a6ukWSNjkmRAcntVC5lEg3K3GcY9ag1e4VrWBkyNsY/MVjG/KBQSMEUAGoOPmLdBXOTT+XNkZANbVz++GQcg1k3FmWYYOQTgUAaWn30bsrKf3g+7W1eATxK4kZNvJYNjJriWgMMmY3/AHq/w1V1HV7mCIwSEjdQB0N7e+Yx3gOq9CR/WuD8SXvk35aMYDDgZ6VMutMqFHDMcevFc3qlyLq43qcjoaAPpr9h85k8bn1+xf8AtxWbqsTNrPiFl76zqP8A6WS1o/sO43eNsf8ATj/7cUlygfU9e5A/4nWo/wDpZNQBzpMkbgSoy+vpUryF1KRsAg4BXvWndNHECZl3JioLeK2mX/RnQn+73FABZQKFy+Tn15q6qooIxkUeU6R4CHIpIo3btz6UAL8vTnA71H0zjnFWTCVHPP0pEhHPSgCJTyCRViFs8nr0psqFAASOemBTQGGAQQTQBZI3HH5VCyFHyOnvVuIHaM/Q1ZeNPlDEHPf0oAqQSmNwGxipmuVAOMc+tV9Rj2Mu0H6iqLSfNg5NAEs0n7zjpjHNLpsn75kPKgZFU5nG6l02XN2+OPloAuahMAh3fxVa0Wb93HjIIcj8qxdVlbbGvctkVqaK2baJwP8AloxNAHSPh4JD/EK5LxIR9lcZ6V1MIBimG4cCuO8SOGhmUdhQB5xq83LBulfRH7IWP+Ffa3jp/bUn/pPb183a44PTr3r6O/Y+/wCSd61/2Gpf/Se3oAZ+2Odvw20c/wDUai/9J56+UIGZtu3qK+rv2yhn4aaR7azGf/Je4r5KtpcR5xknk0AdPp7hQOefSugs5Rxk1ytlJlFYYzitWG5wOaAOmF2iDAOKa1x5nIPtXPfa/MbAxxVuCYg9aANqN8dT7VPbv8+c8A1nJKCAMirKyAKMcgUAdDYkseKtLKVfB6VzcV8yIQDir9vfRkbnOKAOmibcowalQMpPPBrHs7hWI2E4bqatS3ohZVZuvSgDXFwFjbcdox1rKeaLDPId/bg81ZjdJ4+fmY9qWHToElL7etAFKWeBYOEcqfzpdORPO3wse3FXLmzSNd8R+U9aj02DZdHZyhOSaAO/0m5FvFCFXJYcmuptNQiVFkYEYOCK4XT5R9pjjd8BuBXWW8Ernywpx06UAdi1xHLCjxDO4fkKpyRxu/yj5qq2yPBCY34x0qWFt5wGFAD/ACFhkyWDYqzbyg9DheuKrXcJMjMGAUcGkjjITK4zjFAEOp3ts0rgHcV4/GvNvE63TNI0iAKeFHtXoEmluJvMDY4wV964z4heZYTQLsLI64Zh2NAHGW9vIrbgM8VPGs8YIUgZpfOBKjfkY7U2W4OMYOKALlvcMIirjmnvJkfOeapQynFEsox6UAOlIPQmqNyAI3BHOO9SmTcOO1Urp8hiemKANfwoVETyHoDXPeKtTk1DUp9rnyYz8uK0tPuFtdIkcnrXJTyBnlII+Y96ACWZtoU9COlV2QgYC5P3vwFRux83GeBzXZeAtAg1mK4u7u4aKCJtjALnPFAG34ts4JvhtpF7BBEsl068gcjA5rxjUF8qQqPvr1r6EGpaNf2K6D5dxPBYjzMbdg475/pXlXxd0uy025sp9JjCJLGSUZyT1oA4qC9CQush+U96urcwm0iWIjcK5eWZnRkxtzUUcptgRK+ASMYoA6S/tzJEZINuT9496wNYiIgIly3HBPapV1GVZWAI2EZJ9axNV137QGWRcr0FAHP3TGM4U8E81UOPxqa5lWRiUGFqCgD6m/Yc6+NvpY/+3FVNRkC6vr43gH+2tR/9LJat/sO/e8bf9uP/ALcVkasjN4g8QEd9a1H/ANK5aAKc9wznZHlt3rVWO0mhkBfcozwV707y3SQN6HtRdTHehLnPp6UAbltfyxBVmYFR69cVdTULKU5BYP3INc75hZATj0qJm2OFzgnmgDr1CvnyJAw7/SmuQo61z9pcywyAg5A5q4+rKw2vFuPtQBoXVysa8qWbGQB2qmmpMXG6M/WqM1wZQX5qEOFU7j+dAHVWt3HIgzgZ71bikVmIK7gtcrpUhebYCSG5Fa0UjxTbmPyk4NAGlqUqy4RFwQORWBPlZMHIIq/PKjXL4NU71eknrQBRkkO7Pb1p2mk+bM7HAC4FVZ2Ktjtmrtv+7g2EZMhzmgCtfSNJPCpHvXTaBGv2RfM4G44zXOsitcDnLLxXUaQVFmCR0OaANmK2x9pbP8PSuB8UbktJGwRnuRXocEpWzumx8zrgVw3ivBjEWMkigDyXWHBLHBPvX0r+x2c/DnWj/wBRqX/0ngr511+zlZXMZH+73r6J/Y6Rk+HGsq6lWGtS5B/64QUAH7YuD8N9HDDIOsxj/wAl7ivj22lKAq+M4xzX19+2Ydvwz0c9ca3Ef/IE9fHc6NFc5kRk3cjcMcUAbunXA4GQMVpmYBTjmuYtn2yDmtdZDs60AaUMgzkd60IZuKxYX4HParavyKANxJBwc1cspdrHJ69aw4pSCPersEik9aANa8lARfLX61VF1kAHkelOhfdlc8Gmx2pe5AIwo70AXIryRAAhYBq2LGdCFMjEkdzSWFpCYsMqnHf0rSsrK2lUoDj1xQBftbhSoaJgR0961opMketZNvp8UB/dkgj1q8rhccZoAsXUaGJ2Y4pmnqUg3KRtpyus4KfezV60VRAYmXaF6cUAX9IgN3fQMQcRkMMdK9PilZY1dFGAOa4XTbgpEohCqcenWuh029dFxJlh3oA6abE1mWb5cjH0qlpmJZdo4IPWrMk0bxKFOF25IrGiknbVEMLbYl6j1oAvSM0olbJ68gVa0lllMg3fMvTNc/qs1zFGRbNhycscUuj38gmJf5GK4OKAOilZlvD12DnNcp4l+w3cskcz7VY9+cmte+1WQIFCZ3jbuHauD8U3ttGq75P3jdh2NAGHeWMdldFEIkXqCewqGVQIs4GPSqNxfvLIGfgDge9MNy2Nu7igCwHVRxxUUkuQSeaqvLx6VA8u1cZNAFhpgCR2qlcyjaw6g9qiM+c+1RySLx6GgCxqUxi0tIM/erm5mKnAFX764MpXP8NZlxKAnPWgCvNM0bE9jxXU+BfFkGjw3NtPA8kcpDfKea4id9x+bOKhcIu1l4PqDQB7Bf8AxCiitHSx0uCMsOZJ2wT+VeU+LPE93rt5HJdshWIbUCrgKKyrpWkUskjMAeAT0NZd3OyR7GO5jzx2oAnLCU7Y2GW65qxc20Zi8uTOMZxkVhRxTIS/ryDmrDXUioC/Ld6AIbx0WB1GVHT5u1c1eoQ2Q+5e1aup6nHKwj2DHQEVj3jFm5xk9aAK/aiiigD6m/Yc+942/wC3H/24qjfZXXPELf8AUa1HH/gXLV79hz73jb6WP/txVW/wdW8QgL839tajz/2+S0AZFym5spxWfOhMvz9RWvL87MqcY61m3RDA46r60AMWU8r6Gnq+Bg9qqh9u3mp1feMg4FAFqJsd6Vjk8cfSmIflznmlXnrQA4jgdaYIssM859e9WFTOKa4KOOelAGhokONxAyRWpsZrdvkO4HgVkafciAkjPFWpNV+Q+WcfWgA6uQR83pSyAuvSsiO53XJZic59a27ZxI2DhqAILfTzPMjkE49qsXduLVGfNaVpPFCwVhgN3NVtWTf9z519j0oA5zfuJLDqa6vRQrWqhScnpXLyxlZgCMCux8ORHykZug5xQBu3iqtosZ4KjJrzbxFcBnlKnpxXd6zMwilbd8+MCvNdYcYfPU0ActrMx2bh6V9CfsisX8Aa4x6nWpP/AEnt6+a9Xk+TGee9fSP7H/8AyTzWv+w1J/6T29AEH7Zkhh+GmjSgAlNbhYAjIOIJzXzp8TtLmex8N6rEWlttQtDKG24CvnDKMdhX0d+2Q0SfDfRWnTfENch3rnGR5E+a8nins7TQtCs2043dlIWIy5YQKf4R6Z60AeK265GTwavRyEKBWr4+0uDRvFc9tZArbMiyKp7ZGaxFYkUAXIZ/mAq/FLk9axVYhxzV2GQsOoHNAGyj4IqzHJ+VZUcmMA9qtQyjcDQBt2shBDZrSS5WJgXbk+lYEMhznNVvtZafJzigDu7d/NQmN+D71oWMrxkEnG3rXD6deSQnKtWw2quYCP4j3oA7aK8SVDhgzDt0pr3DAj5sD0FcZZ6sbc4lGUPUjrVltdiaUBSNvegDpl1B4pd0fatCy1gyBwz4Y9BiuXOoQzIpUr74NW7Mb1OVxnoR6UAdrYXty4wj7ce1b+naxdAASAMB046/WuU8P3SglJCMrxzXVaOrXMxSND8p+bj1oA7OyvxqNnG6oUdRtOPWm21xJBIw2ZHq3FNsoDby4QbYhyajuH81ipfgnigC3qbt9lWYJ96udc3AuW2kAdhmugaQy2YQk/LWJcszXMeOQOOKAOf8T6jqUSW8VvKgGd0g3c/hVCeyhu4VeZ8S9dxrd1TSfPuVcYBx/FVW/wBIuI7GSZNpCjnnoKAOFvFMFyyg70HQ1CZSBzioZWmkmIb5UB4pxTigBHnIGccVBNN8varKrvUj9aznUFmznNAETT4AIBxSK4Od/ek2YBB7HimyY2gdKAI5WHOBkVlahIAmTV2aQldq1z+rzEuVPAoAilkdiNoBUelVZLjbyV796jjnKEhTSthjwRg9c+tAEEtwFfCkfMc49KksIEdmlkG7B6GqVzErMSvBqxbx3BjDxsNvQjNAF2ZQ4ZSqqw5AB7Viahk2jgfePStO4Y7lznfjFZt+cSBFPTrxQBydxGyk7ug7ZqEnPuav6gVJY9WzWf79qACiiigD6m/Yc6+NvpY/+3FUdRlxrPiJV+8NZ1H/ANK5avfsO/e8bf8Abj/7cVi6uWPiHxIsed/9tah/6Vy0ARzTBYzhfm+tZly+UGBgnrU94kqRGTPArOMhbG7lu9AE1vE0zBcYHuKuRWhBwOfam6eeTjrUokdZiWO0AUAWFttqYI5pYovm4FM85scEHjOanjOFGc5NADZMIOuDUJBc9ealdd7fOQAKicoD8rYGOaAEOUGMdeM1UlkPmDHSpJJQe+c9KpsxLH60AW7OGa5lPkjPv6V1ekWEqKBJgk9Mmue0WVo5PKX5QeSa6uK6WMYY/IPutQBma9JJazmNlIK1kR6nNGm7Pyk9Ca3tRk+1SFZVHAxuz1rn7qxZRmNSwORQBrWUsN5IjHA7fjXaadAEtl4xuGcjtXl1hK1pcDOQnOfY13Wma35dvEpw+5e9AFjWn+dwP7tefa0AxkI6L1PrXoupvDeQM8X+sI6V53rYI8xFGGPrQBwOtlgu5QMfyr6U/Y6O74cayfXWpf8A0ngr5u114IYy0rABffrX0j+xzKs3w31mSMAKdalwB/1wgoAh/bQ4+GGkn/qNRf8AoievmjQfHuq2ME0Ms8ckEiBPLdBhcdCK+l/20v8Akl+k/wDYai/9ET18XntQBtarqk+q38l3cy+ZK3APtTbZsnnuKy4T89aMTYxQBYIxinRNtb60wN1yKYT3FAGor8D0qyjjGayopjnFWlbAHPWgDVimxzn71NeQCXbjNU4XJOK0YlV8Z60AT25Ln5QfwrZsoz0OT7VBZxxIqhTz7VqwMq84HFAFeTTnYlwhC+gqmdGaU8bk5roRcgLneQv1qdZVeMZHFAGFbaTLCdyuWA7Vt27uqKrlg46basK0aAlSMntVi3u4I1JZULeuOaAL9gkxjMoYZP557V65oyfYdFtH4eeQDzGHc+leMWF21xN5cIb5jjivYPD5ElvFbSSDcoyM+tAG/ZXDTR3Bcd+az38xZmUFRjnce1aSBbWIqCpYnLVham7SEqhGD1AoA1El2sy5yrpy1U4932kbSrITxViG1f7BGBkgqUJ7j3rntNlmtpXDuTgkDcaANLWraZwrxOTjqtUHmkfS7yNS2fLIINbFtchmImxg8Z9Ky/EGo2dlbyJC6kkfP7igDytpB5m09QcYpwkVUILqo+tZut3HlXTNbIywud2TVDzDKmSTz2zQBtS3SKhCtz7VSeQ7PXmqWTjpUu47AOPWgCQSjHNQTSDBoc7hjHPaqlwGC7mzx2FAEbONx+asjU8ox2jfG3c9RVuUnO7BUjsazr6Q7Ny9M8mgDP8AKCAshJAqvPLhP1q1MyGNgm4HP4VRuIy6Bc80AVpbjC8VYs7r5Mhqz7uIR5O7J9BRaf6nI6mgC/PcmWdcZGO9VNSZooZGQ5JIzTlwoBznB+bNRak2bV+DzzzQBztwxZ/m5J71EfrQ5yc0hoAKKKKAPqb9h3r42+lj/wC3FYmqSIviXxGN2G/trUO3/T3LW3+w597xt/24/wDtxXPaxk+KfEgA/wCY1qHP/b1LQBFeyM1q6Y+YmswjbgHqKvICQWJxWdMSJGI6ZoAtQThCDTppQ5244xms8y7R7k4Bq1bIyMHc5BHQUAaFuGyh2Aj3rWUO1vlVAI6CqtjBuXLL7VsyrGtsgB+egDnRHLK7EKcA1XlBDNnjit8MkQxjg1QvYomwUJye1AGUikqQOR3pyxBRuU5A61osgWDoAaziC0hA6ZoAvWBCPvxVm6uPuBTgZ7VTiyqge1PCknA70AXFbcQWY+wq9CXZhuwFqkE224kbqooW4YISTgfzoAZqVvDLIwD4Jq1b6XeRQQyQjfhMgE81jvcZuVOc4NdvYzh4o3b7wXg0Acrqd3cWafvY5UYflXPa3r9pNas7ZEmMV3viiTfYS+aNy4rwfX3AkkxkD0oAxfEd2Lk53FiT+VfWv7FX/JLNV/7DUv8A6Igr45v9zKCB8lfY37FX/JLNV/7DMv8A6IgoAX9tL/kl2lf9hmL/ANET18YV9oftpf8AJLtK/wCwzF/6Inr4voAch+bPer8R4rPH3hVxflIoAvKdy/4VEzbTinRcVHJywxQBIOuc1Mjsvc1EAdoqaAZxmgCWW6FuF29T1zWlpd8k8uDkGue1AZdAwwD0FXdPAjkByBj9aAOq3yRT71BKH0q/a3TFx5inb/KqlhiWLpn8elaD2gZBs4zQAy9ug6kI2xQc02y1SR9qMpZeeVqf+z2CDChs+tPtLGSJFwoGCckUANbUNkygK5Bqw7TzttgXHuRVuKGFT833j1pj38cKlE4WgDQ8OO9jcmW4mII6DsTXe6Lq80sqMsyhlO7PtXi9/evMwUMcD0PNamhXs8cgSOWQMR60AfSsF7by2Kzs7MDwcetZsmsW8bnZCzmuO8NXkv2AxTyPsbkBugNOnMySMwkOM9uc0Ael2OsedZBvI2hkPHvXGXett9qYvAiDd0HUVFZ3M0SW5+cbWYkDuK5rUp2Fy+4Hkk59KAO3XXLdLZ5JVAwMj0rz3VdWgubmSUygAnOKsDzby1eNAeRgHOBXK6rpktqjMyggdcc0ASXl8lyvlr8y579qqj5QdtUon+XqBgZqdHIU56EUASqSV5NNllZCO9Rs+eh/CkYbyoY4oAnhky5J/WmPJ+8K5xn+I0wIcrtOR0qOdtpO8Db3oAhvyu4FiGHtWJfuFWQdRWtMwkXGMVlX0YKkd6AMWSRyp4IANQSXOF6nPWrM0eM4J+lZU4w59KAIZpt2c4z3NPsZtxZTwOxqtLgVGu1TnJBoA19+13yBsUZrGuLp3jdT0zUr3bAFBn0qjcNlsBf/ANdAEB4pKKKACiiigD6m/Yc+942+lj/7cVy/iK4MfifxGFYAjWtQz/4FS11H7Dn3vG3/AG4/+3FcT4pIHi/xNkH/AJDV/wD+lUtAEb3m9SF+X6d6YhyMk1XGBT4yFwKAEmXDK3f0rQjkURozn5vT0qrdBfIzzvz2qvFL0U4Y0Adtph86FCfl5q5Mq+Wdx59fSsfSZfLi2ufzqe8mKKRu4bpQBDeTEsAhwPbpTImwSH9KaFPUimOdw+XvQAIvmTBS4EZ4Yk9Ku/2UVXzE+dB0Yd6w2SRZCOSBzzWppmrzWRCn54+6n+lAFo2WRgnYfemxQY5Az9a0rbUbG9++wjk7h+lPubdeHhYE9wKAMu6dhERjHtWaJGdWRs8Hj2rVuImeRiTg+lVHiwaAMwK32kY4OevtXb2znyoxkD5egrmEjVpFBGea6e3tWOGwQgXj1oAoeIrxTtiLHb3HrXmev6fbzSs6DI64ArtvE0cgl6ACsQQIVyGyxHINAHmOrW6qjBAfYYr6w/YuQx/C/VlbqNZl/wDREFfNviElJlEewhTjAFfTn7IJB+HutEY/5DUnT/r3t6AKn7aX/JLtK/7DMX/oievjCvtD9tL/AJJdpX/YZi/9ET18X0AKOtXYmDD5uao1PASB+NAFwkjgUnJYYNNZgaRM7qALanrnnipE6c1EnTntUkRB+YjKjrQBZnhE0II6ioLcgS7W/A1ZtHVgQOAKpdZOARzQB1elyGI7sHaeorajvU38qVB6CuRsLpokIY5Xua3rYeZtYcoelAG1FeoQSGHHvVO/1KSMBQAD9azZY9k7YyMmq82/eGY5xwKALBvp3LYY4I59qhd5C6kvkYq5YorRsTjf6VPbRFpCrICOxoAgs7KW8uVj4UHnOe1eieDvDOnT3vzmaYoMEqcDPpXFR27CY7HKsFJwK9YtLqOz0u0SxjVJpoFdnHUnvQB22n6VYw20YFr8ijBDtTZJtPst0k1ui7eijnNU/Dd8tzZyeaS2Bgt71ja+We5DIGMY60AdlHqFnd6fbT29sqctuBFYGsatZG6NuI41cd9maZo7TCyIX05HpXMa0FfUZGLFSuKAOz004McZjiP/AAAdKSaCG7SdAlvktj5l6j0rM0y8BuIlzztwPyqncmSCzlZmbeJdwxQByvijR1tbiRZYVt2Q8Y/irmfLxuBJBFdV44vXmksgWwUT957ntXNxyK6EYyaAKxjwwyeKtJHuTjHtVdlfPSlDNnIJzQBaBKEDA6VFLEj5LjPt60qSErhhyKjaYAkOMigDNvAEb5TkDtWVdMBIx3fhWvcrGAWRiD6VjXQyxNAGZdOOeRmsu45NXbsfMapOwB+bvQBRnGeKZDCJASTgVLc4zkUxCyrhuB1oAaI18wI3fofSql1hZCgU5FWln82QgEEjjJqrd4DEkfM1AFU0UppKACiiigD6m/Yc+942/wC3H/24rh/FjY8XeJQpGf7av/8A0qlruP2HPveNvpY/+3FcD4r/AOR28T56f21f/wDpTJQBWiOW2nqanK4wfSqUbfPkc1eLZhXjmgCWPD4GOMU22tA0wYAkZ6U6F8bR0JrTjVYY96kZPbNAFm0j/f7W+6eOO1SXEDM5yysq9AKh05j5u9jnnOK0ZniUho8cnkUAUxyMNilhi3SAbST2FRStvk+UbW9Kn09pFnDEjatAFa9tp43YtEwGM9Kz1yzZUke9dyz+cglThiMFeorKubSGeT95Cqt/ejoA5udQq8DJ9abb6nd2xHzkgeprdl0AOu6KYKPRqybzQb6PkRFv92gDTsvEEU3yXkXHTco5/Gtd7WKW18+3ZZE7gcla4Q2dxHuDwyjHtU1hqt5pDCSHcYyfnRh1oA6KCNVuVlJBiTJJH8qVtauTcOVIWJcbR7Vk6hr8dzbOYYWhkZTnHSmD/VqO+xSaANqeePVFAzlhwayobQPNKhQ5Hy4FM0JxFfTxqecZBJqJrxra/eaNy4Zu3egDitdgazFwHAGWOCa+kv2NG3fDTWDnOdal5/7YQV8vfELVDcTlEccnnBr6c/Yq/wCSWar/ANhqX/0RBQA79tL/AJJdpX/YZi/9ET18XivtD9tL/kl2lf8AYZi/9ET18X0AFSRtyAKjpQcHIoAtk/MBmhW5qsWZjk9aVZCOw+tAGgJOgz7VIjdqzROwbggHscU8XMg5CgUAbMJIRwo61Du2n5utUYbuU7mBGB7U37Q8j/eXPpQBu2eHPtnpW5Zh1kyjFQMVy9jdSK2SF461vwXsrBSoB/CgDSmeTcQp3/hVJ8gZLEe1WYp5ip2qAKrPK4Y78AfSgCWJ3jk347VbsZzJcl5SRxwKz3unYAA9OnFLBcuj5BHPtQB1USxIC+/PFdxoxivNEhcTBZYm8vk4rxm5vLmNSVmIXr0rb0S5vnsgizOc/vG4oA9+062NrYBY2DM7ZYiq12zmRt6DDcCsbwhqd7PpOy4ceYvRzgE1JfT3JcIX6dKAOq0OCVLKa4PzwvwB6VzGuxSLfO5QBAvIrW0+9uodEADMWDc4FYviKa4eUyF2ww6begoAdp8bm4Dp+H0rortLM6ZNcTnyxGu4+5rjdOluBcDdKwUf7NS+ItRlubdrNJCd68kDrQBxvinUYrjU38kPggEE1kQMzE/Mc+tT+JtMuY7eO6RyQBtbisO0upNhQybe1AHTWrkqqMCadPGFJKg1zIup0cfvTxxxVj7XMW5due9AG4Bhcspyarz4Klgp/OsubUHRG+ZuB3rLk1STBLSHJ6CgDYuXxwAc1kXL4J6/nWZcajnJMhBrMnvWLH52x2oA0bltx6HFZ82C3FVN88udgdveqxgu3Yg5WgC4ql5hkZWkmj812UHAHtTbWxnYHErKaZPpl7uOzfKOpIoAjiiKyMFHA/WqUrFpOfyqSWO4ib94r7qhPX5gQfcUAIeTSUUUAFFFFAH1N+w597xt9LH/ANuK8+8YMw8Z+Kjjga1f/wDpTJXoP7Dn3vG3/bj/AO3Feb+MJMePPFScnOtX3A/6+ZKAKkLnd1rQViQMGsyIEEHNXIH3EDPNAF4Moxnr606ZjkEEn2pI9pkXcOBUr7N4Cnr3oAs2T7QAQQTV1E/dhmzjNR6dGm8bjkmrbqjDaGx81AEnkqF8xWB9KmsMPdHeMjFIrItuRxnpTtPhcFnUcHjpQBbaT5mAO0D9ajZnLcDPvUiRnKlh05FSJGXLNjp2oAYJWC/MKdBet90Fuf7wqRFDAjGapOG8wA8EUAa3nM0YGY9x9RVOZEnR0uII2VhgELjmms3Ax95qnFxDFFiXBY8CgDzm5gdZrmJU+dSQorrrHRnkRN/+tZBlfbFa0UMF06BIF3AgFsda6trZba2fdGcHHOOaAPN7HSXj1BmH8SEYrH1y0+y/MOFwcV6JqqrZ26yRA5J/OuK12TzYJlcg5NAHg+vSNJfSFum419hfsU/8ks1X/sNS/wDoiCvkPxJD5d7JgHAavrz9ir/klmq/9hqX/wBEQUAO/bS/5JdpP/Yai/8ARE9fGAGe1fZ37af/ACS7Sv8AsMxf+iJ6+MKAF4z7U+OJ5T8ik1ZsLGW7fAGE9a6W3so7eEADLDvQBzsGlzSYLfKK0E0SIYMspxWwAqR5JGT2xTF+cfMOBQBRGjw4wgK45znNWDp0CgNtOAMYq6X2plulLFE5JJzgcgUANs9LtSC3l8+maePDthJLuXeM+9X7KLchycVchh2tu5BHODQBRg8K2xQvE7s4P3W71di062t2KSLg47mpVu2JIX5T7VY8tb5dsnyyj9aAC2tLfBCj3zS3NjbyINyfMO1RSpNZxYVgVz1qaC5Bj3SN83sOKAM+SxiTny+PeojbW5yAmDXQLbC5hDdF9agbSCQWjYHv1oAwoLGGW6j3g7FPIr0Dw/aWEUJ+eIKRtwa5rTtHuJLkqUYkng9q7Ox8NzSxbRgKnPI70Adj4fh02GMuAshxhRngVp3tzZxP/qrVSBxkdaz9J0dLaz+4TIoyT2rC8UWDuqzrkkHBGaAOoh1yyS3nRZICwGcAVTu9dsp4tz+X8oz93g1w+kIiXx3oQGGDkd62dR0oCIuhUJ06/wBKALln4m0+a4WEPEpbgjbVfVbiz+1jPlgjj5fSsKy0h0uEdlwVP8I6it/VLK38oZRjIw4JoAyNVu7M25QR7t3AHbPrXnssESXMigAAHPSu+l0qUMhbPkk4JHNcjf6dJBfPkZUtwfagCkpheTaFA98VL8sYAMQIz19aux2UZGWG0+/eoboBFCDOPUigDNvVLLlUAA7Vm/ZVJy+D7YrVmbaOeecVp6TpXAmnXHdQe9AHOxeH3uPmZEWL+8etTT6baW8eyKJGbuzCurmG44wAo7AVharHhSV6mgDFKokhBCDPoOlQyxIrnABPqRTJdyMTnNKj7sluoFAE9s6RsQyLtI9M1dtYkV2ZnVEYfn+FN061Rh5j8jsDVi5iEjKq7MDoO9ADZoLYoXjjRwOrMK5HVbS3ndmQKD7V2Nyqx2zQMu0uuciuN1AiAYSgDElsCqkqcn0xVNkKHDZBrZEm9eRg+tQyorDkZHrigDKNFTXEXlnK8iocc0AfU37DnXxr9LH/ANuK8l8aNdr8TPFpCkwnWr7Yf+3h8161+w597xt/24/+3FeVeObow/EHxWHzsGtX2Mf9fElAEI/g+bJPWrlrIok2jr3rES6iaUAPk9xWnbAg7wc8UAbcXzKM9TS5YOADwPaq1s52jmrK5LZJ49KALUMzBgSfrxVmORWPf161RHbmp7UhZgDzmgDdgQiMGQbieQa17aNtuzaQAM4FZukNDPP+84Xpkmuzt9N3AeSAwI4xQBjRQbslh83arEduFzu5c9K1xYSKPmiOe2KZ9nZZBvUg44oAzIodrnK5NUp7ctKSQDW64AQkqV4rKkRgG+YHHegCnHaOZgkXJ7d8VV1G0kD5K5HXNaX2o2lrPKB8yx8E1hafrjSYS5/i75/SgDV8PArOjFTy1ej39v8AaLVNnUgHHrXH20cUEMNwD8rEHp+ld/ZzRSaUZUxuC5HPSgDzfxvcJCkERULjrXl+pXywJLJMcL1z612Xj/WYXuCsifdycg15F4punuVdF+56A9KAOX1jV47wyBrcFtxw3Svrj9ir/klmq/8AYal/9EQV8a3qYOccjrX2V+xV/wAks1X/ALDUv/oiCgBf20v+SXaV/wBhmL/0RPXxvZQNPcKgHuT7V9kftpcfC7Sv+wzF/wCiJ6+TNLiFvaNMx+Y9KANCIx2y7VIAqYzbl3K1ZMbGYkt1znmrLcKMdKAJGlyx55q1DIuzDHAzWd3qeJiqkBc0AaIRHjG9jtB4zWgHZI4ygB9RWarZjG4AVegYbRz2oAvWrFi+VGBV2EnZljnPUGs+2kRJAPWn3zyhMJxk0AaEliXJeIbT1qW0iOcN94Dmk0q6YRxifBbHWuisrNZn3JjnrQBnRRqyiKZcqwxzWHc2stldOjLm3PT0z6V2N7p8iSA44HpVS4smuohC6tlvun0NAGFpkrkFBIIj2QnNacU8isAcCsUwPaX7rMn71Plx6+9aEVxwCwDN29qAOv8ADQabUovmwg5xjvXbTw3EzlLcceg4P1riPC0qzXUZZgrg9M17BplxbW6BzDmRl2ls0AYMEE9pZ5kLlm4I9KpzKzKqyrwT3FdRNNHcLwMc9DWTeuWBV9kZHQtQBg29vaxTyPcJuAORWq8tjdWpRYNgxkZqnILO5PyXBG3+HFMkubazi815GJAwq460ALHasE3Bc+nHarCac2owum0idDwOhIrPttYSdmUsyDgYP1rp7OVkkBYBmwNpU80AUbHRyLZ0m3DjGNtebeIbbydRlUfdU4wRXt19fb7ULEVjJ4cn1ryPxpJbtJJtYCROc+tAHMSMqIcAMPU9qydQkyPvZAp8tz5qbd2KtaZpv22bMnEKcsfU0AV9C0xnlF5dj5B9xD/Ea2rglX7nHbstXWiCFQBx0A9qlmtc2zPt4AoAxplBQNkViXzeYdmOa1LotbKzN8wz0qoQJAZgMZ7UAYU9nkNis0xkFh71vXMgALN8o71zct2jXR5+XpmgDZ0i5RFZJCvHTJ70+5k+bchUnvisEKoBa23bs9e1aVhfN9nKXSHcDxgdaAHXV3tiVps7sHA9q46/m8yXdWjrV41xcbt2ABjArELZ60AN5B46GklkKACn8Acmorj5kOOlADoGS4BQna5HSqTLsZkI5pFZkO4dqt3QWaFZl6jhhQB9M/sO/e8bfSx/9uK8Z+JF5FD8QfGC8tIutXvygZ/5eHr2b9hz73jb6WP/ALcV4346tk/4Wd4zmk43azegH/tu9AHJWcj/AGxZ2JIJ6V3FnJvjDbcBhkCueaGJB8q9KjbVZLeUKGxkYX2oA7GGbjrVlJ8kDPasO0kkeBHJ5PJzV+3YFxjr3oA1o23Gp4w28MOg71UhPzGtC2Xd15oA2dPaMsGcYP8Adres7iRD+6uTGPTdXN2sLtwqs/bgVfggkWQl42U46YNAHULrF0i/fLAdCT1qJtfuS4JRTtrNts7SCOO1OeIPwDgn1oA2V8SxPhZody9+KGudKmBaO48psdGXArniqg4HJ9qU2Tum14zk/wB4E0AXNYW3NjLmeJty8bHBrh5l2EKBxnKmt27tWtEIkRQrDjjBrGSFnuQAuRuxigDr/CGoNcwG3m529F616FChh0m5AQ5MZxg15n4asJoNVRgMK3Br12A5iMZHG3n8qAPnrxRFIXcy8MCQR1rgr6Pakg71694+tPKuGIGAWrzrULFmEjDgCgDz3UYcKeOor66/Yq/5JZqv/Yal/wDREFfLOq25RtxHbjFfVH7F/wDyTDV/+w3N/wCiIKAHftnLv+GWkL661F/6Inr5HuZQIUhX7oFfXn7Ywz8N9HH/AFGo/wD0nuK+OiN7c/SgCzbKQQauIPmzgc0yxQthT1qw0fkkgnIPSgCF49pzk1Nbj5s0PGSM/jSxq2c0AWN7ZwOner1qN4+Vc1UjBJUYFXk3oDgY44A70AXLdELc430MJG3JIR14qrB8/LHa1a0EXmREKQzAZ3dqAFhXcVBxXRWUr2yoUbk1kx2hKqSefaup0CyS4kRJAfl5BxQBqqWvH242yKoPFVJo54pdrAkYx+Fb8Vt5Goylcn5AOlVNQuAsihlBJ6nHFAGLqOjLdKt63LINp45IrmrvTpLSQybC0Tcgr2r0SGWNJF3KWVxjaOlQ3Kw28rIFElsw5zzigDidN8yOVLlN20AgEeteoeDNTmu9NAmceaOx9KzbCwtZk2QKpi5PHqa2tI0JIWUo5ULzx3FAG9agorvIVJAyK4zUZJ7udjO7Aqx2rnqK7+e1jWzDAkk8CuZuLGDLblbrnOaAObjlWKQhSc5HNO1eVpXXgBU6Yq7Jp8JOSWA9jTZbON16ufxoAwmPmFssd3GK9C0sqsVv5z/vgAQB6VztrYQCVSynb0JJrp50t4LNblWIkXCrzQBV8VX7WlhhFxubBwK8t8VRySxRXIDN5uV4FdVqmoyt5nnPvVj07VSuLtZLONFUEJ0GKAOHg0uSJUecZlfhV9B610ttatEEiiBAwM+5rS0e0WUSTzDLj7uegq1AsZf5s7s5oALLSzLMA5ySOM1ZazIs5osDAPJrZ0lAZN5zwtFin2iK6CrkEnOaAPNdXtGMx3bdvpWbOoghdmwK6vVLdd5PPXmuH1+5BLIn3RQByniS+cgIh4PUisK3+clAC7Hn6Vc1X5y2eDmodIQm7APyigDf0/S5WTzFbEa8kVRlVmmlK8KvpXRRNiBo1b5m446VyV2ZY7iRVb5c84oAzrrBLYPfrVPZlxnpVqRScjB5NN8sjkjigCrNgHAqOQHyjjvVop8/HehoTsYmgDJ7etPV8QsoPWlMR3EjtTM4B9aAPqT9hzr41+lj/wC3FeJ/EmZR8TfFcQPzHWr3j/t4evbP2HOvjb6WP/txXgnxMJHxc8XbQCf7bvP/AEe9AEE04XCq/wAx7VdtbSJ7cG5j+bO6ubtUM14zhvnU8Zro4PtUrgNnYPve1AGqhAxtI2gcKKs2zs5DKMYqhHEkV/C287WHC9iK0bUbi3bk0Aa8ByeDk+latmRj7tYdgcO3r2rbtSAv3jmgDt9CuESyARUB78Vt2962fnETf7wrldDYmBcd+tb0DYG0jPPWgDZjmizk21vn1AqcG1kIJt4fyrH3DPH41JDKNxX9aANofY4QClnCWPtTJ3G7IjVPdarQycdacspecADg/lQBi+KdNn1CBHhVmZehNZWh6C9vIbi8QeYBwtdtd3hhaOFFztXBFS6YttNJiQAs3rQBgW8ezW/ukKADjFegWYi2KWI54rl9Wtfs2oRyH7rL1HetlZSLVXQcigDjPihZQQRxzAhsnpXlF2qybmU4GPu16P8AECZp02scY6V5pcLgjjqPzoA4/XYVaNiqmvpb9jQBfhprAHT+2pf/AERBXzjq6sUbaMc9q+kf2ORj4b6yP+o1L/6IgoAb+2U2z4aaO3prUX/oievkaNFkbng19bftn/8AJMdIz/0Gov8A0RPXyZZIPMAZuvQ0AaNhBluh3AcmrJg3ZB5I6Vf0+2BdAvP0qzPbkSEquBQBkCAkgYqRbdRywxVvymVs4pGRn6CgB0cKgqfer6RqxHqKihQAAH8Kv2SK8gXoTQBnyWroysq5FaUISSIquVOMYFTXEDgKF6iprRVhQM3zEntQBdsYg9sGkPK8Y9a6zwohNwVJwMcAf1rmFwsL+S28jnArpvDZcPFKg5YgH86ANss8Wo3SMeFwpz3rL1CLkq65UnINaurEHXZu4IyQPpTS8dxG8bYMuCMelAGWku2JVVSPUmi4CtE2QQQMj3p0kBiVVY5qMIZZkjzz6e1AFzQJpXhkVEVNo64rorG+AEe48jhh61i6OPJvJoQMqRWjLarszC4Vhzz3oA6tbyGWJIwR8vNV5oI5M7RuJ9KxId9shcsCSPyq/p9wwRmkBLHpigCpc2Lbyi4BqpNaPDGxUDIrckuY/P3SKRUF5cRsSBGSG70Aci9+wl2MwGTxV2HVLd7V0dmbjAHYGsbWYWS/XyYxtzk57Uw2qPAVkkPfgdjQBFd+bNMY12lW79qZNGYUEeMv7dKuCLyEiRTj3qHfEb1UbJI6mgC7FmHT1Bwrd/emwoNxY9+1OuXVlA3AgVDbZVvnI9qAOj0+Ty7eRwD93FaOgIfsUxXktknFZNu+bZ19cVueGv3bzxHj5cjNAHBeJnEEW3+JyenavMdXJy3TpXpfjNSt1JuBO015prCnJwcYoA58WpuJf3gAUUSac6SAwKRgVo6daSXILZO1T19a6C0CIoWUHgYxigDmoI544GcnBxism5X5yOueT711erGNZHWNQAR1rnLpPmyMc0AZpXB5HvTzHuTIHNK65ODzT7YYc7iAPegCstt83pjtTzbloWx1zV2MFmwAOvU1baHZYhsDJPUd6AOU1KIQIAv3u5FZB9a19ROZGDdCayWHJFAH1J+w518a/Sx/9uK8I+I8W74ueLmY4Qa1e5P/AG3evd/2HPveNfpY/wDtxXh3xJBX4meNMoxL61ebD2/170AYc9mWJeNhCM8HvV/S5ZYL0RzSb45R1FCWpaANLnHbNTaPArN+9AyOntQBqPsRog2Sy9CK17eILEh7setVWhUxKV5A7mrEp3INpOFXIx60AXrCEh2Lde1bUURCg461iWUUjWCurfviehrd01nKKlxww9aAOj0IAQZ5yDxW4gBYsD71kaREFtyDxzxWvArFtoyG9xQBNErMQatRwfMQB1q7Y2MhCjb0rQhsZfMP7s+9AGbDayHGBVq2tWku8E4CjJNaMdpOudqjFZt+l3FuWMAblwfWgCnqkTzXLGJ1KheCD1qXSo5EjjldSBnk45rlYXms72RXkck578CvQvDV1Hc6ctuQrSHqTQBcuo0v/IIT7tM1GJUttmSnbinWcc9rfbWUlWyBxxVTWWkBaJxhjzn1oA888axO6hVO4HqTXnlwxjfDLkL616rq0SPbneeVOea4fUbVGc4UbTzQBw2pvDIHVQQ3qa+iP2Q08v4f64mQca1J0/697evn3xVpyGElOCec5r379j1dnw61pT21qXr/ANe8FAEP7aBx8MNIP/Uai/8ARE9fJELHC+tfW37aX/JLtK/7DUX/AKInr5GsRuVMigDs9AlBKgn5vWt64t/3gGOozXM6OxDqqDmuzmAZbeR/vYxQBgSKUf5hxTAg6HvWtdW4die+aqCH5gCMc0AMjiyQe1XIAI3DdxS+WR15HakK45FAGps81SR1xSCzO3GaLdsxL6rW7psayKS/Q9KAMu0tnZ9hOFI4Ndj4WgAdYSCSORVeC1ScYPDfw4q/pVvLb3PyqeDyfWgCbVY2XWJjGMPtHJqGRm3IhIWQjP1rRvISdctJXYkOpG3FZstjI93JIudyvgZ9KAI2mZo2WUfd71BaRru3q2W7Vbe12J5bdSetNSLyZXQGgBVZvtaupw2MGugiVJVGTjiqNjaxxW7Xd0wREHysepNZd34ntY2KQB2yfvigDo4ozLOsXJXPerMRBeUr0bhfrXPaH4msJroxXDSIx43HpXYQ2PnRk28kUq4yhzQBWiDLuWRcqRwTWZqEDLIGRi2OcV0y2NyFjHlHJHNQTaNL5xYnYvTLHigDhZzJJdJ+6KhjznvS/YZVnLsPkz0rorv7HpqO1zMrBRnEa5auG1vxXHHc4tIJWhP9885+lAG3MYjlY+Xxx9a5qVpFvdzsMk4p+n+I0ldWmteM8mty5trfUbd7jTnWQAfOp4KUAUB0wRzSRh1CrsJGetMtkkjKKAever8UsjxEumTk84oAu24DRKq5BPvXT+Hyz6jIqjIWIZxXMwxCWBQQU+YGuk8Jyf8AE4lLPgKuBQBleIbWK4lIaNize1eeeItGjkVtiZPbHeva9cg3BwAGz+lcTdxAsVkGPY0AeXWEUdhGy38BQHke1V5723dsQzblI7Dp7V13ii1EcAKKTle/SuFjtRGxkwoJ7CgCrMvXJJ75NZkibpCf4e1asquS2O/rVYQAnGPc0AZssIOcCkhhG7kVpPDyNoNSxw4IOMGgCqIRHGDxz2ouzt01RjqTVyb7pJI6VnaiwNhGAc8tQBx2pN8x4rNY5NaGoKQ3HSs8jBNAH1L+w597xt/24/8AtxXjfxFgLfEbxZMjZKazfZB6D/SJK9l/Ye6+NfpY/wDtxXi/xBlVPiX4wAYhjrV7u9P+Ph6AMtpJNy+bwhGRTo0bOVPPfFS6nazToklvhdigEVM6rHBuncCUrwo70AXLWRjAFJyeo961dKKOh8xgMcc+vpWdpBV4kZ1KnHNXdLt0bz3LErngD1oA6GCNQqspH0Har+nxs8nzcr6mqGnFliHQqeOa6PS7ZmG1RkjmgDqdO0l3ijLq3IGOOK6rTNCkUIWjYt2OO1ZPhuTULVA8MwMOBkSDNdRFrEsmPMZQc9hjFAGtaaPJldyYAGRmrkOklXcmSNR9ax0v+dxd+fQ1BJqhO9QrnPcmgDomsEVSftEePXNc5qUVpbyN512cAGqNxdSOhOcf8CxWUbK4vZiCsjGgDnNV2NcTOhO3PBNdH4dsXt7aG53NzWfqekSRyeTscHaMjFd5pOnyS2KW8SnKqM569KANGyUSyRE5J9K2tU0O21CIHbslA+VqxtNt51lAlyoRuD7+ldepyAfagDwTxXYSWMhjlB+8e1cLqakOSBx617p8QbPz7gq0O4HvXjOv2RtpThWK0AcNr6mSIMDx/Kvc/wBkgY8Ba6P+o1J/6T29eKaygeN+MD0r239ksY8C68P+o1J/6T29AGf+2l/yS7Sv+wzF/wCiJ6+R9PwYga+uf20Tj4X6T/2GYv8A0RPXyRo43Q4PrQB0mikhs5wfWu7i/e6fEerK2MmuH0tdkqmu2tXDaUVP3g+RQBIYlaMkj5u9V2i5GcVctSW+XFPkQEjI5oApNEAOKaYjjirzR4YEimRwlpMnp6UALYw8kHoetb9kmbdAoxt7VSsLcNIB27kdq1VXZKB0WgC+ikEY4BrpNNYNsVjkY6YrDiBeJMYxWzpaMjjHHFAGhqsSh7eSMYZOnHSobm3C7LlR8pGGq7IRMnlsQD2PqahtZkjWS0uMbm6UAZOqwBBCq/dfkN6VWmdISrvj5eo9a1NRKW+nAzHKrIBn+lc9rxHnyNwEAwBmgDN1nUJL9sBv3a/KsfTHvWYsKpGySOpVuSDxUN08rD90+wAdh1qv5YzvZm5HIPNAGjbQ2yxsEZA/bnNdjod+sGnogdg6ng9AK87WBZXQKdhY8GursZWNokBYMq9cjFAHd6brUxkbExO31NVNd1i4mjwzkLnrmsW32hl2Fl9femayR+7IB5PNAFe5uBPI0aMAGH7xzXJ3NzZQ3bxgeYy8dOn41f1E/vm8sN9RXP3iRiZiDh2oAlNxbtMQCy/hxV3S7mS3vEa3fAY8gdDWU0RMIBP4im2rmGVGU4wwGKAO+ikFw4KMEctgD0rQs7R2ujbsMqCST7VyOnTvJqDqmeWHP92u60e8jnnuIoX3ygBWNAEllaiVzkEQoTg+ta2hQDzGuYyFUnAGKz7idreSO0h4yctjtWml5BCgiTG5R0HXNAF3UZVGDKcjpXJa8qpukYgAdTVrW55JY2WPcuO5rhNavLh0EMkjH+tAFLVdTjublYIySp43Vg3trsmYKeOua0rKxMt4eMDvV67045ZhyF4oA5CaEM2BwRzUBhJbgZNbk0Ayy4wBzmqRjZSduDz0oAo+UQeeDUiRkZJq95IGC4zntSbRzgUAY+pLtXAHWsV/9RIpOT2roNZDBlQfnWBcIyngevPpQBy98Bk59elZUoIatW+B84555rNlOZDjtQB9RfsP/e8afSx/9uK8j8awK3xM8XTuVyutXoVT3/0h69c/Ye6+NPpY/wA7ivHfHKxP8UvFpk3B4tYvSpHr9okoAinnYuyRBgR1LDFUWlEjxxzR5DD7wqa4mlyE3q2e/WpEhl3Qu5QoTg4FAHRaHaBokhjQFj0JqxDYTWnn5ZSScbataTCltBDcQOZCzYKjsK3bbTZLq/EZT5ZDkk80AUdD0+4kZAwGCa9I0XTAvlq/y++Kv6ZpUNrEsIiBkA6YratNODgtKGVh0AFAE6QxxRhFjyMYNRPZfvC4VV/3qvRpIPLWMZfODn0roLLRYrqEG8bByfk6cfWgDlLRZmk2InmY647VpReH724JO3Yh6k129jYQ2sYWONAPUDk/WrYUAkgc0Acfa+GouPMUs/ete00hI2GcZ9uK19rMTuOB6CnIoQYUUAU5NKtJFXzIgxHfuakEccBGxNq5A4q1TCmZA1IRXntN0oaMgAc7ferQ6DNLRQBzHiMrJcZjb5l65FcVrWmJexFRGMkHnHNelaxZLcwMe/tXH3di6IfJkIPfNMZ4Z4v8PS2e6RUO1uTzXp37Kq7fBniADtrb/wDpNb1R8RWRuIJUkye2a3P2cLT7DoHie3/ua2362tsf60Ac7+2j/wAkv0n/ALDUX/oievkvRQPOKE4BBxzX1p+2j/yS/Scf9BqL/wBET18iWjGNlYdR2oA6ywUl8HgV2WnrutVVOnf1ridMvI5jub5ZB29a7XSPnhLx898DtQBoWOPMx6cVf8kMM45zUFsoZgRj3PvW5DAjR5PWgDKkjyQMdKiSAB+D1rSuIjgdOvrTYE3cOgoAs2dr+8TYCV7kVqi13xDK4YevFT6NFlgDgLjtW3NabYiVGfrQBiQR7XUdq6GzhIRcDOSBWTCmHwV5B5xXV6QiO6BjjigCneQ4wicyeg71m6nPBp1uJL0BZOwz835Vn+NvidbabdtpmmWCSTJ8rXGeRXmOoeInvpi920kr5zuz+lAHY+IPETahpoto4wkSOHDdzTZpvttgsu7Jb0FcO93JcNydqHsK6DQLxVjeAHIA4z3oAJECkqT8tNJhAwTuyMfQ0+RcuWPOefeoTGuScY/rQBRaV/O2lMIDwRXZaDDDJbtNcS5wMIg71zWIwQWAweprW0y48tNu3A7e9AG207o+FIP0onMk0WWYdMe+aqrMiH94Mye1WUYSLlnC7jnBoApyWDGzeR5AJF7DniuMvpSZiQB6ZNdtd3KxRzpu3fhXJXEUcjZ6HrQBVtrxcNGSpI6g0FFaYupyMggVNBYLcMdqgHvxVmSyFu6IOc96ANXT0WKbzCCA4GKpw3raRqU2x2SWRtyuOc067uRBZJlTv6Ag1z0kjzFpH5IPB64oA9QsvEsN2sUV9ECcYMsY5H1rqdM0eG4VZbO9t5Mckbxu/KvnmeWVFIEjfgTzVW01S40+/jnsriSGVDn75xmgD6U1uxL27Kcg9OnNefX+lGW4woLH1rs/AnilPFfh+SSVc38AAmHqPWq14C0xWFAq+tAHOWeleS21R+9A7097MfMshx610ttZsq7ycnHWqrW6NJLI4JZRjZ60AcNqVkkTHaAQ3Q1hTRkEjA/AV1WqMstwfLGxh/D2rMmspJgSooAw/I3kDJ4qSSBY1LEEACtaDT3Dc4qjroa3i8sYyaAOUvpTLK3HPaue1bU7YKYkkBfocdqm8R6i1nGYomxcPxj+6K4iVC2SeWJ6+9AD7u4ByE5PfNU+O5+tPKcfzqM9/SgD6o/YgGD4z/3bE/rcV4p8RGaP4l+MWjbDNrN6Mnt/pD17Z+xD18Zf7tj/AO3FeB/FG7ki+KXi8AgoNavfl/7bvQBHb5RUkdBszjBPNbDLtRT0T7y4OfwxWDokqXMDPdSAEnC57GtzSrKW5uVSBy+5uG7EUAdT4QeV9kMYyztkZHSvXdIt10+EM6h7jGT6AVzmjaRBY2kbbPnI3H3/ABrct7kSxkKxPGNpHegDqrK7DclQzMOo4xWzDk7Hi3B/rmuU0kOJkXByeOa7jSbAlkL8CgCzo1oHleWTIY8Y966aK3kAAGMYxk1RtLdcja3Q81tjoMUAIi7FAzmnUUUhBRRRQAUUUUAFFFFAB169KyNW0xHjaWBAGA5UdDWvSHofpQB5Lrduw34HJ7Y6VofAsYsvFoxj/id9P+3O1q34qtH8yR0XDnqKr/BFWW38XBvvDW+f/AO1pjOO/bN/5JlpH/Yai/8ARE9fIVuCfrX1/wDtkjPw10cH/oNRf+k89fJECjvzQBNEpzlWwa1LDUbyzkV4pTx94Z6iqSKMcU8L8/vigD0jw9rEV1hiOvVa7nT9synaMAjp6V4Vp1xNZXKSxHCqcsB3r17wnqQup4SMFZO3pQBv3NmoIOM8VAtsfMGFwM9a6Oe1MciKRnPOfalltlTGBn2xQBX007BtBAI74rpdO/0oMHwF7CsNRIqLtXGTjmrlrdpDOSBtEZ5Ud6AJL+18hztGDt5qPULv+ztFvrpSd8duSpHY10TRRahbsU2+YV5Fc14ispH8P6pa4wXgO32xzQB87XFy0kxlckyyEsT9alttzPnNRTxlo0JUBgOlPs2yMngUAacCZByau6bIYbgNn5h0PtVSADbT/mWXPoO1AHRklxvB5P8AOnEFY9xbkdM1UsJQFw3ORmri/vHBXlV6igCeAwpGqPtZm5wR1qfQ7dri8ZEwwXkZ6CsbWPllQxt8zDpW1oExsLFhO+Xk5yOuKALWpGO1Y55eqdtdPNNs5yTkD0pNTbzrpSCGwOadbqLZRNJ8rE/Lj09qANRtJkeFpmYFuuKw5YIwSZDtLNzit77YwiJTPPb1rnNZVxOJWUgegoAY8CwzbopT9PWoTIGmwu5nbj5ugqvHITIG7Hjk1v2mmi7ibaNiFeMetAGXqcM0UcbMAdtYsjZVj0yeRXaXdukkKWpY71Ayx71yOp232a5K87TQBmyfPGQvAFZM9qzSqe2a3kiURHBqJkG4ZoA674LzSReJbm1VsJPbkn/gNeqXMB85dqYz6V5h8G7VpPFsk4y0cVu4P417bFFFbQC6us7P4F7596AKE8S21gFkXBYZ3Vy81wCsiIdi52lj1Jre1TUZb6V0xheyjpWC9vLcHYMKR39qAMOTT8FgG3gndnHNOktB9nyflCjJHrWrcwtAu4MHxwW/pVVnFzEEON3TIoAxI41M0h3EACuF8Z6klqJX3ZYAgezV6hPZx29nczSAFVBOT6V8/wDjaZpLkjO5Sc0AcxcSPcStLcMWkbkmqzrnqMVdjweG57802WLK5BoAzpF61VkGDV6RMZz1qpOvzUAfUv7Ef3vGWP7lj/7cV89fFjj4p+Mv+wze/wDo96+hv2JPveMv9yx/9uK+ePix/wAlT8Zf9hm8/wDR70AVdBeK4geCSHLR/OCD1r1DwG6WqDNm8jucbB/B7V5t4S+S5jfyQ6P8rnuB616Z4Qv3sbqRZbVijnlx3FAHpRkCDyjGdzDOD2pLb9xIispG48Gq1nfRahPHHAHBXj5q7jSPDCzSpPcMdoFAF3w9b+cytMMDgjFd/Y26+UocYX1rMs4YInVE+6vT3NdDbR5wWII9KAFdAo+RPx9adab8tvGB6elTlQV2449KUDAwOlAhaKKKQBRRRQAUUUUAFFFFABRRRQBi+Io1eIZXmub+EaeXL4zX01sf+kVpXb3kAngZT97HBrjfhajR3vjVXGGGtjI/7cbSmM4L9sgZ+Guj5/6DUX/pPPXyTaDnivrf9sb/AJJvo+f+gzH/AOk9xXybaAb/AJaALsafLyMVJEu6QECpADgCp4kC9uRQBG6BQRXVeB75oL+JPfODXPW0DzSEleK2NEspZb+EQAh1OfrQB9KRxpcWFvMwwWjBGe9Zz7lkztzjvWxofk3+kWZVt3loEbHQH0rRl0vKZjiJ98UAc44L24wqhh0BpbS2iljYHG89Sa2XtHQbjDlR2x1rOkwFljjUAnkGgCFJpdOuowxwO7djXQyQRappsxj2+YYz9DXJSzMm0N88Tfwt1WtTw9eNHdLAeYXHRe31oA8K8UaT9g1m4iK7VYlk/wAPpXP+X5UuW+76dq9k+IGmi7M8ZVRcW5Lhl7r6fWvI5vutxjnHPagC9alDgAjkU6Ug7gAKy7a7USgAZxxWisqk8dSKANXTgksa9io4rUt2VIn3cN1+tYlnKIHTB/KtG5uURQ7dOw9TQBFNH5twDjK571sQRofvsBgcCodGZriIPJEI+eN/GRWrFZRTK86kADqDQBmeWryytHknPSnpKlwfs5xvT1PWrsscUT+ZDnbjmqdhpjXl+0q5QDkHpmgCxLHvhQ8oy8f/AKqtDT47qIJJw5HBPc0XtjOtuJFG7aOCapHWrm1CNJakgdCaAGQaDDDdEXALJnt61oz2w0uPz4tzW5/PNTWt0bqWOR02q2D83rV3ULy3t4GjlBKgZGemaAOduRIf9KCsA46DtXNarI8lwuTXdWN/b3Fv5LBdtc7r9hHFcF4+UI4IoA5tiN+3jg0sy4xwMfrQIgZGySD1FaukaY+qX8Fsn8WCx9B3oA9F+BumGCx1HUJxtWUBVyP4R3rp/EV7KWdehHHHetDw9a/YvDc/lIfKB8tARyQO9czqQlDMXYsx7igCO3lkjdSUbLDgnoaklVmkUZI9SKqIsjzoWcEAcDNb2l6Fd6hJvdTDBnO4mgCpLYNMgRUAY8gHoazxprwhnWFmI449a9Cg0vT7VQZrtWZBjGaZKukiMlboKAdx3dzQB5/rVj5/h6/iic+cIsbSOc18x+Ioma7KkEMvDCvqnXGie3vSmpxRowwqnj9a+dPGUVumrsLV1kGPnZehNAHFrHz8w5PeoZAU7ZFa1xCu3K9RVWSLcn1oAzZMMvr9azb1QGUDvXQCFFXa459axtXRVkUDFAH05+xMMSeMx/sWP/txXzz8VUZ/ir4xVASx1q84H/Xd6+iP2KeJvGf+5Yf+3FfPfxOme3+LXi+WPIK6ze/+j3oAn8LaRdSXarEdjMuXHriu6srySFI1lH70nG31+lZXgK9a6hf5Q1z2wK9v8NeDVS2e91JY3dhlI2A+WgB3g3TfMkhuPIQblBwB0r1mNFa0VEjCjGT71y/h5IrVvLUADpXYsrG1WOLk5B3Ac4oAq2UIJ5GApyBW/Yrgg5PSorK1ynzKMjvWiAAMAYAoAWiiikIKKKKACiiigAooooAKKKKACiiigArk/A6lde8dA9f7aj/9N9nXWVy3gv8A5GLx3n/oNR/+m+zoBHmn7Yn/ACTjRv8AsMx/+k9xXyVbIzONoNfaX7SnhPXPGHgrTbHw1YG+u4dTS4eMSxxkRiGZScuyjq68ZzzXgFp8F/H8bL5vhW4wOflvbTP/AKOpjPP40Y9ePx6VpQW07LiNGOfavR7f4U+NYwQ3hC8YHr/pln/8frVtPh34wtj8vg7UCP8Ar8sv/j9AHmUFpLEoLK3TmtPw/qM+l6nFd2gRpIzko/QivR28CeK2HzeDNS/8C7L/AOSKavw98Ru4EvgnU1jH9y7ssn/yYoA3fCfjyxVJJILAxTSkeZCvOW9QK9NsvEUlzaxvDbFTjlWFeTWng/xLZyK9r4L1ZGHGftVic/8AkxXZaa3ii2iCzeC9cYjri5sP/kmgDqZNbuVGHs8j/drPnn06/LZhaGc+2BTE1LXtpD+BtfOR/wA/Gn//ACTWdqker3qjb4G8QRuvQrc6f/8AJVAFPUtIlj3MrqVByD603TpBaTKSuXxyB1JpMeMlG1fB+slegDXNhx/5M0Q2viQ5M3gnW1c8lkubA8/jc0AT+NbONJbTUYh+7kTD46e9eLeNdKFjqDTRD/R5xkY6Cvc7h9fufDz6fP4I15pAcxv9o0/A+v8ApNcLq3hHxXqWlSWs3g3VfMBzG/2qx/X/AEigDw7JiusKD+NatrkkMx4rpZfhT4/ebePCd1j3vbP/AOPVKPhf8QRwPCl1j/r9s/8A49QBi7snj8xV2wudr7ZQGHoe1a9t8N/H0Z+fwleEf9ftn/8AHqnf4eeOy2V8IXo/7fLP/wCP0AVbq8R0CQ9O5z0q5YakBF5JPXvmli8A+PE3bvCN6c/9Pln/APH6f/wgPjoE48I33/gZZ/8Ax+gDRtpluJFCglE6jHWtgJG2yaA+UM4IPeszSvCfjS0iKyeD9SZj3F3Zf/H62INE8VwwFB4N1cknPN1Y8f8AkxQA3xI6WdhGY0d5iQwx0xWbFYpeBZJ22GRc47Cta90fxbewCObwdq/y9CLqx/8AkimQ6L4sSDafBerbxwCLuxxj/wACKAMm8mjs7XYWLlOmBXO61eG9j3chVGMCunufDPjOYtnwbqWDwP8AS7L/AOP1mXHgXxmw/deEdSB9Gu7L/wCP0Acxp2piJgCuO3NXtRvzcQqowABkVZb4c+ONxK+Eb7P/AF+Wf/x+mp8OvHoB3eE70+n+mWf/AMfoAxLeEyoT1O7tXoHw90uWO3mvipzMdkeR29RWPZeA/G0SKk3hHUNpPzFbyyzj2/f16XpEWt6fHYwDwPrxtrcDIFxp+Sf/AAJoA6nU3FhpllaLH8+wPJ9feudnfzASIs59BV7V77Wb+7Ev/CD+IgoAG03GnjOP+3qs2STxGoJtvA2tIx9bmwwP/JmgC3p1rb2ERur5VyTlUbgmlkvNQ1eXyrZTFbDgMOMe1Y6W/iWWdHvPBmuuOrYubA5+g+010kGqaxBGqReA/EAA/wCm+n8/+TVAEaaA0cZM88hPqDXP+J47e3tmVGkLgHjPWugvNV8QTKQngfXwfe40/wD+Sq5rUrPxNeZI8Fa1u97mw/8AkmgDyTxLBO6SbJJFJ+6D0FcFeW00Eh+0A5P8Q6Gva9R8HeL7mYung/VF+t3Zf/JFZVx8OfGFwrJL4S1Iqf8Ap6suP/JigDx90wuGxVKbCn2Fepn4R+NgxC+Fb9kz1a8swf8A0fVW4+DnjqQny/Ct4B73ln/8eoA8tmy4yO1YusoVkQ84r11/gr8RMnb4Vmx739p/8dqlqPwL+I9yyGPwvIAvUNfWv/x2gD0z9in/AF3jP/csP/bivDvHeivq/wAUfG/luQY9ZvTjHX9+/Svpj9l7wH4l8FS+J28UaWdPF4toIM3EUu/Z527/AFbNjG9euOtcZdfDLxhB4+8R6pH4Xurm3vNTuriKWK7tAHjeZ2Q4aYEZUjggGgDB+DPhY2rm6vEYTxKPLRxgMPU19CSwiWxBQKpXGK5eHTPEAMDyeCdbEkabTsuLDBP/AIE1rpL4jChG8E69tHf7TYZ/9KaANHTLPL7ycsT16V11suIAU5IGK4+31DXYVCr4H18j3uNP/wDkqtO21/V44wH8CeI92c8T6f8A/JVAHXW6ssfzYz7VJXK/8JPq/wD0IniT/v8A6d/8lUf8JPq//QieJP8Av/p3/wAlUhHVUVyv/CT6v/0IniT/AL/6d/8AJVH/AAk+r/8AQieJP+/+nf8AyVQB1VFcr/wk+r/9CJ4k/wC/+nf/ACVR/wAJPq//AEIniT/v/p3/AMlUAdVRXK/8JPq//QieJP8Av/p3/wAlUf8ACT6v/wBCJ4k/7/6d/wDJVAHVUVyv/CT6v/0IniT/AL/6d/8AJVH/AAk+r/8AQieJP+/+nf8AyVQB1VFcr/wk+r/9CJ4k/wC/+nf/ACVR/wAJPq//AEIniT/v/p3/AMlUAdVRXK/8JPq//QieJP8Av/p3/wAlUf8ACT6v/wBCJ4k/7/6d/wDJVAHVVy3gz/kYvHf/AGGo/wD03WdJ/wAJPq//AEIniT/v/p3/AMlUvgSDUPtfie/1LS7nTP7R1NbiCC5kieTy1tLaLJ8p3UZaJ+N2cUAdXRRRTGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior (A) and lateral (B) radiographs of a T12-L1 fracture-dislocation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Whang PW, Vaccaro AR. Fractures and dislocations of the thoracolumbar spine. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RB, (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26755=[""].join("\n");
var outline_f26_8_26755=null;
var title_f26_8_26756="Dermatosis papulosa PI";
var content_f26_8_26756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratosis on dark skin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    People with dark skin can have a type of seborrheic keratosis that causes black growths.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26756=[""].join("\n");
var outline_f26_8_26756=null;
var title_f26_8_26757="Ovine polyvalent crotalidae North and South American snake antivenom: Drug information";
var content_f26_8_26757=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ovine polyvalent crotalidae North and South American snake antivenom: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/16/39171?source=see_link\">",
"    see \"Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/24/19845?source=see_link\">",
"    see \"Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6516314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CroFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6516318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antivenin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6519231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Crotalid envenomation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Initial dose: 4-6 vials; treatment should begin as soon as possible and preferably within 6 hours of envenomation; monitor for 1 hour following the infusion. Some clinicians recommend an initial dose of 8-12 vials for patients who present with immediately life-threatening effects (eg, shock, serious active bleeding) (Lavonas, 2011). Repeat with an additional 4-6 vials if control is not achieved with the initial dose. Continue to treat with 4- to 6-vial doses until local manifestations, coagulation tests, and systemic signs are normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maintenance dose: Once control is achieved, administer 2 vials every 6 hours for up to 18 hours. Optimal dosing beyond 18 hours has not been established; however, treatment may be continued if deemed necessary based on the patient's condition.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6519230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/24/19845?source=see_link\">",
"      see \"Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"     <b>",
"      Note:",
"     </b>",
"     Clinical trials included patients as young as 11 years of age. Use has been reported to be both safe and effective in children as young as 1 year of age (Johnson, 2008; Schmidt, 2005; Seifert, 2009). Antivenom dosage is based on venom load and severity of symptoms and not on patient size; therefore, a reduced,weight-based antivenom dose in pediatric patients is",
"     <b>",
"      not",
"     </b>",
"     recommended (Behm, 2003; Offerman, 2002). Clinicians are encouraged to contact their local poison control center or clinical toxicologist for consultation when treating any envenomed patient, but especially pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6519232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6519242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CroFab&reg;: Derived from",
"     <i>",
"      Crotalus adamanteus, C. atrox, C. scutulatus",
"     </i>",
"     , and",
"     <i>",
"      Agkistrodon piscivorus",
"     </i>",
"     snake venoms [contains thimerosal; derived from or manufactured with papain]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6516316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6519233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. over 60 minutes at a rate of 25-50 mL/hour for the first 10 minutes. If no allergic reaction is observed, increase rate to 250 mL/hour. Monitor closely. Epinephrine and diphenhydramine should be available during the infusion. Decreasing the rate of infusion may help control some adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6516320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of patients with North American crotalid envenomations (eg, rattlesnakes [",
"     <i>",
"      Crotalus",
"     </i>",
"     ,",
"     <i>",
"      Sistrurus",
"     </i>",
"     ], copperheads, and cottonmouth/water moccasins [",
"     <i>",
"      Agkistrodon",
"     </i>",
"     ])",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6519436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not always defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Chills, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Anorexia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Asthma, cough, dyspnea, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reactions (5% to 19%), serum sickness (5%), anaphylaxis, anaphylactoid reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Angioedema, chest discomfort, dizziness, erythema, headache, hyperhidrosis, lip swelling, musculoskeletal chest pain, tachycardia, tachypnea, tongue swelling, tracheal edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6515398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation (including papaya or papain), unless the benefits outweigh the risks and appropriate management for anaphylaxis is readily available",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6515399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concern related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Derived from sheep plasma; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to sheep protein. Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available prior to administration. Incidence of acute hypersensitivity reactions may be lower than previously thought (Buchanan, 2009; Cannon, 2008; Lavonas, 2011). This product lacks the immunogenic Fc fragments and proteins found in the older equine-derived product. Sensitization may occur with repeated doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Processed with papain and may cause hypersensitivity reactions in patients allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross allergenicity with dust mite and latex allergens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Crotalid envenomation: Should be used within 4-6 hours of the envenomation to prevent clinical deterioration and the development of coagulation abnormalities. Coagulation abnormalities are due directly to snake venom interference with the coagulation cascade. Recurrent coagulopathy occurs in approximately 50% of patients and may persist for 1-2 weeks or more. Repeat dosing may be indicated (Miller, 2010; Ruha, 2011). Patients should be monitored for at least 1 week and evaluated for other pre-existing conditions associated with bleeding disorders. In severe envenomations, a decrease in platelets may occur, lasting hours to several days. Blood products are generally ineffective as they are rapidly consumed by circulating venom.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Product contains thimerosal with 0.03 mg of mercury per vial. Developing fetuses and young children may be at higher risk for mercury-related toxicities.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6519209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6516321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6516322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Products contain thimerosal which may be associated with mercury-related toxicities, including neurological and renal toxicities in the fetus and very young children.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6516323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6519235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; CBC, platelet count, prothrombin time, aPTT, fibrinogen levels, fibrin split products, clot retraction, bleeding and coagulation times, BUN, electrolytes, bilirubin; size of bite area (repeat every 15-30 minutes); intake and output; signs and symptoms of anaphylaxis/allergy. CBC, platelet counts, and clotting studies are evaluated at 6-hour intervals until patient is stable.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6519216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A venom-specific fragment of IgG, which binds and neutralizes venom toxin, helping to remove the toxin from the target tissue and eliminate it from the body.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6519218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Stability of patient or reduction in symptoms may be seen within 1 hour of administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Unbound Fab: 110 mL/kg (Seifert, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 12-23 hours (based on limited data)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Speculated to occur via reticuloendothelial system (Dart, 1997)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Behm MO and Kearns GL, \"Crotaline Fab Antivenom for Treatment of Children With Rattlesnake Envenomation,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(6 Pt 1):1458&ndash;9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/14654633/pubmed\" id=\"14654633\" target=\"_blank\">",
"        14654633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer LV, Seifert SA, and Cain JS, &ldquo;Recurrence Phenomena After Immunoglobulin Therapy for Snake Envenomations: Part 2. Guidelines for Clinical Management With Crotaline Fab Antivenom,\" Ann Emerg Med, 2001, 37(2):196-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/11174239/pubmed\" id=\"11174239\" target=\"_blank\">",
"        11174239",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Buchanan JA, Varney SM, Mlynarchek SL, et al, \"Immediate Adverse Events (AEs) After Administration of Crotalidae Polyvalent Immune Fab (Fav AV),\"",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2009, 47(7):703.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cannon R, Ruha AM, and Kashani J, \"Acute Hypersensitivity Reactions Associated With Administration of Crotalidae Polyvalent Immune Fab Antivenom,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2008, 51(4):407-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/18191286/pubmed\" id=\"18191286\" target=\"_blank\">",
"        18191286",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RF, Williams SR, Nordt SP, et al, \"Successful Treatment of Crotalid-Induced Neurotoxicity With a New Polyspecific Crotalid Fab Antivenom,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1997, 30(1):54-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/9209226/pubmed\" id=\"9209226\" target=\"_blank\">",
"        9209226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dart RC, Seifert SA, Carroll L, et al, \"Affinity-Purified, Mixed Monospecific Crotalid Antivenom Ovine Fab for the Treatment of Crotalid Venom Poisoning,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1997, 30(1):33-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/9209222/pubmed\" id=\"9209222\" target=\"_blank\">",
"        9209222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goto CS and Feng SY, \"Crotalidae Polyvalent Immune Fab for the Treatment of Pediatric Crotaline Envenomation,\"",
"      <i>",
"       Pediatr Emer Care",
"      </i>",
"      2009, 25(4):273-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/19369845/pubmed\" id=\"19369845\" target=\"_blank\">",
"        19369845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson PN, McGoodwin L, and Banner W Jr, \"Utilisation of Crotalidae Polyvalent Immune Fab (Ovine) for Viperidae Envenomations in Children,\"",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2008, 25(12):793-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/19033492/pubmed\" id=\"19033492\" target=\"_blank\">",
"        19033492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keating GM, \"Crotalidae Polyvalent Immune Fab: In Patients With North American Crotaline Envenomation,\"",
"      <i>",
"       BioDrugs",
"      </i>",
"      , 2011, 25(2):69-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/21443271/pubmed\" id=\"21443271\" target=\"_blank\">",
"        21443271",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavonas EJ, Kokko J, Schaeffer TH, et al, &ldquo;Short-Term Outcomes After Fab Antivenom Therapy for Severe Crotaline Snakebite,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2011, 579(2):128-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/20952098/pubmed\" id=\"20952098\" target=\"_blank\">",
"        20952098",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lavonas EJ, Ruha AM, Banner W, et al, \"Unified Treatment Algorithm for the Management of Crotaline Snakebite in the United States: Results of an Evidence-Informed Consensus Workshop,\"",
"      <i>",
"       BMC Emerg Med",
"      </i>",
"      , 2011, 11:2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/21291549/pubmed\" id=\"21291549\" target=\"_blank\">",
"        21291549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynch MJ, Ritter SC, and Cannon RD, \"Successful Treatment of South American Rattlesnake (",
"      <i>",
"       Crotalus durissus terrificus",
"      </i>",
"      ) Envenomation With Crotalidae Polyvalent Immune Fab (CroFab&trade;),\"",
"      <i>",
"       J Med Toxicol",
"      </i>",
"      , 2011, 7(1):44-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/20658221/pubmed\" id=\"20658221\" target=\"_blank\">",
"        20658221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller AD, Young MC, DeMott MC, et al, \"Recurrent Coagulopathy and Thrombocytopenia in Children Treated With Crotalidae Polyvalent Immune Fab: A Case Series,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2010, 26(8):576-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/20693856/pubmed\" id=\"20693856\" target=\"_blank\">",
"        20693856",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Offerman SR, Bush SP, Moynihan JA, et al, \"Crotaline Fab Antivenom for the Treatment of Children With Rattlesnake Envenomation,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2002, 110(5):968-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/12415038/pubmed\" id=\"12415038\" target=\"_blank\">",
"        12415038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quan AN, Quan D, and Curry SC, &ldquo;Improving Crotalidae Polyvalent Immune Fab Reconstitution Times,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 2010, 28(5):593-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/20579555/pubmed\" id=\"20579555\" target=\"_blank\">",
"        20579555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruha AM, Curry SC, Albrecht C, \"Late Hematologic Toxicity Following Treatment of Rattlesnake Envenomation With Crotalidae Polyvalent Immune Fab Antivenom,\"",
"      <i>",
"       Toxicon",
"      </i>",
"      , 2011, 57(1):53-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/20920516/pubmed\" id=\"20920516\" target=\"_blank\">",
"        20920516",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schmidt JM, \"Antivenom Therapy for Snakebites in Children: Is There Evidence?\"",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2005, 17(2):234-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/15800419/pubmed\" id=\"15800419\" target=\"_blank\">",
"        15800419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert SA and Boyer LV, \"Recurrence Phenomena After Immunoglobulin Therapy for Snake Envenomations: Part 1. Pharmacokinetics and Pharmacodynamics of Immunoglobulin Antivenoms and Related Antibodies,\"",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2001, 37(2):189-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/11174238/pubmed\" id=\"11174238\" target=\"_blank\">",
"        11174238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert SA, Boyer LV, Benson BE, et al, \"AAPCC Database Characterization of Native U.S. Venomous Snake Exposures, 2001-2005,\"",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2009, 47(4):327-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/19514880/pubmed\" id=\"19514880\" target=\"_blank\">",
"        19514880",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seifert SA, Boyer LV, Dart RC, et al, \"Relationship of Venom Effects to Venom Antigen and Antivenom Serum Concentrations in a Patient With",
"      <i>",
"       Crotalus atrox",
"      </i>",
"      Envenomation Treated With a Fab antivenom.",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      1997, 30(1):49-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/9209225/pubmed\" id=\"9209225\" target=\"_blank\">",
"        9209225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yin S, Kokko J, Lavonas E, et al, \"Factors Associated With Difficulty Achieving Initial Control With Crotalidae Polyvalent Immune Fab Antivenom in Snakebite Patients,\"",
"      <i>",
"       Acad Emerg Med",
"      </i>",
"      , 2011, 18(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/8/26757/abstract-text/21166732/pubmed\" id=\"21166732\" target=\"_blank\">",
"        21166732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10129 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26757=[""].join("\n");
var outline_f26_8_26757=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516314\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516318\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519231\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519230\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519232\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795911\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795912\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519242\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516316\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519233\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516320\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519436\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6515398\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6515399\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519209\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516322\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6516323\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519235\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519216\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6519218\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10129\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10129|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/16/39171?source=related_link\">",
"      Ovine polyvalent crotalidae North and South American snake antivenom: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/24/19845?source=related_link\">",
"      Ovine polyvalent crotalidae North and South American snake antivenom: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_8_26758="Arc welders lung PA";
var content_f26_8_26758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arc welder's lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows coarse reticular changes with preserved lung volumes in this patient with siderosis. Incidental note is made of an azygos fissure in the right upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26758=[""].join("\n");
var outline_f26_8_26758=null;
var title_f26_8_26759="Contraception for women with inherited thrombophilias";
var content_f26_8_26759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Contraception for women with inherited thrombophilias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Tanya Siddiqi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26759/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/8/26759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism (VTE), including deep vein thrombosis (DVT), pulmonary embolism, and cerebral vein thrombosis. Women with inherited thrombophilias are at higher risk of VTE, especially in settings such as during use of estrogen-progestin contraceptives or pregnancy (the risk of VTE is much higher in",
"    <span class=\"nowrap\">",
"     pregnancy/postpartum",
"    </span>",
"    than with use of an estrogen-progestin contraceptive [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/1\">",
"     1",
"    </a>",
"    ]). In making contraceptive choices, women need to balance the risk of VTE associated with use of effective contraception against the risk of VTE associated with an unintended pregnancy resulting from use of less effective contraceptive methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INHERITED THROMBOPHILIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor V Leiden (FVL) is the most common hereditary risk factor for VTE. In unselected Caucasian patients with an initial symptomatic episode of DVT, 12 to 20 percent will be heterozygous for the FVL mutation compared with approximately 6 percent of asymptomatic controls [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence of FVL heterozygosity in Caucasian American women is about 4.85 percent and is less frequent in Hispanic Americans (2.21 percent), Native Americans (1.25 percent), African Americans (1.23 percent), and Asian Americans (0.45 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prothrombin gene mutation (G20210A) is the second most common genetic risk factor for VTE: G20210A heterozygosity is identified in 6 percent of patients with VTE compared with 2 percent of asymptomatic controls; deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inherited thrombophilia is discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link\">",
"       \"Overview of the causes of venous thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link\">",
"       \"Activated protein C resistance and factor V Leiden\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=see_link\">",
"       \"Antithrombin (ATIII) deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link\">",
"       \"Protein C deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=see_link\">",
"       \"Protein S deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=see_link\">",
"       \"Prothrombin gene mutation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Homozygosity for methylenetetrahydrofolate reductase (MTHFR) polymorphisms (C677T, A1298C) is a relatively common cause of mildly elevated plasma homocysteine levels, but these mutations do not appear to increase the risk of VTE in pregnant or nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/5,6\">",
"     5,6",
"    </a>",
"    ] and therefore would not be expected to increase the risk of VTE in women using hormonal contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRACEPTIVE OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonhormonal methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonhormonal methods of contraception (eg, copper releasing intrauterine contraception [IUD], male or female condom, diaphragm) are safe and effective in women with inherited thrombophilias (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ), as these methods have no effect on hemostasis.",
"   </p>",
"   <p>",
"    Nonhormonal methods of contraception are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=see_link\">",
"     \"Male condoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5334?source=see_link\">",
"     \"Female condoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20070?source=see_link\">",
"     \"Barrier contraception: Diaphragm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Progestin-only methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with a thrombophilia or past history of VTE, the Centers for Disease Control and Prevention (CDC) classifies progestin-only methods as having advantages that outweigh theoretical or proven risks (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ). Progestin-only methods (progestin-only minipills [POPs] containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    , depot",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    [DMPA], a high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    -releasing IUD [Mirena or LNg20], progestin-only implant [Nexplanon]) are effective and most available data have not demonstrated a significantly increased risk of thrombosis in users. These data are limited by the relatively small number of thromboembolic events in women of reproductive age. The safety of progestogens is supported by three studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an international, multicenter, case-control study performed by the World Health Organization, current use of oral and injectable progestin-only contraceptives was associated with no or minimal increase in risk of cardiovascular disease (stroke, VTE, or myocardial infarction) compared to nonusers (adjusted OR: POPs 1.19, 95% CI 0.82-1.74; progestin-only injectable adjusted OR 1.02, 95% CI 0.68-1.54) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/7\">",
"       7",
"      </a>",
"      ]. When only risk of VTE was considered, the adjusted OR was higher but not statistically significant (POPs OR 1.82, 95% CI 0.79-4.22; progestin-only injectable OR 2.19, 95% CI 0.66-7.26).",
"     </li>",
"     <li>",
"      In a case-control study performed by the Boston Collaborative Drug Surveillance Program, women who used progestin-only methods of contraception (oral, injectable, implantable) were not at significantly increased risk of VTE compared to nonusers (RR 1.3, 95% CI 0.3-6.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a national cohort study including over 10 million Danish women of reproductive age, the risk of VTE was not significantly increased in women who used progesterone-only pills (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      or norethisterone POPs RR 0.59, 95% CI 0.33-1.03) or progesterone-releasing intrauterine devices (RR 0.90, 95% CI 0.64-1.26) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, emerging data indicate an increased risk of VTE associated with injectable progestins [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In a systematic review of cohort, case-control and randomized studies of women treated with progestin-only contraception (oral, injectable, intrauterine) versus a no-hormone control group, VTE risk was similar for women taking a progestin for contraception and those not using hormonal contraception (RR 1.03, 95% CI 0.76&ndash;1.39), whereas subgroup analysis suggested a higher risk of thrombotic events for women using an injectable progestin (RR 2.67, 95% CI 1.29&ndash;5.53), but not for those using progestin-only pills (RR 0.90, 95% CI 0.57&ndash;1.45) or a progestin-releasing intrauterine device (RR 0.61, 95% CI 0.24-1.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/11\">",
"     11",
"    </a>",
"    ]. A limitation of this analysis is that the patients on injectable progestin contraception may have higher baseline risks of VTE than those taking oral progestins.",
"   </p>",
"   <p>",
"    Given possible pro-thrombotic effects of injectable progestins and the availability of oral and intrauterine alternatives that have not been associated with increased thrombogenicity, the authors feel it is prudent to avoid injectable progestins for contraception in women with inherited thrombophilias. However, as discussed above, the CDC, and others, continue to consider progestin-only methods as having advantages that outweigh theoretical or proven risks (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Progestin-only contraceptive methods are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"     \"Progestin-only pills (minipills) for contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"     \"Depot medroxyprogesterone acetate for contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"     \"Overview of intrauterine contraception\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=see_link\">",
"     \"Etonogestrel contraceptive implant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Combined estrogen-progestin methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined estrogen-progestin contraceptive methods include combined oral contraceptive pills (COCs), the contraceptive transdermal patch, and the contraceptive vaginal ring. Most experts discourage use of combined estrogen-progestin methods in women with inherited thrombophilias because the relative risk of VTE in this population is increased.",
"   </p>",
"   <p>",
"    Observational studies have consistently reported a two- to seven-fold increased risk of VTE in users of COCs compared with nonusers; the absolute risk is about 1 in 3500 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/9,12-18\">",
"     9,12-18",
"    </a>",
"    ]. This risk is about 1.5-fold higher in women using third generation COCs compared with those using second generation COCs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/19\">",
"     19",
"    </a>",
"    ]. Risk clearly varies by type of progesterone and dose of estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/9,18\">",
"     9,18",
"    </a>",
"    ]. As an example, a population based case control study found that oral contraceptives with desogestrel, gestodene,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    , or drospirenone were associated with a significantly higher risk of venous thrombosis (odds ratios of 5.6 to 7.3 compared to nonusers) than oral contraceptives with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    (odds ratio 3.6 compared to nonusers) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/18\">",
"     18",
"    </a>",
"    ]. Another study compared VTE risk for COCs containing levonorgestrel with VTE risk for COCs containing other progestins but the same dose of estrogen and length of use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/9\">",
"     9",
"    </a>",
"    ]. Compared to levonorgestrel, VTE rate ratios for other progestins were: norethisterone 0.98, norgestimate 1.19, desogestrel 1.82, gestodene 1.86, drospirenone 1.64, and cyproterone 1.88 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H11#H11\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Venous thromboembolic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased risk of VTE associated with COCs is even higher in users with inherited thrombophilias, and highest in users with a combination of thrombophilic defects or homozygosity for the defect [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/13,20,21\">",
"     13,20,21",
"    </a>",
"    ]. As an example, in the Leiden Thrombophilia Study, the relative risks of first VTE in normal controls, COC users, FVL carriers, FVL carriers using COCs, and FVL homozygotes using COCs were approximately 1, 4, 7, 35, and 100, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of women on COCs will never experience a VTE, given the low incidence of VTE in healthy women of child-bearing potential. The baseline risk of VTE in this population has been reported in various studies to be as low as 1 per 10,000 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. The absolute risk of VTE in women of reproductive age without documented inherited thrombophilia reportedly increases to about 3 to 4 per 10,000 person-years during COC use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/14\">",
"     14",
"    </a>",
"    ]. However, these estimates may have been too low. A 2007 systematic review that included methodologically acceptable community and cohort studies estimated the most valid VTE incidence for young women to be about 5 to 10 per 10,000 women-years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/22\">",
"     22",
"    </a>",
"    ]. Given this high background incidence of VTE among young women, the additional VTE risk that can be attributable to COC use may be smaller than previously thought.",
"   </p>",
"   <p>",
"    In women with an inherited prothrombotic defect, VTE in the first year of COC use is 10-fold greater than in subsequent years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/16\">",
"     16",
"    </a>",
"    ]. Although data are conflicting, smoking may increase the risk of VTE and may potentially have a synergistic effect with oral contraceptive use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SHOULD WOMEN BE SCREENED FOR INHERITED THROMBOPHILIAS BEFORE INITIATING COMBINED HORMONAL CONTRACEPTIVES?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most experts do not suggest routine thrombophilia screening prior to starting COCs. An estimated 10 million American women are currently using COCs; approximately 5 percent of these women are likely to carry the Factor V Leiden (FVL) mutation. In young women, both the incidence of VTE with COC use (30 to 40 events per 100,000 person years) and the estimated mortality rate from VTE (3 in 1 million for COC users and 14 in 1 million in COC users with FVL mutation) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/23\">",
"     23",
"    </a>",
"    ] are so low that the number of women who would need to be screened for inherited thrombophilias to prevent one death is very large (more than 92,000 FVL carriers in one American study [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/23\">",
"     23",
"    </a>",
"    ]) and the cost of screening to prevent one death would be excessive (more than $300 million) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A family history of any VTE is a poor predictor of inherited thrombophilia; the positive predictive value ranges from 6 to 50 percent in published reports [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/27\">",
"     27",
"    </a>",
"    ]. It should not be used to select women for laboratory screening prior to initiating estrogen-progestin contraceptives due to the relatively low absolute risk of VTE among carriers of the common thrombophilias (ie, Factor V Leiden, prothrombin G20120A). However, we feel laboratory screening may be reasonable in women with a strong family history consistent with inherited thrombophilia, such as VTE in several relatives under the age of 50 years. Thus, it is important to thoroughly question the patient regarding her family's history of thrombotic events before prescribing COCs.",
"   </p>",
"   <p>",
"    Laboratory evaluation for prothrombic defects is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H23#H23\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Technical screening issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     USE OF COMBINED HORMONAL CONTRACEPTION BY WOMEN WHO HAVE OR MAY HAVE A THROMBOPHILIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Personal history of venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of estrogen containing contraceptives is contraindicated in all women who have had prior venous thrombosis or thromboembolism (VTE) because of the high risk of recurrence. This applies to both provoked and unprovoked VTE, but the risk of recurrence is higher if the episode was unprovoked. However, women with this history, but on chronic anticoagulation, may use COCs.",
"   </p>",
"   <p>",
"    In special circumstances, such as severe, refractory endometriosis where no satisfactory therapeutic alternative exists, combined hormonal contraceptives may be used if oral anticoagulant therapy is also administered. Anticoagulation should be closely monitored to ensure the International Normalized Ratio (INR) is in the desired range (goal range 2 to 3). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Familial, but no personal, history of VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strong family history of VTE in a first degree relative (\"strong\" refers to life-threatening events or unprovoked events at young ages [less than 50 years of age]) could indicate the presence of an inherited thrombophilia in the patient's pedigree. Ideally, the woman will be able to find out if her clinically affected relative has a hereditary thrombophilic defect.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If such a defect has been documented, we suggest screening the woman for this defect; combined hormonal contraception is contraindicated if she also carries the defect, but is acceptable if she does not carry the defect. If the clinically affected family members have not been tested for inherited thrombophilia, ideally, they should be tested. If this is not possible, and the family history of VTE is strong, the woman may benefit from screening.",
"     </li>",
"     <li>",
"      If the family member has been tested, but there is no evidence of inherited thrombophilia, this individual may have an as yet unidentified prothrombotic condition that places",
"      <span class=\"nowrap\">",
"       him/her",
"      </span>",
"      at a higher risk for a first VTE event. Patients with this family history may choose to use combined hormonal contraception after appropriate counseling regarding the risks and benefits of these contraceptives.",
"      <br/>",
"      <br/>",
"      If estrogen-progestin contraceptives are used, we suggest use of a low estrogen dose (10 to 35 mcg of ethinyl estradiol) pill. Decreasing ethinyl estradiol from 35 mcg to 20 or 10 mcg theoretically should be associated with fewer thromboembolic events, but this had not been proven. We also suggest that the progestin component be",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      , or ethynodiol diacetate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     No personal or family history of VTE, but positive testing for inherited thrombophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic carriers of inherited thrombophilias are identified as a result of overzealous screening for inherited prothrombotic states. These women have an increased relative risk of VTE, although the absolute annual risk of VTE is quite low. We discourage use of combined hormonal contraception in such women, but patients may choose to use these drugs after appropriate counseling regarding their risks and benefits. As an example, we inform women heterozygous for factor V Leiden that they would have a 0.35 percent per year increase in their risk of VTE if they use combined hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26759/abstract/3\">",
"     3",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H6\">",
"     'Combined estrogen-progestin methods'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inherited thrombophilia is a genetic tendency to venous thromboembolism. Use of estrogen containing contraceptives increases this risk. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Combined estrogen-progestin methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not suggest routine screening of all women for inherited thrombophilia prior to starting combined estrogen-progestin contraceptive methods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Screening is reasonable in populations at increased risk of having an inherited thrombophilia because of a personal or strong family history of venous thromboembolism. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Should women be screened for inherited thrombophilias before initiating combined hormonal contraceptives?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women at high risk of venous thromboembolism, we suggest use of nonhormonal or progestin-only contraceptive methods rather than estrogen-progestin methods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Women at high risk include (1) women with a personal history of venous thrombosis or (2) women who test positive for one or more prothrombotic defects AND have a positive family history of venous thrombosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraceptive options'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Use of combined hormonal contraception by women who have or may have a thrombophilia'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Given possible prothrombotic effects of injectable progestins and the availability of oral and intrauterine alternatives that have not been associated with increased thrombogenicity, we suggest avoiding injectable progestins for contraception in women with inherited thrombophilias (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Progestin-only methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carriers of inherited thrombophilias who have a negative personal and family history of venous thrombosis are at increased risk of venous thrombosis, but the absolute annual risk is quite low. We suggest such women avoid use of combined estrogen-progestin contraceptives (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, women who place a higher value on the effectiveness and convenience of these contraceptives than on the low risk of venous thrombosis may choose to use these drugs. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'No personal or family history of VTE, but positive testing for inherited thrombophilia'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If estrogen-progestin contraceptives are used, we suggest use of a low estrogen dose (10 to 35 mcg of ethinyl estradiol) pill. Decreasing the ethinyl estradiol from 35 mcg to 20 or 10 mcg theoretically should be associated with fewer thromboembolic events, but this had not been proven. We also suggest that the progestin component be",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      , or ethynodiol diacetate.",
"     </li>",
"     <li>",
"      For women with a strong family history of venous thrombosis, but the affected family member has no evidence of inherited thrombophilia, we suggest avoiding combined estrogen-progestin contraception, given an as yet unidentified prothrombotic condition may be present (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, women who place a higher value on the effectiveness and convenience of these contraceptives than on the uncertain risk of venous thrombosis may choose to use these drugs. We suggest they use a low estrogen pill with a progestin component of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone acetate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      , or ethynodiol diacetate. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Familial, but no personal, history of VTE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/1\">",
"      van Vlijmen EF, Veeger NJ, Middeldorp S, et al. Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood 2011; 118:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/2\">",
"      Bauer KA. The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/3\">",
"      Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/4\">",
"      Mohllajee AP, Curtis KM, Martins SL, Peterson HB. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review. Contraception 2006; 73:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/5\">",
"      Domagala TB, Adamek L, Nizankowska E, et al. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002; 13:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/6\">",
"      McColl MD, Ellison J, Reid F, et al. Prothrombin 20210 G--&gt;A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. BJOG 2000; 107:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/7\">",
"      Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/8\">",
"      Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/9\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339:b2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/10\">",
"      van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/11\">",
"      Mantha S, Karp R, Raghavan V, et al. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345:e4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/12\">",
"      Dugdale M, Masi AT. Hormonal contraception and thromboembolic disease: effects of the oral contraceptives on hemostatic mechanisms. A review of the literature. J Chronic Dis 1971; 23:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/13\">",
"      Vandenbroucke JP, Koster T, Bri&euml;t E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/14\">",
"      Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/15\">",
"      Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/16\">",
"      Cosmi B, Legnani C, Bernardi F, et al. Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med 2003; 163:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/17\">",
"      Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/18\">",
"      van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009; 339:b2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/19\">",
"      Spitzer WO, Lewis MA, Heinemann LA, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 1996; 312:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/20\">",
"      Konkle BA. Counseling of women with thrombophilia. Thromb Res 2005; 115 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/21\">",
"      van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/22\">",
"      Heinemann LA, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception 2007; 75:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/23\">",
"      Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/24\">",
"      Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/25\">",
"      Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/26\">",
"      Wu O, Greer IA. Is screening for thrombophilia cost-effective? Curr Opin Hematol 2007; 14:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26759/abstract/27\">",
"      Grimes DA, Stuart GS, Levi EE. Screening women for oral contraception: can family history identify inherited thrombophilias? Obstet Gynecol 2012; 120:889.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5479 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26759=[""].join("\n");
var outline_f26_8_26759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INHERITED THROMBOPHILIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRACEPTIVE OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonhormonal methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Progestin-only methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Combined estrogen-progestin methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SHOULD WOMEN BE SCREENED FOR INHERITED THROMBOPHILIAS BEFORE INITIATING COMBINED HORMONAL CONTRACEPTIVES?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      USE OF COMBINED HORMONAL CONTRACEPTION BY WOMEN WHO HAVE OR MAY HAVE A THROMBOPHILIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Personal history of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Familial, but no personal, history of VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      No personal or family history of VTE, but positive testing for inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 1\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20070?source=related_link\">",
"      Barrier contraception: Diaphragm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5334?source=related_link\">",
"      Female condoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=related_link\">",
"      Male condoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=related_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/55/13176?source=related_link\">",
"      Protein S deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20743?source=related_link\">",
"      Prothrombin gene mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_8_26760="Intermittent explosive disorder in adults: Treatment and prognosis";
var content_f26_8_26760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intermittent explosive disorder in adults: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26760/contributors\">",
"     Emil Coccaro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26760/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26760/contributors\">",
"     Susan McElroy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26760/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/8/26760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H23115140\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent explosive disorder is characterized by recurrent, impulsive aggressive behavior that is unplanned and grossly exceeds the response that is justified by the precipitant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The disorder is distinguished from premeditated (predatory) aggression as well as defensive aggression provoked by an immediate threat [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the treatment and prognosis of intermittent explosive disorder. The epidemiology, pathogenesis, clinical features, assessment, and diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15049?source=see_link\">",
"     \"Intermittent explosive disorder in adults: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87218172\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent explosive disorder is one of several impulse control disorders that are marked by an inability to resist a drive or temptation that is harmful to the patient or others [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Patients with intermittent explosive disorder are periodically unable to restrain aggressive impulses and thus repeatedly assault others or destroy property [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis of intermittent explosive disorder is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef65924 \" href=\"UTD.htm?42/28/43467\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/1\">",
"     1",
"    </a>",
"    ]. The essential criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recurrent episodes of physically assaulting others, verbal outbursts, heated arguments, verbal threats to assault others, and destroying property",
"     </li>",
"     <li>",
"      Aggressive behavior is impulsive (unplanned)",
"     </li>",
"     <li>",
"      Aggressive behavior is grossly out of proportion to the provocation",
"     </li>",
"     <li>",
"      Marked subjective distress or psychosocial impairment",
"     </li>",
"     <li>",
"      Aggression is not better accounted for by another disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intermittent explosive disorder is not diagnosed if the impulsive, aggressive behavior occurs only in the context of a different, active psychiatric disorder (eg, schizophrenia, schizoaffective disorder, unipolar major depressive disorder, bipolar disorder, substance intoxication,",
"    <span class=\"nowrap\">",
"     attention-deficit/hyperactivity",
"    </span>",
"    disorder, or autistic disorder) or a general medical disorder (eg, dementia, delirium, or temporal lobe epilepsy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/1\">",
"     1",
"    </a>",
"    ]. The exception is that intermittent explosive disorder is diagnosed if the impulsive aggressive behavior occurs in the context of personality disorders (eg, borderline personality disorder and antisocial personality disorder).",
"   </p>",
"   <p>",
"    The diagnostic criteria for intermittent explosive disorder and its clinical features are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15049?source=see_link\">",
"     \"Intermittent explosive disorder in adults: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23114327\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172988312\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent explosive disorder can be treated by a variety of clinicians. The disorder is usually treated with pharmacotherapy by a psychiatrist, internist, or nurse practitioner. If cognitive-behavioral therapy (CBT) is used in addition to or instead of pharmacotherapy, a psychologist generally provides the psychotherapy. However, psychiatrists, internists, and nurse practitioners can provide all of the treatment if they are trained to administer CBT; treatment by a single clinician is often preferable because it allows for a better understanding of the patient and more consistent care. Patients who are either resistant or refractory to treatment are typically referred to a psychiatrist.",
"   </p>",
"   <p>",
"    The goal of treatment for intermittent explosive disorder is remission, which is defined as resolution of symptoms or improvement to the point that only one or two symptoms of mild intensity persist. For patients who do not achieve remission, a reasonable goal is response, ie, stabilizing the safety of the patient and others, as well as substantial improvement in the number, intensity, and frequency of symptoms. Response can be quantified (eg, improvement from baseline &ge; 50 percent) with standardized rating scales such as the clinician-administered Overt Aggression Scale-Modified [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/5\">",
"     5",
"    </a>",
"    ], but this is not standard clinical practice.",
"   </p>",
"   <p>",
"    Patients with intermittent explosive disorder should be advised to avoid intoxication with alcohol and other substances. Epidemiologic studies suggest that substance use disorders significantly increase the risk of violent behavior in schizophrenia, bipolar disorder, and major depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, a laboratory study with 56 healthy men found that alcohol intoxication significantly increased aggressive behavior, especially at lower levels of provocation, when most individuals are inclined to behave non-aggressively [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172988769\">",
"    <span class=\"h2\">",
"     Acute treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that clinicians treat intermittent explosive disorder with pharmacotherapy plus cognitive-behavioral therapy (CBT), based upon randomized clinical trials that have demonstrated the limited benefit of each treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. However, no head-to-head trials have compared CBT plus pharmacotherapy with pharmacotherapy alone or CBT alone. In addition, no trials have compared pharmacotherapy alone with CBT alone. Thus, it is reasonable to use either treatment alone based upon treatment availability, patient preference, prior response, and cost.",
"   </p>",
"   <p>",
"    CBT teaches patients to anticipate and better manage aversive environmental stimuli and may thus prevent aggressive impulses. Medications may increase the threshold at which an aggressive impulse triggers an explosive outburst.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2535417\">",
"    <span class=\"h3\">",
"     Monitoring outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of treatment outcome in patients with intermittent explosive disorder generally ranges from daily to monthly, depending upon the severity of persistent symptoms. Hospitalized patients are monitored daily. Outpatients are commonly seen on a weekly basis until they have responded (ie, the safety of the patient and others has stabilized and the number, intensity, and frequency of symptoms has improved substantially) for two to four weeks. At that point the patient can be seen every two to four weeks until they remit. Patients who subsequently deteriorate may need to resume a more frequent schedule of visits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23115154\">",
"    <span class=\"h3\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several medications have demonstrated efficacy for treating impulsive aggressive behavior in patients with intermittent explosive disorder or other psychiatric disorders (eg, borderline personality disorder).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23115147\">",
"    <span class=\"h4\">",
"     First-line",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest selective serotonin reuptake inhibitors (SSRIs) as first line pharmacotherapy for intermittent explosive disorder because of their demonstrated efficacy, tolerability, and ease of use.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     Fluoxetine",
"    </a>",
"    has been studied most often and is thus preferred. However, other SSRIs are reasonable alternatives. Based upon the duration of treatment in most randomized trials, we suggest 6 to 12 weeks of treatment (beginning from day one) before determining whether the drug is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ]. Clinicians can expect that approximately 66 percent of patients will respond [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    is 20 mg taken once daily. For patients who do not respond within two to four weeks, the dose is increased by 10 to 20 mg per day, depending on how well the medication is tolerated. Patients who remain unresponsive to treatment should receive additional increases of 10 to 20 mg per day every two to four weeks as tolerated, to an effective dose. The maximum dose is 60 mg per day. The dose schedule for other SSRIs and the adverse side effects of SSRIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=see_link\">",
"     \"Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for treating intermittent explosive disorder with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    includes a 12-week randomized trial that compared fluoxetine with placebo in 100 patients with intermittent explosive disorder plus a personality disorder (primarily obsessive-compulsive, paranoid, or borderline) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. Moderate to large improvement occurred in significantly more patients who received fluoxetine than placebo (66 versus 29 percent). Side effects that occurred significantly more often with fluoxetine included sexual dysfunction, sleep disturbance, nausea, vomiting, and restlessness.",
"   </p>",
"   <p>",
"    Other studies indirectly support using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    to treat intermittent explosive disorder. A meta-analysis of an unspecified number of randomized trials (3992 patients treated for a variety of psychiatric disorders) found that impulsive aggressive behavior occurred in significantly fewer patients who received fluoxetine than placebo (0.2 versus 0.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, other randomized trials have found that fluoxetine reduces impulsive aggressive behavior in borderline personality disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/13\">",
"     13",
"    </a>",
"    ] and alcoholic perpetrators of domestic violence [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23115162\">",
"    <span class=\"h4\">",
"     Resistant patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intermittent explosive disorder often do not respond to an SSRI within 6 to 12 weeks of starting the drug. For these resistant patients, we suggest tapering and discontinuing the SSRI over one to two weeks at the same time that another medication is started and titrated up. (Response is defined as stabilizing the safety of the patient and others, as well as substantial improvement in the number, intensity, and frequency of symptoms.) The SSRI is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    40 mg per day is decreased by 10 mg per day, every one to two days.",
"   </p>",
"   <p>",
"    We suggest using the following drugs in sequence for resistant intermittent explosive disorder rather than trying a second SSRI, because of the demonstrated efficacy of the drugs listed below and the lack of evidence that a second SSRI is effective in patients resistant to an initial SSRI trial. The following drugs are listed in order of preference, based upon how often each drug has been studied and how well it worked [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/15\">",
"     15",
"    </a>",
"    ]. We suggest 6 to 12 weeks of treatment (beginning from day one) before determining whether the drug is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ]. The proportion of patients who respond to any specific drug may be as high as approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      &ndash; The initial dose of phenytoin is 100 mg three times per day or 200 mg in the morning and 100 mg in the evening [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/17,18\">",
"       17,18",
"      </a>",
"      ], depending upon tolerability and problems with adherence. A 12-hour serum trough level should be checked two weeks after the first dose, and one week after any dose change. Although there are no data correlating serum levels with efficacy in reducing impulsive aggression, toxicity can be prevented by maintaining the serum concentration &le; 20",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      Most studies have maintained the drug at 300 mg per day, but patients who do not respond after two to three weeks may benefit from increasing the dose by 30 mg per day each week to 400 mg per day. The pharmacology of phenytoin (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H4#H4\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Phenytoin'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence of efficacy for treating impulsive aggressive behavior with phenytoin includes a systematic review of seven randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/19\">",
"       19",
"      </a>",
"      ] and a pooled analysis of three trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/9\">",
"       9",
"      </a>",
"      ], which both found that symptoms decreased significantly more with phenytoin than placebo. As an example, a six-week trial compared phenytoin with placebo in 29 patients with intermittent explosive disorder, and found that the mean number of explosive outbursts per week was significantly fewer with phenytoin (0.6 versus 1.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       Oxcarbazepine",
"      </a>",
"      <strong>",
"       (or",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      <strong>",
"       )",
"      </strong>",
"      &ndash; Oxcarbazepine and carbamazepine have a similar chemical structure, probably have a similar mechanism of action, and are generally regarded as comparable in efficacy for treating impulsive aggressive behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/9\">",
"       9",
"      </a>",
"      ]. Oxcarbazepine is generally preferred because it usually causes fewer side effects and drug-drug interactions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/16\">",
"       16",
"      </a>",
"      ]. However, carbamazepine may be less expensive and is a reasonable alternative.",
"      <br/>",
"      <br/>",
"      The initial dose of oxcarbazepine is 150 or 300 mg per day. The dose is increased every two to four days by 150 to 300 mg per day, taken in two divided doses, to a target dose of 1200 to 2400 mg per day as tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/16\">",
"       16",
"      </a>",
"      ]. The pharmacology of oxcarbazepine (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H6#H6\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Oxcarbazepine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Carbamazepine is usually started at a dose of 200 mg per day in two divided doses. The dose is increased every five days by 200 mg per day to a target dose of 800 to 1800 mg per day as tolerated. Although there are no data correlating serum levels with efficacy in reducing impulsive aggression, toxicity may be prevented by maintaining the serum concentration &le; 10 to 12",
"      <span class=\"nowrap\">",
"       mcg/mL;",
"      </span>",
"      extended release formulations can provide more stable serum levels.",
"      <br/>",
"      <br/>",
"      Carbamazepine often induces hepatic enzymes and the metabolism of concomitant drugs. Specific interactions of carbamazepine with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions. The pharmacology of carbamazepine (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence of efficacy for treating impulsive aggressive behavior with oxcarbazepine or carbamazepine includes a systematic review of four randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/19\">",
"       19",
"      </a>",
"      ] and a pooled analysis of two trials [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/9\">",
"       9",
"      </a>",
"      ], which both found that symptoms decreased significantly more with either drug than placebo. As an example, a 10-week randomized trial that compared oxcarbazepine with placebo in 45 patients with intermittent explosive disorder found that response occurred in significantly more patients who received oxcarbazepine (62 versus 25 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For resistant patients with intermittent explosive disorder who do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    within 6 to 12 weeks of starting the drug, or do not tolerate the drug, we suggest tapering and discontinuing it over one to two weeks at the same time that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) is started and titrated up. Phenytoin is generally tapered by 50 to 100 mg per day, every two to three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99464254\">",
"    <span class=\"h4\">",
"     Refractory patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;After not responding to an SSRI and to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , patients with intermittent explosive disorder often do not respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    within 6 to 12 weeks of starting the drug. For these refractory patients, we suggest tapering and discontinuing oxcarbazepine over one to two weeks at the same time that another medication is started and titrated up. (Response is defined as stabilizing the safety of the patient and others, as well as substantial improvement in the number, intensity, and frequency of symptoms.) Oxcarbazepine is generally tapered by 300 to 600 mg per day, every two to three days.",
"   </p>",
"   <p>",
"    We suggest using the following drugs in sequence for refractory intermittent explosive disorder; the drugs are listed in order of preference, based upon how often each drug has been studied and how well it worked [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/15\">",
"     15",
"    </a>",
"    ]. We suggest 6 to 12 weeks of treatment (beginning from day one) before determining whether the drug is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ]. In our clinical experience, approximately 25 to 50 percent of refractory patients respond to one of these third-line medications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      &ndash; The initial dose of lamotrigine is 25 mg per day for weeks one and two. For weeks three and four, the dose is increased to 50 mg per day, taken in two divided doses (an extended release formulation is available for once a day dosing). The dose can then be titrated up by 25 to 50 mg per day, one week at a time for each increase. This slow titration reduces the risk of life-threatening skin rash. The target dose ranges from 50 to 200 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/20\">",
"       20",
"      </a>",
"      ]. The pharmacology of lamotrigine (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence of efficacy includes an eight-week randomized trial that compared lamotrigine and placebo in 27 patients with borderline personality disorder, and found that impulsive aggression improved significantly more with lamotrigine [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      &ndash; The initial dose of topiramate is 50 mg per day, taken in two divided doses. The dose is increased by 50 mg per day every week, to a target dose of 200 to 300 mg per day as tolerated [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The pharmacology of topiramate (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H21#H21\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Topiramate'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of treating impulsive aggressive includes two randomized trials that compared topiramate with placebo for eight weeks in patients with borderline personality disorder (N = 42 and 29) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. Both trials found that impulsive aggression decreased significantly more with topiramate.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"       Valproate",
"      </a>",
"      <strong>",
"       (divalproex)",
"      </strong>",
"      &ndash; The initial dose of valproate is 250 mg twice daily, which is increased by 250 mg per day every 3 to 7 days as tolerated, to an effective dose [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/23\">",
"       23",
"      </a>",
"      ]. The maximum dose is 30",
"      <span class=\"nowrap\">",
"       mg/kg/day.",
"      </span>",
"      Although there are no data correlating serum levels with efficacy in reducing impulsive aggression, some authorities aim for a 12-hour serum trough level of 80 to 120",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      to maximize efficacy and minimize toxicity. The pharmacology of valproate (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H19#H19\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Valproate'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence for the efficacy of treating impulsive aggression with valproate is mixed. The largest randomized trial compared valproate with placebo for 12 weeks in 116 patients with intermittent explosive disorder and found no benefit for valproate [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/23\">",
"       23",
"      </a>",
"      ]. However, other trials suggest that valproate may reduce impulsive aggressive behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/15,19\">",
"       15,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"      &ndash; The starting dose of lithium is usually 300 mg two or three times daily. The dose should be increased by 300 to 600 mg every one to five days as tolerated. The goal is to reach a therapeutic serum level, which generally occurs with a dose of 900 mg to 1800 mg per day. The target serum level is between 0.8 and 1.2",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and levels should usually not exceed 1.2",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Patients who cannot tolerate a level of 0.8",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      may respond to a level of 0.6",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      The pharmacology of lithium (including adverse side effects) is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=see_link&amp;anchor=H182696749#H182696749\">",
"       \"Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects\", section on 'Prescribing lithium'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Evidence of efficacy includes a 12-week randomized trial that compared lithium with placebo in 59 prisoners with chronic impulsive aggressive behavior, and found that aggression decreased significantly more with lithium [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For refractory patients with intermittent explosive disorder who do not respond to one third-line drug within 6 to 12 weeks of starting the drug, or do not tolerate the drug, we suggest tapering and discontinuing the failed medication over one to two weeks at the same time that another third-line medication is started and titrated up. The failed medication is generally tapered by the same amount for each dose decrease. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    200 mg per day is decreased by 50 mg per day, every two to three days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2535510\">",
"    <span class=\"h3\">",
"     Cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impulsive aggressive behavior can be reduced with cognitive-behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/10\">",
"     10",
"    </a>",
"    ]. CBT teaches patients how to manage aversive stimuli in the day-to-day environment, and may thus prevent aggressive impulses that can trigger explosive outbursts. Efficacious anger management interventions for patients with disorders other than intermittent explosive disorder typically make use of CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific techniques used in CBT include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cognitive restructuring (ie, modifying faulty assumptions and dysfunctional thoughts about frustrating situations and perceived threats; the patient is encouraged to examine the validity of the assumptions and thoughts in light of all the available evidence)",
"     </li>",
"     <li>",
"      Relaxation training (eg, deep breathing as well as progressive muscle relaxation that consists of tensing and relaxing different muscle groups while imagining situations that provoke anger)",
"     </li>",
"     <li>",
"      Coping skills training (eg, role playing potentially provocative situations and rehearsing responses such as walking away)",
"     </li>",
"     <li>",
"      Relapse prevention (educating patients that recurrence of impulsive aggressive behavior is common and should be viewed as a lapse or &ldquo;slip&rdquo; rather than failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CBT works best for highly motivated patients who value a problem-solving approach to their illness. Conversely, CBT is contraindicated for patients who cannot learn the specific techniques that are taught (eg, patients with moderate to severe cognitive deficits) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBT can be administered in either a group or individual format. Patients typically receive 8 to 16 sessions of therapy, but some treatment plans may call for 20; each session lasts approximately 60 minutes. The skills taught in therapy are practiced in between sessions.",
"   </p>",
"   <p>",
"    Evidence of efficacy includes a 12-week randomized trial that compared group CBT, individual CBT, and a wait-list control condition in 45 patients with intermittent explosive disorder who were not receiving pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/26\">",
"     26",
"    </a>",
"    ]. A clinically large and statistically significant reduction of impulsive aggressive behavior occurred in patients who received CBT compared with the control group; only minor differences were observed between group and individual CBT. In addition, treatment effects persisted at the three-month follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H218296\">",
"    <span class=\"h4\">",
"     Nonresponse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our clinical experience is that CBT should be reconsidered for patients who make little progress after four to eight sessions, depending upon the total number of sessions called for in the initial treatment plan. Motivation should be reassessed and the use of pharmacotherapy discussed if a medication has not been prescribed. CBT should be terminated for patients who do not engage in treatment (eg, skip appointments without calling ahead or make no effort to complete homework) despite repeated efforts upon the part of the clinician. Patients who terminate treatment should be allowed to return when they are ready to actively participate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23115231\">",
"    <span class=\"h2\">",
"     Maintenance pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest maintenance pharmacotherapy for intermittent explosive disorder using the same medication and dose that induced remission. Based upon our clinical experience, the risk for recurrence of impulsive aggressive outbursts generally persists for months to years. However, there is little high quality evidence to guide decisions about maintenance treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1960049\">",
"    <span class=\"h3\">",
"     Adverse side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance pharmacotherapy for intermittent explosive disorder may cause side effects (eg, sexual dysfunction due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ) that necessitate lowering drug doses within the target dose range. Side effects and target dose ranges are discussed separately. (See",
"    <a class=\"local\" href=\"#H23115154\">",
"     'Pharmacotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with intermittent explosive disorder who cannot tolerate maintenance pharmacotherapy with the minimum target dose of the drug that induced remission, we suggest switching to another drug. The failed medication is tapered and discontinued over one to two weeks by the same amount for each dose decrease. (As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    40 mg per day is decreased by 10 mg per day, every one to two days.) At the same time, the new drug is started and titrated up. The choice of the new drug depends upon which medications, if any, were unsuccessful during acute treatment. Medication options, doses, and side effects are discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H23115162\">",
"     'Resistant patients'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H99464254\">",
"     'Refractory patients'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172988821\">",
"    <span class=\"h3\">",
"     Monitoring the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have remitted from intermittent explosive disorder should be interviewed regularly and monitored for recurrence of symptoms as well as medication side effects. Particular attention is given to explosive outbursts, including physical assaults, verbal threats of interpersonal violence, and destruction of property. Symptoms of intermittent explosive disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15049?source=see_link&amp;anchor=H3220792#H3220792\">",
"     \"Intermittent explosive disorder in adults: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring can be tapered for patients who remit and remain stable, with progressively longer intervals between assessments. As an example, a patient who is seen every two weeks at the time of remission can be seen every two weeks for one or two more visits, then every month for one to three visits, and then every two months for one to three visits. Continuously stable patients can ultimately be seen every three to six months. More frequent visits should be scheduled for patients who develop symptoms or side effects; monitoring acutely ill patients is discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H2535417\">",
"     'Monitoring outcome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172988947\">",
"    <span class=\"h3\">",
"     Duration and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon clinical experience, we suggest that patients who remit from intermittent explosive disorder receive maintenance pharmacotherapy for at least two years. However, the duration is not established, and some patients require treatment for many years. The duration depends upon clinical factors and is generally longer in patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Residual symptoms, particularly aggressive impulses and chronic anger",
"     </li>",
"     <li>",
"      Ongoing comorbid psychopathology",
"     </li>",
"     <li>",
"      Psychosocial impairment or stressors",
"     </li>",
"     <li>",
"      A history of suicide attempts or nonsuicidal self-injurious behavior",
"     </li>",
"     <li>",
"      A greater number of prior explosive outbursts (eg, &ge; 30 physical or verbal outbursts)",
"     </li>",
"     <li>",
"      Duration of illness for several years (eg, &ge; 5 years)",
"     </li>",
"     <li>",
"      A history of more severe impulsive aggressive behavior (eg, physical assaults that lead to hospitalization)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the decision is made to discontinue maintenance pharmacotherapy for intermittent explosive disorder, we suggest slowly tapering the medication over one month to increase the probability of detecting incipient symptoms (eg, subthreshold incidents in which patients briefly scream) before full-blown explosive outbursts recur. Based upon clinical experience, we decrease the dose each week by approximately 25 percent of the dose used during maintenance treatment. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    40 mg per day is reduced by 10 mg per day each week until it is discontinued.",
"   </p>",
"   <p>",
"    If symptoms recur during the taper, the dose should be titrated back up to the full dose used initially to achieve remission. If full-blown explosive outbursts develop despite increasing the dose, and the safety of the patient and others does not stabilize and the number, intensity, and frequency of symptoms do not substantially improve within 6 to 12 weeks of increasing the dose, the recurrence is treated as a new acute episode. Acute treatment is discussed elsewhere in the topic. (See",
"    <a class=\"local\" href=\"#H172988769\">",
"     'Acute treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172824559\">",
"    <span class=\"h3\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent symptoms during maintenance pharmacotherapy for intermittent explosive disorder are initially treated by optimizing medication doses. For medications that do not have a suggested therapeutic serum concentration, such as selective serotonin reuptake inhibitors (SSRIs),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , the dose should be increased within the target dose range as tolerated. For medications that have a suggested therapeutic serum concentration, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , clinicians should ensure serum concentrations are in the therapeutic range, and increase the dose to achieve a higher serum level within the therapeutic range, provided that side effects do not intervene.",
"   </p>",
"   <p>",
"    If impulsive aggressive behavior recurs during maintenance pharmacotherapy and optimizing the dose does not control symptoms within 6 to 12 weeks, the recurrence is treated as a new acute episode. (See",
"    <a class=\"local\" href=\"#H172988769\">",
"     'Acute treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with intermittent explosive disorder who decide to stop maintenance pharmacotherapy and successfully taper and discontinue their medication, but subsequently relapse, we suggest restarting the same medication that was discontinued. The relapse is treated as a new acute episode. (See",
"    <a class=\"local\" href=\"#H172988769\">",
"     'Acute treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23114334\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prospective follow-up studies of intermittent explosive disorder have not been conducted. However, a retrospective study of 463 patients found that the mean duration of the disorder was 12 years and the mean number of lifetime impulsive aggressive outbursts was 56 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/27\">",
"     27",
"    </a>",
"    ]. Other retrospective studies suggest that the mean duration of the disorder may be as long as 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. A review of 16 studies of aggressive behavior in males found that the number of aggressive outbursts may decrease as patients get older, while aggressiveness as a trait (eg, chronic anger or confrontational behavior with others) may persist throughout adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26760/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23115127\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of intermittent explosive disorder is summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef65924 \" href=\"UTD.htm?42/28/43467\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H87218172\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For acute treatment of patients with intermittent explosive disorder, we suggest pharmacotherapy plus cognitive-behavioral therapy (CBT) rather than pharmacotherapy alone or CBT alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, monotherapy with either treatment modality is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H172988769\">",
"       'Acute treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermittent explosive disorder who receive acute pharmacotherapy, we suggest a selective serotonin reuptake inhibitor (SSRI) as first-line treatment rather than other medications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       Fluoxetine",
"      </a>",
"      has been studied most often and is thus preferred. However, other SSRIs are reasonable alternatives. (See",
"      <a class=\"local\" href=\"#H23115147\">",
"       'First-line'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT works best for highly motivated patients. Conversely, CBT is contraindicated for patients who cannot learn the skills that are taught, eg, patients with moderate to severe cognitive deficits. Specific techniques used in CBT include cognitive restructuring, relaxation training, coping skills training, and relapse prevention. (See",
"      <a class=\"local\" href=\"#H2535510\">",
"       'Cognitive-behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermittent explosive disorder who do not respond to or tolerate acute treatment with an SSRI, we suggest switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      rather than other drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23115162\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermittent explosive disorder who do not respond to or tolerate acute treatment with an SSRI, and subsequently do not respond to or tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , we suggest switching to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      rather than other drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H23115162\">",
"       'Resistant patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with intermittent explosive disorder who remit, we suggest maintenance pharmacotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We use the same drug and dose that induced remission. (See",
"      <a class=\"local\" href=\"#H23115231\">",
"       'Maintenance pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retrospective studies suggest that the mean duration of intermittent explosive disorder is approximately 12 to 20 years. (See",
"      <a class=\"local\" href=\"#H23114334\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/1\">",
"      Coccaro EF. Intermittent explosive disorder: development of integrated research criteria for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Compr Psychiatry 2011; 52:119.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/3\">",
"      Siever LJ. Neurobiology of aggression and violence. Am J Psychiatry 2008; 165:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/4\">",
"      Dell'Osso B, Altamura AC, Allen A, et al. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 2006; 256:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/5\">",
"      Coccaro EF, Harvey PD, Kupsaw-Lawrence E, et al. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 1991; 3:S44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/6\">",
"      Van Dorn R, Volavka J, Johnson N. Mental disorder and violence: is there a relationship beyond substance use? Soc Psychiatry Psychiatr Epidemiol 2012; 47:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/7\">",
"      McCloskey MS, Berman ME, Echevarria DJ, Coccaro EF. Effects of acute alcohol intoxication and paroxetine on aggression in men. Alcohol Clin Exp Res 2009; 33:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/8\">",
"      Coccaro EF, Lee RJ, Kavoussi RJ. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/9\">",
"      Jones RM, Arlidge J, Gillham R, et al. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 2011; 198:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/10\">",
"      Alpert JE, Spillmann MK. Psychotherapeutic approaches to aggressive and violent patients. Psychiatr Clin North Am 1997; 20:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/11\">",
"      Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/12\">",
"      Heiligenstein JH, Beasley CM Jr, Potvin JH. Fluoxetine not associated with increased aggression in controlled clinical trials. Int Clin Psychopharmacol 1993; 8:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/13\">",
"      Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/14\">",
"      George DT, Phillips MJ, Lifshitz M, et al. Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. J Clin Psychiatry 2011; 72:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/15\">",
"      Stanford MS, Anderson NE, Lake SL, Baldridge RM. Pharmacologic treatment of impulsive aggression with antiepileptic drugs. Curr Treat Options Neurol 2009; 11:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/16\">",
"      Mattes JA. Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2005; 25:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/17\">",
"      Stanford MS, Houston RJ, Mathias CW, et al. A double-blind placebo-controlled crossover study of phenytoin in individuals with impulsive aggression. Psychiatry Res 2001; 103:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/18\">",
"      Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997; 17:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/19\">",
"      Huband N, Ferriter M, Nathan R, Jones H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010; :CD003499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/20\">",
"      Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/21\">",
"      Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/22\">",
"      Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/23\">",
"      Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003; 28:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/24\">",
"      Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/25\">",
"      Morland LA, Greene CJ, Rosen CS, et al. Telemedicine for anger management therapy in a rural population of combat veterans with posttraumatic stress disorder: a randomized noninferiority trial. J Clin Psychiatry 2010; 71:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/26\">",
"      McCloskey MS, Noblett KL, Deffenbacher JL, et al. Cognitive-behavioral therapy for intermittent explosive disorder: a pilot randomized clinical trial. J Consult Clin Psychol 2008; 76:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/27\">",
"      Kessler RC, Coccaro EF, Fava M, et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2006; 63:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/28\">",
"      Coccaro EF, Schmidt CA, Samuels JF, Nestadt G. Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. J Clin Psychiatry 2004; 65:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/29\">",
"      McElroy SL, Soutullo CA, Beckman DA, et al. DSM-IV intermittent explosive disorder: a report of 27 cases. J Clin Psychiatry 1998; 59:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26760/abstract/30\">",
"      Olweus D. Stability of aggressive reaction patterns in males: a review. Psychol Bull 1979; 86:852.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16694 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.131.41.98-0FBBA5EC0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26760=[""].join("\n");
var outline_f26_8_26760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23115127\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23115140\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87218172\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23114327\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172988312\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172988769\">",
"      Acute treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2535417\">",
"      - Monitoring outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23115154\">",
"      - Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23115147\">",
"      First-line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23115162\">",
"      Resistant patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H99464254\">",
"      Refractory patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2535510\">",
"      - Cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H218296\">",
"      Nonresponse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23115231\">",
"      Maintenance pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1960049\">",
"      - Adverse side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172988821\">",
"      - Monitoring the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172988947\">",
"      - Duration and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H172824559\">",
"      - Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23114334\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23115127\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16694\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16694|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/28/43467\" title=\"table 1\">",
"      Research criteria for intermittent explosive disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43065?source=related_link\">",
"      Bipolar disorder in adults and lithium: Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/44/15049?source=related_link\">",
"      Intermittent explosive disorder in adults: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/56/31626?source=related_link\">",
"      Unipolar depression in adults and selective serotonin reuptake inhibitors (SSRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_8_26761="Approach to the patient with nontyphoidal Salmonella in a stool culture";
var content_f26_8_26761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with nontyphoidal Salmonella in a stool culture",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26761/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26761/contributors\">",
"     Elizabeth L Hohmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26761/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26761/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/8/26761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salmonellae are frequently isolated from the stool of patients with gastroenteritis. In a 2005 survey from FoodNet of laboratory-confirmed causes of acute foodborne illnesses in ten states in the United States, nontyphoidal Salmonella was the most commonly isolated pathogen, occurring in 39 percent of cases, followed by Campylobacter in 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology and epidemiology of salmonellosis\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salmonella typhimurium and S. enteritidis are the most frequently isolated serotypes of Salmonella found in stool cultures in the United States. S. enteritidis, a common cause of foodborne disease outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/2\">",
"     2",
"    </a>",
"    ], is most frequently associated with eggs or egg-containing products [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/3\">",
"     3",
"    </a>",
"    ]. A nationwide epidemic of S. enteritidis infection in the United States in 1994 was associated with contaminated ice cream [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/4\">",
"     4",
"    </a>",
"    ]; another epidemic was associated with the ingestion of raw eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most nontyphoidal Salmonella infections occur in otherwise healthy individuals. However, a variety of host defense alterations result in increased susceptibility to infection with Salmonella spp, including impaired cellular immunity due to AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], corticosteroid use [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/9\">",
"     9",
"    </a>",
"    ] or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/10\">",
"     10",
"    </a>",
"    ], and alteration in the intestinal flora due to prior antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A number of other factors may also be important in selected patients (",
"    <a class=\"graphic graphic_table graphicRef51300 \" href=\"UTD.htm?24/18/24875\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/13-25\">",
"     13-25",
"    </a>",
"    ]. These may result in more severe initial infection and more serious sequelae such as bacteremia, metastatic foci of infection, or prolonged infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19033?source=see_link\">",
"     \"Pathogenesis of Salmonella gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major issues involved in the therapeutic approach to the finding of nontyphoidal Salmonella in a stool culture will be reviewed here. A more detailed review of the microbiology and epidemiology of salmonellosis and the microbiology, epidemiology, pathogenesis, clinical manifestations, treatment, and prevention of typhoid fever are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=see_link\">",
"     \"Pathogenesis of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=see_link\">",
"     \"Treatment and prevention of typhoid fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroenteritis due to Salmonellae is clinically indistinguishable from gastroenteritis caused by many other pathogens. Furthermore, enteric infection with nontyphoidal Salmonellae may be clinically mild or even asymptomatic, which can complicate clinical decisions about treatment interventions. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Asymptomatic carriage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The cardinal features -- nausea, vomiting, fever, diarrhea, and cramping -- usually occur within 8 to 72 hours of ingesting contaminated food or water. A higher ingested dose of bacteria correlates with increases in the severity of diarrhea, the duration of illness, and weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there have been descriptions of clinical characteristics associated with salmonellosis (eg, \"pea soup\" diarrhea), there are no clinical characteristics that reliably distinguish Salmonella infection from other forms of gastroenteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Invasive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fewer than 5 percent of individuals with documented Salmonella gastroenteritis develop bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Bacteremia can lead to a variety of extraintestinal manifestations such as endocarditis, mycotic aneurysm, and osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/29\">",
"     29",
"    </a>",
"    ]. Two species, S. choleraesuis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/30,31\">",
"     30,31",
"    </a>",
"    ] and S. heidelberg [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], appear to be more invasive. In addition, antibiotic resistant strains of S. typhimurium, are associated with a two- to threefold increase in the risk of bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/28,34\">",
"     28,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nontyphoidal Salmonella gastroenteritis is usually self-limited. Fever generally resolves within 48 to 72 hours, and diarrhea within 4 to 10 days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/5\">",
"     5",
"    </a>",
"    ]. Diarrhea persisting more than 10 days should lead to consideration of other diagnoses. Mortality rates of 0.5 to 1 percent have been reported in outbreaks of S. enteritidis, but these are most likely overestimates since milder cases tend to be unrecognized [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/28,35\">",
"     28,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory isolation of Salmonellae from stool cultures usually requires a minimum of 48 hours; 72 hours is needed if overnight enrichment broth incubation is used in addition to primary plating of stool samples. Salmonellae are gram-negative, facultatively anaerobic Enterobacteriaceae, which are differentiated from the normal gram-negative flora of the intestinal tract, in part, by the color of the colonies on indicator plates. The sensitivity and specificity of single or multiple stool cultures for diagnosis of salmonellosis are unknown.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Salmonella and Shigella are lactose-negative organisms that form translucent colonies on MacConkey agar. Less than 1 percent of Salmonellae are lactose-positive, which can rarely cause difficulties in identification.",
"     </li>",
"     <li>",
"      Most nontyphoidal Salmonellae produce hydrogen sulfide, which causes colonies to appear light greenish with black centers on Hektoen enteric agar or white with black centers on Salmonella-Shigella agar.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Enrichment broths (tetrathionate or selenite) are used to facilitate identification of Salmonella or Shigella when low numbers of organisms are present. Overnight incubation in these broths inhibits the growth of E. coli but not Salmonella or Shigella.",
"   </p>",
"   <p>",
"    Suspicious colonies from plates are further evaluated biochemically, and subsequently confirmed as Salmonella with commercial polyvalent antisera specific for Salmonella O and Vi antigens. Simple grouping based upon O antigen is usually reported initially before more complete serotyping is available. S. typhimurium belongs to group B, and S. enteritidis and S. typhi belong to group D. Salmonellosis is a reportable illness in the United States, and laboratories are required to report isolates to state authorities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of clinical settings in which therapy is considered after a stool culture for Salmonella returns positive for nontyphoidal Salmonella. The discussion below will address recommendations for the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Treatment of symptomatic patients",
"     </li>",
"     <li>",
"      Preemptive treatment and special hosts",
"     </li>",
"     <li>",
"      Asymptomatic carriage of nontyphoidal Salmonellae",
"     </li>",
"     <li>",
"      Food handlers and health care workers with salmonellosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of therapy of symptomatic individuals with Salmonella gastroenteritis is replacement of fluids and electrolytes. As noted above, the illness is usually self",
"    <strong>",
"     -",
"    </strong>",
"    limited; in addition, the vast majority of Salmonella infections are undiagnosed and are not associated with complications.",
"   </p>",
"   <p>",
"    However, the lack of rapid diagnostic testing methods for enteric pathogens requires that decisions about therapy be made empirically at the time patients present. The issue of empiric antimicrobial therapy for infectious diarrhea in general (including enterotoxigenic E. coli) is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of controlled trials have addressed the role of antimicrobial therapy in otherwise healthy patients with Salmonella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. A meta-analysis of 12 trials with 767 otherwise healthy individuals with nontyphoidal Salmonella gastroenteritis found no significant benefit from antimicrobial therapy on the length of illness, diarrhea, or fever [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, we do not recommend antibiotic treatment for immunocompetent adults or children over 12 months of age with mild to moderate symptoms of gastroenteritis from Salmonellae.",
"   </p>",
"   <p>",
"    However, treatment should be considered in a subset of severely ill immunocompetent individuals on an individualized basis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/38\">",
"     38",
"    </a>",
"    ]. These include patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe diarrhea (more than 9 or 10 stools per day)",
"     </li>",
"     <li>",
"      High fever",
"     </li>",
"     <li>",
"      A need for hospitalization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of bloody diarrhea does",
"    <strong>",
"     not",
"    </strong>",
"    necessarily indicate the need for antimicrobial treatment. Many patients with Salmonellosis have occult blood detectable in stool samples, while overtly bloody stools are more likely to be due to Shigella or enterohemorrhagic E. coli.",
"   </p>",
"   <p>",
"    For individuals with the above characteristics, three to seven days of antimicrobial therapy has generally been recommended. This recommendation is based upon studies suggesting that antimicrobial treatment in these settings may be associated with improvement in symptoms and more rapid clinical recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/40\">",
"     40",
"    </a>",
"    ]. Studies of empiric antimicrobial therapy (before cultures are back) in severe community-acquired diarrhea have also found a reduction of disease duration by one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a general rule, the potential for improvement of severe illness and prevention of complications (eg, bacteremia, focal infection or persisting symptoms) appear to outweigh the small risks of antibiotic treatment, although this has not been definitively demonstrated in large, randomized placebo-controlled trials.",
"   </p>",
"   <p>",
"    Appropriate antibiotic choices for adults with relatively normal renal function and no known drug intolerances include a fluoroquinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg orally twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg orally once daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (160",
"    <span class=\"nowrap\">",
"     mg/800",
"    </span>",
"    mg orally twice daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (500 mg orally thrice daily), or, if intravenous therapy is required, a third generation cephalosporin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    1 to 2 g intravenously once daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    2 g intravenously every eight hours).",
"   </p>",
"   <p>",
"    Antibiotic resistance patterns should be taken into account when making treatment decisions. In 2003, the antimicrobial agents with the highest prevalence of resistance among non-typhoidal Salmonellae were",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    , sulfamethoxazole,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    (all in the range of 13 to 16 percent); these values had not changed much over the preceding ten years. In contrast, the prevalence of resistance to fluoroquinolones and third generation cephalosporins is increasing; between 1996 and 2003, nalidixic acid resistance rose from 0.2 to 2.3 percent, and ceftiofur resistance rose from 0.2 to 4.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Organisms with multiple drug resistances are common, highlighting the need for sensitivity testing. (See",
"    <a class=\"external\" href=\"file://www.cdc.gov/narms\">",
"     file://www.cdc.gov/narms",
"    </a>",
"    ). (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=see_link&amp;anchor=H8#H8\">",
"     \"Microbiology and epidemiology of salmonellosis\", section on 'Antimicrobial resistance'",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    Because of their activity against most common gram-negative enteric pathogens and their favorable side effect profile, the fluoroquinolones are probably the most appropriate agent for most individuals without contraindications to these medications. Although increasing data show that fluoroquinolones are safe in children [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/44\">",
"     44",
"    </a>",
"    ], other agents are advisable initially for children or pregnant women because of possible damage to growing cartilage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Preemptive treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive therapy in an attempt to prevent complications of Salmonella intestinal infection, such as bacteremia and metastatic foci of infection, is considered in some patients, even with less severe infection.",
"   </p>",
"   <p>",
"    Older adults and the very young are at increased risk for complications. Neonates with gastroenteritis, particularly those born prematurely",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to mothers with gastroenteritis, are at risk and may not appear toxic or acutely ill [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/33,45,46\">",
"     33,45,46",
"    </a>",
"    ]. Salmonella meningitis is a feared complication with a high case fatality rate that occurs primarily in infants. In most cases, infants less than three months of age should receive antimicrobial therapy for symptomatic salmonellosis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/47\">",
"     47",
"    </a>",
"    ]; in addition, some authorities treat all children less than one to two years old unless the child is afebrile and clinically improving at the time the culture results become available [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults over 50, particularly, those with known atherosclerotic disease, are at higher risk of endovascular infection and aortitis if bacteremia develops. Approximately 10 percent of adults over 50, who are identified on the basis of a nontyphoidal Salmonella bacteremia, will be found to have infective arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Those with endovascular or osseous prostheses may reasonably be considered in this group, and similarly treated even if not severely ill with gastroenteritis.",
"   </p>",
"   <p>",
"    The duration of therapy in these groups at the extremes of age has not been studied. Most experts would recommend 3 to 10 days of treatment depending upon the specific clinical situation, suspicion of bacteremia, laboratory findings, and microbiological data. It seems prudent to limit the exposure to antibiotics in normal hosts, because of their potential to paradoxically prolong carriage (see below) and adverse drug reactions, and concerns about antibiotic resistance in general.",
"   </p>",
"   <p>",
"    Preemptive therapy is definitely warranted in immunocompromised patients, including those with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An organ transplant",
"     </li>",
"     <li>",
"      AIDS",
"     </li>",
"     <li>",
"      Those receiving corticosteroids or other immunosuppressive drugs",
"     </li>",
"     <li>",
"      Sickle cell disease, hemoglobinopathies, disorders of the reticuloendothelial system, (eg, cirrhosis)",
"     </li>",
"     <li>",
"      Cancer or lymphoproliferative disease with current or recent chemotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is impossible to know how many patients with these conditions who get mild to moderate gastrointestinal salmonellosis go on to develop bacteremia and complications. However, it is likely to be a significant percentage and a cause for worry. In two reports (one from Malawi and the other from Taiwan), 31 and 43 percent of HIV-infected adults (who had not been treated with antiretroviral therapy) developed recurrent Salmonella bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the above provides a rationale for preemptive therapy, its benefit has not been documented in a well-designed prospective randomized trial and is unlikely to be so tested. Similarly, the optimal duration of therapy has not been studied with respect to persistent carriage, or other complications. Because Salmonellae persist in the reticuloendothelial system, and these groups of patients have impaired immune clearance mechanisms (especially those with advanced HIV or organ transplants), a longer duration of therapy seems advisable.",
"   </p>",
"   <p>",
"    Most experts would treat such patients longer initially (eg, 14 days or even longer [weeks to months]), in an effort to prevent persistent or relapsing infection. These patients should be evaluated carefully for bacteremia, and treatment decisions made in an individualized fashion. Consultation with an expert in infectious diseases is recommended. The high tissue and intracellular concentrations achieved by fluoroquinolones may make them particularly effective (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg orally twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg orally once daily); other agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    or beta-lactams would also be appropriate choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women acquire nontyphoidal Salmonella infection at rates similar to the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Pregnancy does not necessarily increase severity of illness, although there are case reports of pregnant women with severe nontyphoidal Salmonella infection, and fetal loss in the setting of disseminated infection is possible in any trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Pregnant woman with fever and gastroenteritis symptoms should be evaluated for salmonellosis as well as other enteric bacterial infections (including Campylobacter and Listeria).",
"   </p>",
"   <p>",
"    Routine treatment of salmonellosis in pregnancy is not necessary, particularly in the setting of mild illness early in pregnancy; antibiotics may not speed resolution or mitigate symptoms, and may prolong Salmonella carriage.",
"   </p>",
"   <p>",
"    Antibiotic therapy for treatment of salmonellosis in pregnancy is appropriate for febrile patients with severe disease, especially in the setting of bacteremia or infection near term. Women with peripartum infection may shed organisms during childbirth with high risk for neonatal transmission of infection, although severity of illness does not necessarily correlate with persistence of infection or duration of shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/57\">",
"     57",
"    </a>",
"    ]. If severe illness occurred early in pregnancy, there is no role for additional treatment at the time of delivery.",
"   </p>",
"   <p>",
"    Prophylaxis of neonates may be appropriate in some situations to prevent complications of systemic neonatal salmonellosis, including meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In addition, outbreaks of salmonellosis in NICUs and maternity wards neonates have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infectious disease consultation is advisable to assist with management and follow-up evaluation; these must be individualized depending on clinical circumstances including the patient, the organism, and presence of antibiotic resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Asymptomatic carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic convalescent excretion of Salmonella bacilli is extremely common after either symptomatic or asymptomatic nontyphoidal Salmonella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"     62",
"    </a>",
"    ]. The influence of antimicrobial therapy on Salmonella carriage is controversial. The conflicting data are due in part to differences in culture techniques, culture intervals, infecting strains and duration of follow-up. Nevertheless, several general statements can be made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median duration of excretion is approximately five weeks for all age groups, with S. typhimurium being more rapidly cleared than other serotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The median duration of excretion is approximately seven weeks in patients less than five years of age, 2.6 percent of whom excrete Salmonellae for more than one year [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The duration of excretion may be longer after symptomatic than asymptomatic infection",
"     </li>",
"     <li>",
"      Intermittent shedding is common, so a single negative culture is not that reassuring.",
"     </li>",
"     <li>",
"      Fecal cultures are generally considered the \"gold standard\" for diagnosis of Salmonella gastroenteritis and should not be difficult to obtain if people are having diarrhea. However, rectal swabs were moderately useful (sensitivity 64 percent and specificity 90 percent) compared with fecal cultures in an inpatient study of a live attenuated S. typhimurium vaccine [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, routine follow-up cultures are",
"    <strong>",
"     not",
"    </strong>",
"    recommended after uncomplicated Salmonella gastroenteritis in immunocompetent patients.",
"   </p>",
"   <p>",
"    Studies performed in the prequinolone era demonstrated that antimicrobial therapy of Salmonella gastroenteritis prolonged the duration of Salmonella excretion. This paradoxical finding has been thought to be due to the deleterious effect of antibiotics on normal intestinal flora, which protects against colonization with enteric pathogens. Prolongation of carriage is not related to the emergence of organisms resistant to the antimicrobial agent used, which is a relatively rare event. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19033?source=see_link\">",
"     \"Pathogenesis of Salmonella gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a 1980 study of children and infants treated with five days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , or placebo for uncomplicated gastroenteritis, 53 percent who received antibiotics had bacteriologic relapse versus none who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/64\">",
"     64",
"    </a>",
"    ]. Of those who relapsed, 38 percent had recurrent diarrhea.",
"   </p>",
"   <p>",
"    It was hoped that the fluoroquinolones would be more effective in eliminating convalescent carriage. This hypothesis has been evaluated in two, small, randomized, placebo-controlled treatment studies of outbreaks of Salmonella gastroenteritis using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    (400 mg twice daily for seven days) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/65\">",
"     65",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (750 mg twice daily for 14 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/66\">",
"     66",
"    </a>",
"    ]. Neither of the treatment regimens in these studies decreased or significantly prolonged the duration of carriage. In contrast, a deleterious effect of norfloxacin was noted in the patients with salmonellosis in the Swedish study described above [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/38\">",
"     38",
"    </a>",
"    ]. In this study, the incidence of negative cultures at 7 to 12 days was significantly lower in the norfloxacin group (18 versus 49 percent with placebo). The median time to negative cultures was also prolonged by norfloxacin (50 versus 23 days).",
"   </p>",
"   <p>",
"    In summary, brief early courses of antibiotics, including the fluoroquinolones, are",
"    <strong>",
"     not",
"    </strong>",
"    effective in shortening the duration of carriage of nontyphoidal Salmonellae. However, antimicrobial therapy or prophylaxis does appear to be effective to prevent infection or suppress excretion of large numbers of organisms acutely. Drug treatment may occasionally be useful in limiting epidemics in closed settings in which full compliance with infection control measures may be difficult, such as pediatric wards [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/67\">",
"     67",
"    </a>",
"    ] or long-term care facilities [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paradoxically, long-term antimicrobial therapy may be of some utility in patients who have prolonged or chronic carriage. Chronic carriage of nontyphoidal Salmonella is defined as the shedding of a Salmonella species for more than one year, as documented by an initial positive culture of a stool sample obtained at least one month after resolution of the acute illness and repeat positive cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/69\">",
"     69",
"    </a>",
"    ]. Prolonged carriage appears to occur rarely (0.2 to 0.6 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/70\">",
"     70",
"    </a>",
"    ] in otherwise healthy subjects but may be increased in older individuals, women, and those with biliary tract abnormalities. If chronic carriage is documented, attempted eradication may rarely be needed for employment or other social reasons like daycare attendance or the presence of a severely immunosuppressed family member (see below).",
"   </p>",
"   <p>",
"    The optimal approach to chronic carriage of nontyphoidal Salmonella is poorly studied [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"     62",
"    </a>",
"    ]. Drawing upon the experience with treating carriage of Salmonella typhi, four to six weeks of antimicrobial therapy is a reasonable approach, although many patients may have side effects related to treatment. When attempting eradication of carriage we use a fluoroquinolone (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg orally twice daily,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    500 mg orally once daily, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    400 mg orally twice daily) for four weeks. Alternative regimens, which have successfully eradicated S. typhi in some patients, include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (160",
"    <span class=\"nowrap\">",
"     mg/800",
"    </span>",
"    mg orally twice daily) for three months or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (3 to 5 g orally in four divided doses) for six weeks (depending upon sensitivities of the isolate).",
"   </p>",
"   <p>",
"    Guidelines for evaluating the efficacy of treatment of carriage have been suggested and include follow-up cultures six months after completing therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, suppressive prophylactic therapy may be warranted in HIV-positive individuals, particularly, in those with a septicemic primary illness or low CD4 cell counts, in order to prevent relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Food handlers and health care workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large numbers of asymptomatic transient Salmonella excreters are undoubtedly employed in the health care and food industries worldwide for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial episode of Salmonella gastroenteritis may be clinically mild and remain undiagnosed",
"     </li>",
"     <li>",
"      The median duration of Salmonella excretion after gastroenteritis is five weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"       62",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Excretion is frequently episodic [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62,72\">",
"       62,72",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nevertheless, only two percent of 566 outbreaks of salmonellosis in the United Kingdom were traced to specific infected food handlers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/73\">",
"     73",
"    </a>",
"    ]. Furthermore, transmission from asymptomatic food handlers has rarely been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. One of these outbreaks in Amman, Jordan occurred despite routine surveillance of kitchen employees for Salmonella carriage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/75\">",
"     75",
"    </a>",
"    ]. The authors concluded that screening was not cost-effective and should not be used as a substitute for health education and proper hygienic practices. A Thai study of asymptomatic food handlers shedding Salmonella randomized people to five days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , or placebo. The study drugs were no better than placebo in eradicating shedding in this area endemic for nontyphoidal salmonellosis. Also, in this endemic setting, selection of drug resistant Salmonella was demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial fecal-oral transmission can occur, and is related to poor handwashing practices [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The importance of handwashing was illustrated in a foodborne outbreak of salmonellosis among nurses; there was no transmission to patients, presumably because of adherence to proper handwashing procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies highlight the primacy of good hygiene and handwashing in control of salmonellosis from infected health care workers or food handlers. It is reasonable and customary to exclude such individuals from work while gastroenteritis symptoms persist [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/80\">",
"     80",
"    </a>",
"    ], since organism excretion is more common and at higher levels during active disease. Some states require one or more negative stool cultures (more than 48 hours after discontinuation of antibiotics, if given) before employees can return to work. A similar approach may be locally mandated, or instituted during outbreaks in day care centers, but scrupulous attention to proper infection control procedures are most important.",
"   </p>",
"   <p>",
"    While reassuring, a single negative stool culture does not ensure that the individual is no longer shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"     62",
"    </a>",
"    ]. Obtaining multiple negative stool cultures from employees may be warranted occasionally in individuals whose work requires direct handling of food consumed without further cooking, or direct contact with infants or immunosuppressed patients. However, this approach does not seem reasonable routinely for employees with lower risk occupations. As national policy for these settings is not mandated, judgments based upon individual employees and local health administration standards are appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/31/27122?source=see_link\">",
"       \"Patient information: Salmonellosis (Salmonella) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastroenteritis due to Salmonellae is clinically indistinguishable from gastroenteritis caused by many other pathogens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nontyphoidal Salmonella gastroenteritis is usually self-limited. Fever generally resolves within 48 to 72 hours, and diarrhea within 4 to 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26761/abstract/5\">",
"       5",
"      </a>",
"      ]. Diarrhea persisting more than 10 days should lead to consideration of other diagnoses. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cornerstone of therapy of symptomatic individuals with Salmonella gastroenteritis is replacement of fluids and electrolytes. The role of antibiotics depends upon the clinical setting. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <strong>",
"       AGAINST",
"      </strong>",
"      using antibiotics in patients ages 2 to 50 years old who are immunocompetent and are only mild to moderately ill, especially if improving clinically (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Brief, early courses of antibiotics, including the fluoroquinolones, are not effective in shortening the duration of carriage of nontyphoidal Salmonellae. Follow-up \"test clearance\" cultures are generally not warranted unless mandated by local health departments. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest giving antibiotics to immunocompetent individuals who are severely ill, especially hospitalized individuals (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Appropriate choices for adults with normal renal function and no known drug intolerances, include a three to seven day course of a fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      500 mg orally twice daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      500 mg orally once daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (160",
"      <span class=\"nowrap\">",
"       mg/800",
"      </span>",
"      mg orally twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (500 mg orally thrice daily), or a third generation cephalosporin (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      1 to 2 g intravenously once daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      2 g intravenously every eight hours) if intravenous therapy were required. However, local resistance patterns should be taken into account. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend giving antibiotics to immunocompromised adults and children (eg, those receiving corticosteroids, organ transplant recipients, AIDS patients) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Most experts would treat such patients for relatively long courses initially (eg, 14 days, or even longer [weeks to months]) in an effort to prevent persistent or relapsing infection. Infectious disease consultation is advisable. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Preemptive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest giving antibiotics to otherwise healthy adults over the age of 50 years who are known or likely to have atherosclerotic vascular disease or endovascular or osseous prostheses, in an effort to prevent complications of bacteremia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Preemptive treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal treatment of those who develop chronic carriage of Salmonella is not well studied but can be reasonably extrapolated from treatment of chronic typhoid carriers. Chronic carriage is defined as shedding of a Salmonella species for more than one year, as documented by an initial positive culture of a stool sample obtained at least one month after resolution of the acute illness and repeat positive cultures. Although some patients may have side effects related to treatment, we suggest four to six weeks of antimicrobial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The most appropriate antibiotic regimen for attempting eradication of carriage is a fluoroquinolone (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      500 mg orally twice daily,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      500 mg orally once daily, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       norfloxacin",
"      </a>",
"      400 mg orally twice daily). Infectious disease consultation is advisable. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Asymptomatic carriage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Food handlers and healthcare workers should remain at home while symptoms of gastroenteritis persist. Good hygiene and handwashing practices should be reinforced. Local health departments should be consulted. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Food handlers and health care workers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/1\">",
"      Centers for Disease Control and Prevention (CDC). Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food--10 States, United States, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/2\">",
"      From the Centers for Disease Control and Prevention. Outbreaks of Salmonella serotype Enteritidis infection associated with consumption of raw shell eggs--United States, 1994-1995. JAMA 1996; 276:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/3\">",
"      Mishu B, Koehler J, Lee LA, et al. Outbreaks of Salmonella enteritidis infections in the United States, 1985-1991. J Infect Dis 1994; 169:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/4\">",
"      Hennessy TW, Hedberg CW, Slutsker L, et al. A national outbreak of Salmonella enteritidis infections from ice cream. The Investigation Team. N Engl J Med 1996; 334:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/5\">",
"      From the Centers for Disease Control. Outbreak of Salmonella enteritidis infection associated with consumption of raw shell eggs. JAMA 1992; 267:3263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/6\">",
"      Gruenewald R, Blum S, Chan J. Relationship between human immunodeficiency virus infection and salmonellosis in 20- to 59-year-old residents of New York City. Clin Infect Dis 1994; 18:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/7\">",
"      Levine WC, Buehler JW, Bean NH, Tauxe RV. Epidemiology of nontyphoidal Salmonella bacteremia during the human immunodeficiency virus epidemic. J Infect Dis 1991; 164:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/8\">",
"      Thamlikitkul V, Dhiraputra C, Paisarnsinsup T, Chareandee C. Non-typhoidal Salmonella bacteraemia: clinical features and risk factors. Trop Med Int Health 1996; 1:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/9\">",
"      Ramos JM, Garc&iacute;a-Corbeira P, Aguado JM, et al. Clinical significance of primary vs. secondary bacteremia due to nontyphoid Salmonella in patients without AIDS. Clin Infect Dis 1994; 19:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/10\">",
"      Wolfe MS, Louria DB, Armstrong D, Blevins A. Salmonellosis in patients with neoplastic disease. A review of 100 episodes at Memorial Cancer Center over a 13-year period. Arch Intern Med 1971; 128:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/11\">",
"      Pavia AT, Shipman LD, Wells JG, et al. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. J Infect Dis 1990; 161:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/12\">",
"      Novelli A, Mazzei T, Fallani S, et al. Betalactam therapy and intestinal flora. J Chemother 1995; 7 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/13\">",
"      Anand AJ, Glatt AE. Salmonella osteomyelitis and arthritis in sickle cell disease. Semin Arthritis Rheum 1994; 24:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/14\">",
"      Okuonghae HO, Nwankwo MU, Offor EC. Pattern of bacteraemia in febrile children with sickle cell anaemia. Ann Trop Paediatr 1993; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/15\">",
"      Workman MR, Philpott-Howard JN, Casewell MW, Bellingham AJ. Salmonella bacteraemia in sickle cell disease at King's College Hospital: 1976-1991. J Hosp Infect 1994; 27:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/16\">",
"      Barrett-Connor E. Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature. Medicine (Baltimore) 1971; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/17\">",
"      Moellering RC Jr, Weinberg AN. Persistent Salmonella infection in a female carrier for chronic granulomatous disease. Ann Intern Med 1970; 73:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/18\">",
"      Mabey DC, Brown A, Greenwood BM. Plasmodium falciparum malaria and Salmonella infections in Gambian children. J Infect Dis 1987; 155:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/19\">",
"      Gopinath R, Keystone JS, Kain KC. Concurrent falciparum malaria and Salmonella bacteremia in travelers: report of two cases. Clin Infect Dis 1995; 20:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/20\">",
"      Wheat LJ, Rubin RH, Harris NL, et al. Systemic salmonellosis in patients with disseminated histoplasmosis. Case for 'macrophage blockade' caused by Histoplasma capsulatum. Arch Intern Med 1987; 147:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/21\">",
"      Gendrel D, Kombila M, Beaudoin-Leblevec G, Richard-Lenoble D. Nontyphoidal salmonellal septicemia in Gabonese children infected with Schistosoma intercalatum. Clin Infect Dis 1994; 18:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/22\">",
"      Kinsella TR, Yogev R, Shulman ST, et al. Treatment of Salmonella meningitis and brain abscess with the new cephalosporins: two case reports and a review of the literature. Pediatr Infect Dis J 1987; 6:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/23\">",
"      Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut 1972; 13:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/24\">",
"      Kochhar R, Ayyagari A, Goenka MK, et al. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol 1993; 16:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/25\">",
"      Baliellas C, Xiol X, Barenys M, et al. [Infectious gastroenteritis in relapses of inflammatory bowel disease. Therapeutic implications]. Rev Esp Enferm Dig 1996; 88:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/26\">",
"      Mintz ED, Cartter ML, Hadler JL, et al. Dose-response effects in an outbreak of Salmonella enteritidis. Epidemiol Infect 1994; 112:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/27\">",
"      SAPHRA I, WINTER JW. Clinical manifestations of salmonellosis in man; an evaluation of 7779 human infections identified at the New York Salmonella Center. N Engl J Med 1957; 256:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/28\">",
"      Helms M, Simonsen J, Molbak K. Quinolone resistance is associated with increased risk of invasive illness or death during infection with Salmonella serotype Typhimurium. J Infect Dis 2004; 190:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/29\">",
"      Cohen JI, Bartlett JA, Corey GR. Extra-intestinal manifestations of salmonella infections. Medicine (Baltimore) 1987; 66:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/30\">",
"      SAPHRA I, WASSERMANN M. Salmonella cholerae suis: a clinical and epidemiological evaluation of 329 infections identified between 1940 and 1954 in the New York Salmonella Center. Am J Med Sci 1954; 228:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/31\">",
"      Wang JH, Liu YC, Yen MY, et al. Mycotic aneurysm due to non-typhi salmonella: report of 16 cases. Clin Infect Dis 1996; 23:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/32\">",
"      Cherubin CE, Neu HC, Imperato PJ, et al. Septicemia with non-typhoid salmonella. Medicine (Baltimore) 1974; 53:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/33\">",
"      Rice PA, Craven C, Wells JG. Salmonella heidelberg enteritis and bacteremia. An epidemic on two pediatric wards. Am J Med 1976; 60:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/34\">",
"      Varma JK, Molbak K, Barrett TJ, et al. Antimicrobial-resistant nontyphoidal Salmonella is associated with excess bloodstream infections and hospitalizations. J Infect Dis 2005; 191:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/35\">",
"      Patrick ME, Adcock PM, Gomez TM, et al. Salmonella enteritidis infections, United States, 1985-1999. Emerg Infect Dis 2004; 10:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/36\">",
"      S&aacute;nchez C, Garc&iacute;a-Restoy E, Garau J, et al. Ciprofloxacin and trimethoprim-sulfamethoxazole versus placebo in acute uncomplicated Salmonella enteritis: a double-blind trial. J Infect Dis 1993; 168:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/37\">",
"      Noguerado A, Garcia-Polo I, Isasia T, et al. Early single dose therapy with ofloxacin for empirical treatment of acute gastroenteritis: a randomised, placebo-controlled double-blind clinical trial. J Antimicrob Chemother 1995; 36:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/38\">",
"      Wistr&ouml;m J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin. A randomized, placebo-controlled study. Swedish Study Group. Ann Intern Med 1992; 117:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/39\">",
"      Onwuezobe IA, Oshun PO, Odigwe CC. Antimicrobials for treating symptomatic non-typhoidal Salmonella infection. Cochrane Database Syst Rev 2012; 11:CD001167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/40\">",
"      Mattila L, Peltola H, Siitonen A, et al. Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis 1993; 17:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/41\">",
"      Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996; 22:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/42\">",
"      Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990; 150:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/43\">",
"      Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/44\">",
"      Grady R. Safety profile of quinolone antibiotics in the pediatric population. Pediatr Infect Dis J 2003; 22:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/45\">",
"      Geme JW 3rd, Hodes HL, Marcy SM, et al. Consensus: management of Salmonella infection in the first year of life. Pediatr Infect Dis J 1988; 7:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/46\">",
"      G&ouml;kalp AS, Toksoy HB, T&uuml;rkay S, et al. Intravenous immunoglobulin in the treatment of Salmonella typhimurium infections in preterm neonates. Clin Pediatr (Phila) 1994; 33:349.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Salmonella infections. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th ed, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.584.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/48\">",
"      Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. Am J Med 2001; 110:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/49\">",
"      Cohen PS, O'Brien TF, Schoenbaum SC, Medeiros AA. The risk of endothelial infection in adults with salmonella bacteremia. Ann Intern Med 1978; 89:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/50\">",
"      Gordon MA, Banda HT, Gondwe M, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/51\">",
"      Hung CC, Hsieh SM, Hsiao CF, et al. Risk of recurrent non-typhoid Salmonella bacteraemia after early discontinuation of ciprofloxacin as secondary prophylaxis in AIDS patients in the era of highly active antiretroviral therapy. AIDS 2001; 15:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/52\">",
"      Roberts C, Wilkins EG. Salmonella screening of pregnant women. J Hosp Infect 1987; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/53\">",
"      Citernesi A, Spinelli G, Piazzesi G, et al. [Screening for Salmonella in pregnancy]. Minerva Ginecol 1994; 46:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/54\">",
"      Gyang A, Saunders M. Salmonella Mississippi: a rare cause of second trimester miscarriage. Arch Gynecol Obstet 2008; 277:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/55\">",
"      Scialli AR, Rarick TL. Salmonella sepsis and second-trimester pregnancy loss. Obstet Gynecol 1992; 79:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/56\">",
"      Coughlin LB, McGuigan J, Haddad NG, Mannion P. Salmonella sepsis and miscarriage. Clin Microbiol Infect 2003; 9:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/57\">",
"      van der Klooster JM, Roelofs HJ. Management of Salmonella infections during pregnancy and puerperium. Neth J Med 1997; 51:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/58\">",
"      Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal infants in Thailand. Pediatr Infect Dis J 2001; 20:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/59\">",
"      Molyneux EM, Mankhambo LA, Phiri A, et al. The outcome of non-typhoidal salmonella meningitis in Malawian children, 1997-2006. Ann Trop Paediatr 2009; 29:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/60\">",
"      Umasankar S, Mridha EU, Hannan MM, et al. An outbreak of Salmonella enteritidis in a maternity and neonatal intensive care unit. J Hosp Infect 1996; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/61\">",
"      Mahajan R, Mathur M, Kumar A, et al. Nosocomial outbreak of Salmonella typhimurium infection in a nursery intensive care unit (NICU) and paediatric ward. J Commun Dis 1995; 27:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/62\">",
"      Buchwald DS, Blaser MJ. A review of human salmonellosis: II. Duration of excretion following infection with nontyphi Salmonella. Rev Infect Dis 1984; 6:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/63\">",
"      Kotton CN, Lankowski AJ, Hohmann EL. Comparison of rectal swabs with fecal cultures for detection of Salmonella typhimurium in adult volunteers. Diagn Microbiol Infect Dis 2006; 56:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/64\">",
"      Nelson JD, Kusmiesz H, Jackson LH, Woodman E. Treatment of Salmonella gastroenteritis with ampicillin, amoxicillin, or placebo. Pediatrics 1980; 65:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/65\">",
"      Carlstedt G, Dahl P, Niklasson PM, et al. Norfloxacin treatment of salmonellosis does not shorten the carrier stage. Scand J Infect Dis 1990; 22:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/66\">",
"      Neill MA, Opal SM, Heelan J, et al. Failure of ciprofloxacin to eradicate convalescent fecal excretion after acute salmonellosis: experience during an outbreak in health care workers. Ann Intern Med 1991; 114:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/67\">",
"      Kassis I, Dagan R, Chipman M, et al. The use of prophylactic furazolidone to control a nosocomial epidemic of multiply resistant Salmonella typhimurium in pediatric wards. Pediatr Infect Dis J 1990; 9:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/68\">",
"      Dyson C, Ribeiro CD, Westmoreland D. Large scale use of ciprofloxacin in the control of a Salmonella outbreak in a hospital for the mentally handicapped. J Hosp Infect 1995; 29:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/69\">",
"      Corrado ML, DuPont HL, Cooperstock M, et al. Evaluation of new anti-infective drugs for the treatment of chronic carriage of Salmonella. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 Suppl 1:S259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/70\">",
"      Musher DM, Rubenstein AD. Permanent carriers of nontyphosa salmonellae. Arch Intern Med 1973; 132:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/71\">",
"      Nelson MR, Shanson DC, Hawkins DA, Gazzard BG. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 1992; 6:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/72\">",
"      Thomas ME, Mogford HE. Salmonellosis in general practice. Observations of cases and their household in Enfield. J Hyg (Lond) 1970; 68:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/73\">",
"      Mandal B. Typhoid fever and other Salmonellae. Curr Opin Infect Dis 1988; 1:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/74\">",
"      Dryden MS, Keyworth N, Gabb R, Stein K. Asymptomatic foodhandlers as the source of nosocomial salmonellosis. J Hosp Infect 1994; 28:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/75\">",
"      Khuri-Bulos NA, Abu Khalaf M, Shehabi A, Shami K. Foodhandler-associated Salmonella outbreak in a university hospital despite routine surveillance cultures of kitchen employees. Infect Control Hosp Epidemiol 1994; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/76\">",
"      Sirinavin S, Thavornnunth J, Sakchainanont B, et al. Norfloxacin and azithromycin for treatment of nontyphoidal salmonella carriers. Clin Infect Dis 2003; 37:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/77\">",
"      Standaert SM, Hutcheson RH, Schaffner W. Nosocomial transmission of Salmonella gastroenteritis to laundry workers in a nursing home. Infect Control Hosp Epidemiol 1994; 15:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/78\">",
"      Weikel CS, Guerrant RL. Nosocomial salmonellosis. Infect Control 1985; 6:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26761/abstract/79\">",
"      Tauxe RV, Hassan LF, Findeisen KO, et al. Salmonellosis in nurses: lack of transmission to patients. J Infect Dis 1988; 157:370.",
"     </a>",
"    </li>",
"    <li>",
"     Benenson AS. Control of Communicable Diseases Manual, 16th ed, American Public Health Association, Washington, DC 1995.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2697 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26761=[""].join("\n");
var outline_f26_8_26761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Invasive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Preemptive treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Asymptomatic carriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Food handlers and health care workers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2697\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2697|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/18/24875\" title=\"table 1\">",
"      Host factors Salmonella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19033?source=related_link\">",
"      Pathogenesis of Salmonella gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/6/21607?source=related_link\">",
"      Pathogenesis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/31/27122?source=related_link\">",
"      Patient information: Salmonellosis (Salmonella) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/58/18345?source=related_link\">",
"      Treatment and prevention of typhoid fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_8_26762="Initial management of shock in children";
var content_f26_8_26762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of shock in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26762/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26762/contributors\">",
"     Mark Waltzman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26762/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26762/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26762/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/8/26762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/8/26762/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/8/26762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a dynamic and unstable pathophysiologic state characterized by inadequate tissue perfusion. Although the effects of inadequate perfusion are reversible initially, prolonged oxygen deprivation leads to generalized cellular hypoxia and the disruption of critical biochemical processes, eventually resulting in cell membrane ion pump dysfunction, intracellular edema, inadequate regulation of intracellular pH, and cell death.",
"   </p>",
"   <p>",
"    Shock develops as the result of conditions that cause decreased intravascular volume, abnormal distribution of intravascular volume,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired cardiovascular function. Aggressive treatment within the first few hours after presentation may prevent the invariable progression and poor outcome that characterize the natural clinical course of shock, manifested clinically by end-organ damage, failure of multiple organ systems, and death.",
"   </p>",
"   <p>",
"    Children with compromised circulation must be identified promptly. Successful management requires rapid initiation of treatment (often before the cause of shock is apparent) and careful assessment of the response to each intervention. Specific therapy must be initiated as soon as the evaluation suggests a cause of shock. Most children will improve with fluid resuscitation. Those who do not must quickly receive more aggressive treatment.",
"   </p>",
"   <p>",
"    This topic will review the initial management of children with shock. The classification of pediatric shock, initial evaluation of shock in children, and management of specific types of shock are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link\">",
"       \"Physiology and classification of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"       \"Septic shock: Ongoing management after resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=see_link\">",
"       \"Hypovolemic shock in children: Initial evaluation and management\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15712116\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a physiologic state characterized by a significant, systemic reduction in tissue perfusion; resulting in decreased tissue oxygen delivery and diminished removal of harmful byproducts of metabolism (eg, lactate). According to Pediatric Advanced Life Support (PALS) course, shock is further classified into the following stages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H3#H3\">",
"     \"Physiology and classification of shock in children\", section on 'Stages of shock'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Compensated shock",
"      </strong>",
"      &ndash; During compensated shock, the body's homeostatic mechanisms rapidly compensate for diminished perfusion and systolic blood pressure is maintained within the normal range. Heart rate is initially increased. Signs of peripheral vasoconstriction (such as cool skin, decreased peripheral pulses, and oliguria) can be noted as perfusion becomes further compromised.",
"     </li>",
"     <li>",
"      <strong>",
"       Decompensated shock",
"      </strong>",
"      &ndash; During this stage, compensatory mechanisms are overwhelmed. Heart rate is markedly elevated and hypotension develops. Signs and symptoms of organ dysfunction (such as altered mental status as the result of poor brain perfusion) appear. Systolic blood pressure falls, although children who have lost as much as 30 to 35 percent of circulating blood volume can typically maintain normal systolic blood pressures. Once hypotension develops, the child's condition usually deteriorates rapidly to cardiovascular collapse and cardiac arrest.",
"     </li>",
"     <li>",
"      <strong>",
"       Irreversible shock",
"      </strong>",
"      &ndash; During this stage, progressive end-organ dysfunction leads to irreversible organ damage and death. Tachycardia may be replaced by bradycardia and blood pressure becomes very low. The process is often irreversible, despite resuscitative efforts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to these stages of shock, three broad mechanisms of shock are recognized: hypovolemic, distributive, and cardiogenic. Each type is characterized by one primary physiologic derangement as follows (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H7#H7\">",
"     \"Physiology and classification of shock in children\", section on 'Classification'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypovolemic",
"      </strong>",
"      &ndash; Decreased preload caused by volume loss including hemorrhage, gastrointestinal losses, insensible losses (eg, burns), or third spacing",
"     </li>",
"     <li>",
"      <strong>",
"       Distributive",
"      </strong>",
"      &ndash; Decreased vascular resistance due to vasodilation caused by sepsis, anaphylaxis, or acute injury to the spinal cord or brain",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiogenic",
"      </strong>",
"      &ndash; Decreased cardiac contractility caused by primary myocardial injury, arrhythmias, congenital heart disease, or acquired obstructive conditions (eg, pneumothorax, cardiac tamponade, or pulmonary embolism)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, a patient may have more than one type of shock (such as an infant with cardiogenic shock from supraventricular tachycardia who is also hypovolemic because he has been unable to drink or a child with underlying cardiomyopathy who is septic). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation of shock in children\", section on 'Clinical classification of shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An algorithm for identifying the cause of shock is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"UTD.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ). Recognition of shock and classification based upon clinical findings is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial evaluation of shock in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EARLY GOAL-DIRECTED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early goal-directed therapy for shock refers to an aggressive systematic approach to resuscitation targeted to improvements in physiologic indicators of perfusion and vital organ function within the first six hours. Targeted interventions are determined by degree of illness and response to treatment within the first hour of care. This approach has been most strongly promoted for children with septic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450185#H19450185\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physiologic indicators and target goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physiologic indicators that should be targeted during therapy (with goals in parentheses) include [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood pressure (systolic pressure at least fifth percentile for age: 60 mmHg &lt;1 month of age, 70 mmHg + [2 x age in years] in children 1 month to 10 years of age, 90 mmHg in children 10 years of age or older)",
"     </li>",
"     <li>",
"      Quality of central and peripheral pulses (strong, distal pulses equal to central pulses)",
"     </li>",
"     <li>",
"      Skin perfusion (warm, with capillary refill &lt;2 seconds)",
"     </li>",
"     <li>",
"      Mental status (normal mental status)",
"     </li>",
"     <li>",
"      Urine output (&ge;1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, once effective circulating volume is restored)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Heart rate is an important physiologic indicator of circulatory status. For children with shock, tachycardia is often a compensatory response to poor tissue perfusion. In this situation, a decrease in heart rate with fluid therapy can be a valuable indicator of improved perfusion in response to treatment (",
"    <a class=\"graphic graphic_table graphicRef77057 \" href=\"UTD.htm?17/33/17947\">",
"     table 2",
"    </a>",
"    ). However, many other factors (ie, fever, drugs, hypoxia, and anxiety) influence heart rate. In addition, an abnormal heart rate may be the direct result of the cause of shock (as with myocarditis or beta blocker ingestion). Although trends in response to treatment should be carefully monitored, specific target goals for heart rate are difficult to define and may not be useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H12#H12\">",
"     \"Initial evaluation of shock in children\", section on 'Circulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevation of serum or blood lactate (&gt;4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    may help identify the severity of shock at presentation. Although evidence is limited in children, reduction in serum or blood lactate levels have been associated with improved survival in adults with shock [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Rapid determination of blood lactate may be obtained at the bedside.",
"   </p>",
"   <p>",
"    Identifying physiologic indicators to monitor the effectiveness of resuscitation for children with shock is challenging. Parameters that are monitored for adults with sepsis (ie, central venous pressure and central venous oxygen saturation) require central venous catheterization, which can be technically difficult and not always practical or appropriate in children.",
"   </p>",
"   <p>",
"    Noninvasive ultrasonic determination of cardiac index, cardiac output, systemic vascular resistance, and stroke volume is feasible in healthy children, and age-based normative values have been published [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/6\">",
"     6",
"    </a>",
"    ]. Although not widely available, bedside Doppler ultrasound shows promise as a noninvasive method to guide vasoactive therapy by calculating cardiac output (CO) and systemic vascular resistance (SVR) from measurements of blood flow over the pulmonary artery or aorta. As an example, in an observational study of children with fluid-resistant septic shock, this method identified warm shock (high CO, low SVR) and cold shock (low to normal CO, high SVR) in 30 children and correlated these shock states with the underlying diagnosis; warm shock in children with central venous catheter related sepsis (15 of 16 patients) and cold shock in those patients with community acquired sepsis (12 of 14 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several physiologic indicators can be readily monitored noninvasively during the initial management of shock and, since many children in shock respond well, invasive monitoring can often be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2\">",
"     2",
"    </a>",
"    ]. Mean arterial pressure can be measured with a blood pressure cuff. Clinical experience suggests that quality of central and peripheral pulses, skin perfusion, mental status, and urine output are useful signs for assessing response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Limited observational evidence suggests that capillary refill time may correlate with ScvO2. In a prospective study of 21 critically ill children, the majority of whom had septic shock, a central capillary refill time &le;2 seconds had a sensitivity of 84 percent and a positive predictive value of 50 percent for a ScvO2 &ge;70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fluid administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence exists concerning the optimal amount and rate of fluid administration for children with shock. Several studies support the use of isotonic crystalloid fluid bolus (ie, normal saline or Ringer&rsquo;s lactate) as a component of goal-directed therapy for shock. However, aggressive fluid resuscitation may be harmful for children who are not hypovolemic or have compensated shock with certain comorbidities (eg, cardiac disease, diabetic ketoacidosis [DKA], syndrome of inappropriate antidiuretic hormone secretion, severe malnutrition, or malaria). (See",
"    <a class=\"local\" href=\"#H1783287\">",
"     'Benefits'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1783323\">",
"     'Risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The etiology and degree of shock determines the volume and rate of initial fluid resuscitation (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/1-3\">",
"     1-3",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H15712116\">",
"     'Definitions'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Decompensated hypovolemic or distributive shock",
"      </strong>",
"      &ndash; We recommend that children with decompensated hypovolemic or distributive shock (as from gastrointestinal losses, traumatic hemorrhage, sepsis, or anaphylaxis), receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per bolus of isotonic crystalloid, such as normal saline or Ringer's lactate solution, infused over 5 to 10 minutes and repeated, as needed, up to four times in patients without improvement and",
"      <strong>",
"       no",
"      </strong>",
"      signs of fluid overload [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,9,10\">",
"       2,9,10",
"      </a>",
"      ]. Additional therapies, such as blood transfusion in patients with hypovolemic shock from hemorrhage or vasoactive drug therapy and corticosteroid administration in patients with septic shock may be required depending upon the response to fluid administration. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hypovolemic shock'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H15\">",
"       'Septic shock'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Observational studies of rapid fluid resuscitation as a component of goal-directed therapy and in conjunction with other critical care interventions such as prophylactic endotracheal intubation with mechanical ventilation and close monitoring by pediatric critical care specialists has been associated with a marked decrease in mortality, especially in children with decompensated septic shock. (See",
"      <a class=\"local\" href=\"#H1783287\">",
"       'Benefits'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Techniques to rapidly deliver intravenous fluid include gravity, applying pressure directly to the bag of fluid with an inflatable device, delivering aliquots of fluid using a large syringe that is refilled through a three-way stopcock attached to the bag (the \"push-pull\" method) or use of rapid infusion pumps designed to deliver high volumes of warmed fluids or blood. Gravity alone is likely insufficient to deliver 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 5 to 10 minutes. This was demonstrated in a randomized trial that compared the rate at which fluid could be delivered to 57 children requiring fluid resuscitation using gravity, an inflatable pressure bag, or a \"push-pull\" method [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/11\">",
"       11",
"      </a>",
"      ]. The median volume of fluid delivered over five minutes by gravity was 6.2",
"      <span class=\"nowrap\">",
"       mL/kg,",
"      </span>",
"      in comparison to 20.9",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for the pressure bag and 20.2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for the \"push-pull\" method. These differences remained significant after controlling for intravenous catheter gauge, age, and weight.",
"     </li>",
"     <li>",
"      <strong>",
"       Compensated hypovolemic or distributive shock",
"      </strong>",
"      &ndash; We suggest that children with compensated hypovolemic or distributive shock receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per bolus of isotonic crystalloid, such as normal saline or Ringer's lactate solution over 5 to 20 minutes. Patients should be closely monitored during fluid administration. Additional fluid boluses may be indicated depending upon the patients&rsquo; response. Evidence suggests that overly aggressive fluid bolus may be harmful in selected patients, including those with cardiogenic shock, DKA, syndrome of inappropriate diuretic hormone secretion, severe malnutrition, or, in resource-limited settings, severe febrile illness in the absence of dehydration or hemorrhage. (See",
"      <a class=\"local\" href=\"#H1783323\">",
"       'Risks'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiogenic shock",
"      </strong>",
"      &ndash; For suspected cardiogenic shock in patients with signs such as a gallop rhythm, pulmonary rales, jugular venous distension, or hepatomegaly, a smaller isotonic crystalloid fluid bolus of 5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg,",
"      </span>",
"      infused over 10 to 20 minutes decreases the likelihood of exacerbating heart failure. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cardiogenic shock'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Diabetic ketoacidosis",
"      </strong>",
"      &ndash; Children with diabetic ketoacidosis (DKA) should receive careful fluid resuscitation (one bolus of 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      infused over one hour) in order to avoid cerebral edema, a rare complication of DKA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment and complications of diabetic ketoacidosis in children\", section on 'Cerebral edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe febrile illness in resource-limited settings",
"      </strong>",
"      &ndash; Children with severe febrile illness without dehydration or hemorrhage and with normal blood pressure who reside in resource limited settings, where aggressive monitoring, endotracheal intubation with mechanical ventilation, and vasopressor therapies are not available, and who have no signs of dehydration or hemorrhage should",
"      <strong>",
"       not",
"      </strong>",
"      receive boluses of isotonic fluid. This approach is associated with increased mortality when compared to blood transfusion and maintenance fluid therapy alone. (See",
"      <a class=\"local\" href=\"#H1783323\">",
"       'Risks'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12495758\">",
"    <span class=\"h3\">",
"     Resource limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children in resource limited settings are frequently malnourished and, depending upon the region, may have a high prevalence of Falciparum malaria. Furthermore, many of these resource limited settings do not have critical care capability with respect to monitoring, mechanical ventilation, and administration of vasopressors. Thus, fluid administration should be tailored to the specific cause of shock and based upon whether severe malnutrition or malaria is clinically suspected. Children receiving intravenous fluid therapy warrant frequent reevaluation of their condition with modification of fluid therapy based upon clinical response.",
"   </p>",
"   <p>",
"    We suggest that children in resource limited settings with signs of shock receive fluid resuscitation according to the emergency triage assessment and treatment guidelines developed by the World Health Organization [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with severe dehydration and diarrhea and",
"      <strong>",
"       no",
"      </strong>",
"      signs of severe malnutrition should receive an infusion of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic crystalloid fluids as rapidly as possible and repeated, as needed, up to three times in patients who do not improve and do",
"      <strong>",
"       not",
"      </strong>",
"      develop signs of fluid overload similar to what is suggested for children managed in settings with critical care capability. After the third fluid bolus of crystalloid, use of colloid (eg, blood, 5 percent albumin) is acceptable although evidence supporting this practice is lacking. This approach is similar to what is suggested for children managed in settings with critical care capability. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      According to the World Health Organization protocol, children with dengue virus hemorrhagic fever and hypotensive shock should receive an initial bolus of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of five percent dextrose in normal saline or Ringers lactate over 15 minutes (",
"      <a class=\"graphic graphic_algorithm graphicRef82833 \" href=\"UTD.htm?30/45/31440\">",
"       algorithm 2",
"      </a>",
"      ). Patients who improve should receive continuous infusion of crystalloid or colloid and undergo regular assessment of clinical condition and hematocrit. Children who do not improve warrant rapid assessment of hematocrit and, depending upon the result, should receive colloid or blood. The treatment of shock in patients with dengue virus infection with significant bleeding is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=see_link&amp;anchor=H11#H11\">",
"       \"Prevention and treatment of dengue virus infection\", section on 'Treatment of shock'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with severe malnutrition and shock who also have lethargy or loss of consciousness should receive 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic crystalloid fluids combined with 5 percent dextrose over one hour. Further care depends upon the patient&rsquo;s response:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the patient&rsquo;s condition worsens during fluid administration, the treatment should be stopped.",
"     </li>",
"     <li>",
"      If the patient improves with fluid therapy, an additional 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      should be given over one hour followed by oral or nasogastric rehydration.",
"     </li>",
"     <li>",
"      If there is no improvement, administer antibiotics, provide maintenance fluid therapy, and transfuse with 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of whole blood over three hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with severe malaria typically require glucose administration for hypoglycemia, antimalarial drugs, and blood transfusion for anemia. Fluid administration should be based upon the degree of dehydration and titrated to maintain urine output. A detailed discussion of fluid management in patients with severe malaria is found separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of severe falciparum malaria\", section on 'Volume management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, we recommend that children in resource limited settings who have severe febrile illness without dehydration or hemorrhage and with normal blood pressures",
"    <strong>",
"     not",
"    </strong>",
"    receive boluses of isotonic fluid. In a randomized trial of bolus fluid therapy versus no bolus in such patients, administration of 20 to 40",
"    <span class=\"nowrap\">",
"     ml/kg",
"    </span>",
"    of isotonic crystalloid solution or albumin was associated with significantly increased mortality. (See",
"    <a class=\"local\" href=\"#H1783323\">",
"     'Risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Crystalloid versus colloid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid therapy for children with shock should begin with isotonic crystalloid, such as normal saline or lactated Ringer's solution, as supported by the following evidence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Randomized trials and meta-analyses have failed to consistently demonstrate a difference between colloid and crystalloid for the treatment of shock in adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Crystalloid versus colloid'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children, randomized trials comparing colloid with crystalloid for hypotensive newborns and for children with dengue shock syndrome have not demonstrated a difference between the solutions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/14-17\">",
"       14-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Colloid solutions are more expensive and patients may develop adverse reactions to them.",
"     </li>",
"     <li>",
"      Many patients in shock are hyperglycemic. Although identification and treatment of hypoglycemia is very important, the rapid infusion and large amounts of bolus fluids to treat shock necessitate exclusion of glucose from the resuscitation fluids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasoactive agents may be useful for children with shock (other than hypovolemic shock) who have not improved with initial fluid resuscitation. These agents have effects on myocardial contractility, heart rate, and vasculature that can improve cardiac output (",
"    <a class=\"graphic graphic_table graphicRef63100 \" href=\"UTD.htm?32/5/32860\">",
"     table 3",
"    </a>",
"    ). Initiation of vasoactive agents prior to or in place of adequately fluid resuscitating the patient, regardless of the etiology of shock, may lead to end-organ ischemia. Furthermore, these agents should be avoided in children with hypovolemic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drugs that are typically used during the initial management of children with shock include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"     dopamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    , norepinephrine,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    , and phosphodiesterase enzyme inhibitors. The choice of agent depends on the pathophysiologic parameters that must be manipulated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effect of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      is dose-dependent. At low doses, it stimulates the heart and improves renal blood flow. At higher doses, it causes vasoconstriction and increases systemic vascular resistance (SVR). In most situations, dopamine should be used first when vasoactive infusions are required to treat shock that has not responded to fluid administration.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       Epinephrine",
"      </a>",
"      stimulates the heart and is a potent vasoconstrictor. It also relaxes bronchial smooth muscle. It is typically used for patients with anaphylaxis or those who do not respond to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      , particularly those with septic shock and increased SVR (cold shock) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Like",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      , norepinephrine stimulates the heart and causes vasoconstriction. Vasoconstrictive effects are usually greater than the effects on contractility and heart rate. It can be used for children who do not respond to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/54/13157?source=see_link\">",
"       dopamine",
"      </a>",
"      and is preferred over epinephrine by some experts for those patients with sepsis and decreased SVR (warm shock) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"       Dobutamine",
"      </a>",
"      increases myocardial contractility and heart rate. It also decreases systemic vascular resistance, which can cause hypotension. It is useful for patients with decreased myocardial function who are normotensive.",
"     </li>",
"     <li>",
"      Phosphodiesterase enzyme inhibitors (ie,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/60/25542?source=see_link\">",
"       milrinone",
"      </a>",
"      and inamrinone) improve cardiac contractility and reduce afterload. They may be used to treat cardiogenic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GOAL-DIRECTED ALGORITHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of children with shock requires the rapid initiation of aggressive treatment. A goal-directed approach can generally be applied to most patients who present with shock, independent of the underlying cause (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 3",
"    </a>",
"    ). During this initial stabilization, however, clues to the exact etiology of shock must also be sought to best direct subsequent therapy and quickly identify patients who may be harmed by or not respond to this approach. (See",
"    <a class=\"local\" href=\"#H1783323\">",
"     'Risks'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest using a goal-directed approach for children who present with shock and are receiving care in a facility with critical care capability as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial management should focus on fluid resuscitation with isotonic crystalloid solution and specific pharmacologic therapies as indicated once the etiology of shock is identified.",
"     </li>",
"     <li>",
"      Interventions must be administered in a rapid sequence, with evaluation of physiologic indicators before and after each intervention. The ideal timeline for the initial management of shock in children is uncertain and may be unachievable in clinical practice. However, clinicians should work rapidly to reverse shock utilizing all resources at their disposal.",
"     </li>",
"     <li>",
"      Once physiologic goals have been achieved, indicating that perfusion is improved, the patient should continue to receive supportive treatment and careful monitoring. Achieving a normal blood pressure is essential for the patient who is hypotensive. For children with compensated shock and normal blood pressures, therapeutic endpoints based upon noninvasive indicators are reasonable targets, but they may be unreliable. Skin perfusion can be influenced by room temperature, mental status may be abnormal as the result of a drug ingestion or central nervous system infection, and accurate measurement of urine output requires bladder catheterization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following algorithm for initiating and reevaluating therapy once shock is recognized has been adapted from consensus recommendations for the management of septic shock in children which were based primarily upon evidence extrapolated from adult studies (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,19\">",
"     2,19",
"    </a>",
"    ]. Although the specific time sequence is not usually achievable in practice in the emergency department, it provides a point of reference that reminds clinicians of the urgency of the patient's condition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Within the initial 5 to 15 minutes of therapy, the following actions should commence:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Life-threatening conditions should be recognized and treatment initiated. Vascular or intraosseous access should be established. Ideally two access sites capable of large volume infusion should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link&amp;anchor=H4#H4\">",
"       \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'Peripheral access'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link&amp;anchor=H17936377#H17936377\">",
"       \"Intraosseous infusion\", section on 'Techniques'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid measurement of blood glucose should be obtained and treatment of hypoglycemia initiated.",
"     </li>",
"     <li>",
"      Trauma patients warrant prompt evaluation by a trauma surgeon to determine the need for operative intervention. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Additional management decisions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Isotonic crystalloid infusion should be started. Rapid infusion of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 5 minutes should be performed in children who are hypotensive and without signs of cardiogenic shock.",
"     </li>",
"     <li>",
"      Patients with compensated shock should also receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 5 to 20 minutes as long as there are no signs of cardiogenic shock, diabetic ketoacidosis (DKA), or other conditions that may worsen with fluid administration.",
"     </li>",
"     <li>",
"      For children with signs of cardiogenic shock who may be hypovolemic, fluid should be given cautiously (5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 10 to 20 minutes).",
"     </li>",
"     <li>",
"      Children with DKA should receive careful fluid resuscitation (one bolus of 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      infused over one hour). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1783323\">",
"       'Risks'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Children with signs of anaphylaxis should also receive intramuscular",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anaphylactic shock'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Heart rate and pulse oximetry should be continuously monitored and blood pressure should be frequently accessed.",
"     </li>",
"     <li>",
"      Other diagnostic studies (ie, CBC, electrolytes, serum or blood lactate, cultures, and type and cross match) should be obtained as indicated by clinical assessment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H15#H15\">",
"       \"Initial evaluation of shock in children\", section on 'Ancillary studies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the initial fluid bolus, the following physiologic indicators (with goals in parentheses) should be evaluated and repeatedly assessed during treatment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Blood pressure (systolic pressure at least fifth percentile for age: 60 mmHg &lt;1 month of age, 70 mmHg + [2 x age in years] in children 1 month to 10 years of age, 90 mmHg in children 10 years of age or older)",
"     </li>",
"     <li>",
"      Quality of central and peripheral pulses (strong, distal pulses equal to central pulses)",
"     </li>",
"     <li>",
"      Skin perfusion (warm, with capillary refill &lt;2 seconds)",
"     </li>",
"     <li>",
"      Mental status (normal mental status)",
"     </li>",
"     <li>",
"      Urine output (&ge;1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, once effective circulating volume is restored)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Within 15 to 30 minutes of presentation, the following should be performed, if possible:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Abnormalities in calcium, and electrolyte measurements should be identified and treatment initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link\">",
"       \"Overview of the treatment of hyponatremia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment and prevention of hyperkalemia in adults\", section on 'Rapidly acting transient therapies'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3820122#H3820122\">",
"       \"Clinical manifestations and treatment of hypokalemia\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hypocalcemia\", section on 'Therapeutic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriate antibiotics should be administered to children who may be in septic shock. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Septic shock'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H9034264#H9034264\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Initial antimicrobial therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children, other than those in cardiogenic shock or with DKA, who have not improved should continue to receive isotonic crystalloid in 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      boluses to a total of 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over the first 30 minutes of treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cardiogenic shock'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link&amp;anchor=H30197583#H30197583\">",
"       \"Treatment and complications of diabetic ketoacidosis in children\", section on 'Fluid repletion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vasoactive drug therapy may be initiated in children with possible cardiogenic shock who have not responded to fluid and to children with signs of septic shock who have not responded to 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      or more of isotonic fluid boluses. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cardiogenic shock'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link\">",
"       \"Use of vasopressors and inotropes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should be evaluated for physiologic indicators of peripheral perfusion and signs of fluid overload (decreased oxygenation, rales, gallop rhythm, hepatomegaly) before and after each bolus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who have not improved after 30 to 60 minutes should be evaluated for other causes of shock. Consultation with pediatric critical care specialists and, in victims of trauma, trauma surgeons with pediatric expertise should be arranged. Additional therapies may be provided, as indicated:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children with hypovolemic shock, reassess the estimated fluid losses, continue fluid replacement, and evaluate the need for colloid or blood transfusion. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hypovolemic shock'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For children with septic shock unresponsive to fluid, initiate vasoactive drug therapy and evaluate the need for corticosteroid therapy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Septic shock'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      catecholamine-resistant shock should be admitted to an intensive care unit where additional monitoring of more precise physiologic indicators (ie, central venous pressure and central venous oxygen saturation) can be performed. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Monitoring'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H21\">",
"       'Disposition'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Children noted to have elevations in serum lactate at the onset of resuscitation, may benefit from serial lactate measurements. Data in adults suggest that patients with persistent elevation in serum lactate (lactate levels remaining within 10 percent of initial value) have a significantly higher mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1783287\">",
"    <span class=\"h2\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following observational evidence supports the elements of a goal-directed approach (including physiologic targets, fluid administration, and pharmacologic therapy) for the initial management of shock in children (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 3",
"    </a>",
"    ). These studies, when combined with clinical experience and an understanding of the pathophysiology of shock, suggest that many children with shock benefit from early, aggressive treatment targeted to improvement in physiologic indicators that are reliable and easy to evaluate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/1,2,21\">",
"     1,2,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An observational study of 1422 children with signs of shock (abnormal capillary refill, tachycardia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension) who were transferred from a community hospital setting to a tertiary care pediatric facility found that early reversal of shock in the community hospital and use of Pediatric Advanced Life",
"      <span class=\"nowrap\">",
"       Support/Advanced",
"      </span>",
"      Pediatric Life Support",
"      <span class=\"nowrap\">",
"       (PALS/APLS)",
"      </span>",
"      interventions were associated with a decrease in mortality and morbidity (permanent neurologic dysfunction) regardless of underlying etiology (eg, trauma, sepsis) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/22\">",
"       22",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      When adjusted for severity of illness, trauma status (trauma versus no trauma), and treating facility, early reversal of shock was associated with a 57 percent reduction in mortality and functional morbidity (odds ratio: 0.4; 95% CI: 0.3-0.7). Death occurred in 16 percent (163 of 996 patients) without early shock reversal versus 5 percent (26 of 514 patients) with early shock reversal.",
"     </li>",
"     <li>",
"      When adjusted for severity of illness, trauma status (trauma versus no trauma), and treating facility, use of",
"      <span class=\"nowrap\">",
"       PALS/APLS",
"      </span>",
"      interventions were associated with a 40 percent decrease in mortality and morbidity (odds ratio: 0.6; 95% CI: 0.4-0.9). Death occurred in 15 percent of children not receiving",
"      <span class=\"nowrap\">",
"       PALS/APLS",
"      </span>",
"      intervention (142 of 946 patients) versus 9 percent of children receiving",
"      <span class=\"nowrap\">",
"       PALS/APLS",
"      </span>",
"      intervention (49 of 564 patients). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an observational study of 136 children with septic shock, mortality was 6 percent (3 of 53 patients) in those who were not in shock on admission to a pediatric intensive care unit versus 19 percent (21 of 83 patients) in those with shock on arrival who did not have shock reversed during emergency department care or transport (p = 0.02) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/23\">",
"       23",
"      </a>",
"      ]. Mean transfer time ranged from 6 to 14 hours and was not different between the two groups. Fluid and vasopressor management followed the 2002 American College of Critical Care",
"      <span class=\"nowrap\">",
"       Medicine/Pediatric",
"      </span>",
"      Advanced Life Support consensus guidelines in only 38 percent of these children with persistent shock.",
"     </li>",
"     <li>",
"      Institution of timely goal directed interventions by a mobile intensive care team, including early and aggressive bolus colloid administration, endotracheal intubation and mechanical ventilation, and vasoactive therapy in conjunction with regionalization of care for 331 children with meningococcemia in the United Kingdom was associated with a decrease in the case fatality rate from 23 to 2 percent over five years (annual reduction in the odds of death 0.41, 95% CI: 0.27-0.62) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of goal-directed therapy has been associated with reduced mortality in children with severe sepsis [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2\">",
"       2",
"      </a>",
"      ]. As an example, in one institution, the mortality rate from purpura and severe sepsis decreased from approximately 20 to 1 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/25\">",
"       25",
"      </a>",
"      ]. Similarly, in the United States, death from severe sepsis was estimated as 4 percent (2 percent in healthy children and 8 percent in children with prior chronic illness) in 2003 compared with 9 percent in 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1783323\">",
"    <span class=\"h2\">",
"     Risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;In resource-limited settings that cannot provide advanced airway and circulatory support, bolus administration of albumin or normal saline may be associated with increased mortality for children with signs of shock and severe febrile illness but without dehydration or hemorrhage.",
"   </p>",
"   <p>",
"    A randomized trial of 3141 children between 60 days and 12 years of age with severe febrile illness (altered mental status, respiratory distress, or both) and impaired perfusion (eg, delayed capillary refill time &ge;3 seconds, weak pulses, or severe tachycardia) and treated in six district hospitals in sub-Saharan Africa found that 48-hour mortality was significantly higher among those who received boluses of albumin or normal saline when compared to controls who did not receive fluid boluses (10.6, 10.5, and 7.3 percent respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. These children had a high frequency of malaria parasitemia (57 percent) and severe anemia (hemoglobin &lt;5",
"    <span class=\"nowrap\">",
"     grams/dL,",
"    </span>",
"    32 percent) although preplanned subgroup analyses did not find a difference in mortality based upon these characteristics. More children in the no fluid bolus group received blood transfusions in the first hour than in the fluid bolus groups (22 versus 2 to 4 percent). However, the overall amount of blood delivered after eight hours was not significantly different among the groups. Of note, none of the patients in this trial had hypovolemic dehydration or trauma as the primary cause of their illness. A subsequent reanalysis of this study found that cardiovascular collapse from cardiotoxicity or ischemia-reperfusion injury in patients receiving fluids accounted for the excess mortality rather than fluid overload [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this study is the only randomized trial of fluid therapy in children with compensated septic shock, it indicates a potential for significant harm if fluid therapy is used indiscriminately among children with severe febrile illness in developing nations. There is no evidence that these findings can be generalized to resource-rich settings where intensive monitoring, mechanical ventilation, and vasopressor support are routinely available and the baseline characteristics of the patients are significantly different. In clinical facilities with these capabilities, observational evidence supports early isotonic fluid resuscitation guided by the degree and type of shock present as a key component of goal-directed therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"     algorithm 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Fluid administration'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1783287\">",
"     'Benefits'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Goal-directed algorithm'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Aggressive fluid replacement may also be harmful in patients with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Severe anemia",
"      </strong>",
"      &ndash; Rapid fluid administration in children with hemoglobin levels below 5",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      may further dilute the hemoglobin concentration, impair oxygen delivery, and precipitate heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/32\">",
"       32",
"      </a>",
"      ]. Blood transfusion is the preferred therapy in such patients, although careful fluid administration may be acceptable if transfusion is delayed. As an example, in a small trial of 38 children with severe falciparum malaria (hemoglobin &lt;5",
"      <span class=\"nowrap\">",
"       g/dL),",
"      </span>",
"      administration of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic saline or 4.5 percent albumin versus maintenance fluid therapy only while waiting for blood transfusion did not cause congestive heart failure and resulted in significantly less need for emergency interventions (0 versus 22 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"      </strong>",
"      &ndash; Aggressive fluid therapy in the absence of hypovolemia can cause cerebral edema in patients with meningitis and adult respiratory distress syndrome in patients with pneumonia as a result of fluid overload caused by SIADH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diabetic ketoacidosis (DKA)",
"      </strong>",
"      &ndash; Cerebral edema, a rare complication of DKA, usually develops during treatment and has been associated with rapid administration of fluids. However, cerebral edema may also occur in optimally managed patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment and complications of diabetic ketoacidosis in children\", section on 'Cerebral edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Cardiogenic shock",
"      </strong>",
"      &ndash; Although many children with cardiogenic shock have some degree of hypovolemia, fluids should be administered slowly and in boluses of 5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in such patients to avoid worsening myocardial insufficiency and pulmonary edema. Clinical findings of cardiogenic shock include gallop rhythm, jugular venous distension, pulmonary rales, and hepatomegaly. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cardiogenic shock'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Severe malnutrition",
"      </strong>",
"      &ndash; Intravenous fluid resuscitation in children with severe malnutrition and signs of shock is controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/34\">",
"       34",
"      </a>",
"      ]. Sunken eyes, lethargy, and tenting may occur from malnutrition alone and can cause clinicians to overestimate the degree of dehydration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/13\">",
"       13",
"      </a>",
"      ]. Some experts believe that malnutrition causes sodium and water retention, overexpansion of the extracellular fluid, and myocardial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. Thus, rapid administration of intravenous fluids to infants and children who do not have fluid depletion or physiologic changes associated with severe malnutrition or both may risk fluid overload, heart failure, and pulmonary edema and is not recommended by the World Health Organization (WHO) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. &nbsp;",
"      <br/>",
"      <br/>",
"      However, evidence suggests that the WHO recommendations for fluid resuscitation in severely malnourished may be too restrictive. For example, in an observational study of fluid resuscitation in 149 severely malnourished children with cholera and severe dehydration, infusion of approximately 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour of an isotonic saline solution over four to six hours was not associated with heart failure in any patient, and all patients survived [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/38\">",
"       38",
"      </a>",
"      ]. Furthermore, in a clinical trial of 61 children with severe malnutrition accompanied by decompensated shock in the majority of patients, administration of 30 to 40",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of crystalloid fluids over two hours failed to reverse shock in over half of patients and was accompanied by high mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/34\">",
"       34",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Thus, pending further study, some experts suggest that severely malnourished children receive fluid resuscitation with careful reassessment according to the WHO guidelines for children with shock and no signs of malnutrition. (See",
"      <a class=\"local\" href=\"#H12495758\">",
"       'Resource limited settings'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADDITIONAL MANAGEMENT DECISIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with signs of shock should receive supplemental oxygen. Early positive pressure ventilation and intubation should be performed in patients with airway compromise or impending respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/18\">",
"     18",
"    </a>",
"    ]. These interventions can maximize oxygenation, decrease the work of breathing, and may redistribute blood flow from respiratory muscles to more vital organs.",
"   </p>",
"   <p>",
"    Intubation should be performed using a rapid sequence technique (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"UTD.htm?17/26/17837\">",
"     table 5",
"    </a>",
"    ). This approach requires that vascular access already be in place. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Vascular access'",
"    </a>",
"    below.)&nbsp;",
"   </p>",
"   <p>",
"    It is important to choose agents that do not worsen cardiovascular status.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"     Etomidate",
"    </a>",
"    is a reasonable choice in many children with shock, other than septic shock, because it typically does not compromise hemodynamic stability. However, limited low quality evidence in children suggests that etomidate may adversely affect outcome in patients with septic shock who already have some degree of adrenocortical suppression, such as those with severe sepsis.",
"   </p>",
"   <p>",
"    We suggest the following approach in children with shock (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H18#H18\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Etomidate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=see_link&amp;anchor=H20#H20\">",
"     \"Rapid sequence intubation (RSI) in children\", section on 'Ketamine'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       Ketamine",
"      </a>",
"      , if available and not contraindicated (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=see_link&amp;anchor=H10#H10\">",
"       \"Sedation or induction agents for rapid sequence intubation in adults\", section on 'Ketamine'",
"      </a>",
"      ), is preferable to sedate a child in septic shock.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      is a reasonable sedative choice for children with hypovolemic and cardiogenic shock.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      should not be used routinely in children with septic shock but may be appropriate if",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      is otherwise contraindicated or unavailable. If etomidate is used, we suggest that patients with septic shock refractory to fluids and vasopressors also receive a single dose of a corticosteroid, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      Hydrocortisone interferes with the short",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/45/29397?source=see_link\">",
"       ACTH stimulation test",
"      </a>",
"      , while dexamethasone does not, so intensivists may prefer the latter if the diagnosis of adrenal insufficiency is unclear. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link&amp;anchor=H19450192#H19450192\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Airway and breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Emergency clinicians should inform the physicians assuming care for the patient in the intensive care unit when",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      has been used for induction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/11/34995?source=see_link\">",
"       Etomidate",
"      </a>",
"      should not be used as an infusion or in repeated bolus doses for maintenance of sedation after intubation in patients with septic shock. The use of corticosteroids for the treatment of septic shock in general is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=see_link\">",
"       \"Corticosteroid therapy in septic shock\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular access must be quickly obtained as soon as circulatory compromise is identified. Peripheral intravenous access should be attempted initially. Intraosseous cannulation should be considered if rapid intravenous access cannot be secured, particularly for children who are hypotensive. Central venous access is warranted in children with fluid refractory septic shock to assist in guiding goal-directed therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Early goal-directed therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=see_link&amp;anchor=H2#H2\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'General approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=see_link&amp;anchor=H3#H3\">",
"     \"Intraosseous infusion\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Life-threatening conditions that can be associated with shock must be rapidly identified and treated include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with upper airway obstruction from anaphylaxis should receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      ). Intubation or a surgical airway may be necessary for patients with complete upper airway obstruction or who do not improve quickly.",
"     </li>",
"     <li>",
"      The cause of shock, severe respiratory distress, asymmetric breath sounds, and poor perfusion may be obstructive such as from a tension pneumothorax that must be promptly decompressed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=see_link&amp;anchor=H20#H20\">",
"       \"Prehospital care of the adult trauma patient\", section on 'Needle chest decompression'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"       \"Placement and management of thoracostomy tubes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with respiratory distress, poor perfusion, muffled heart tones, pulsus paradoxus, hepatomegaly,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distended neck veins may have obstructive shock from cardiac tamponade. Fluid must be drained as quickly as possible, preferably in the operating room.",
"     </li>",
"     <li>",
"      Poor perfusion as a result of brady- or tachyarrhythmias requires immediate medical attention.",
"     </li>",
"     <li>",
"      Supraventricular tachycardia or ventricular tachycardia with poor perfusion should be treated with synchronized cardioversion (",
"      <a class=\"graphic graphic_table graphicRef53559 \" href=\"UTD.htm?21/42/22189\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=see_link&amp;anchor=H3#H3\">",
"       \"Management and evaluation of wide QRS complex tachycardia in children\", section on 'Unstable patient'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with bradycardia who are not hypoxic should receive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      (or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/13/25816?source=see_link\">",
"       atropine",
"      </a>",
"      if increased vagal tone or primary AV block is suspected) and may require cardiac compressions (",
"      <a class=\"graphic graphic_algorithm graphicRef52446 \" href=\"UTD.htm?20/4/20545\">",
"       algorithm 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=see_link&amp;anchor=H15#H15\">",
"       \"Guidelines for pediatric advanced life support\", section on 'Bradyarrhythmia management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SPECIFIC MANAGEMENT DECISIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whenever clinical features suggest a cause of shock, specific therapy should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation of shock in children\", section on 'Clinical classification of shock'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypovolemic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular fluid loss (whether from hemorrhage, vomiting, diarrhea, osmotic diuresis, or capillary leak) is the principal feature of hypovolemic shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H8#H8\">",
"     \"Initial evaluation of shock in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of hypovolemic shock focuses on fluid replacement and preventing ongoing fluid loss. Vasoactive infusions will not improve perfusion.",
"   </p>",
"   <p>",
"    For hypovolemic shock, most children should receive 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per bolus, repeated as needed. Each bolus should be infused over 5 to 10 minutes. Rapid infusion of fluids should be performed with caution in children with severe malnutrition. (See",
"    <a class=\"local\" href=\"#H12495758\">",
"     'Resource limited settings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Considerations for children who have not improved after receiving a total of 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over 30 to 60 minutes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The amount of fluid loss may have been underestimated (as with burn injury) or there may be significant ongoing fluid loss (ie, from hemorrhage with blunt abdominal trauma or capillary leak with bowel obstruction).",
"     </li>",
"     <li>",
"      Other conditions may be causing or contributing to shock (ie, a child with multiple trauma who has a spinal cord injury).",
"     </li>",
"     <li>",
"      Colloid is suggested for patients with capillary leak or hypoalbuminemia who have not improved after initial therapy with crystalloid solutions [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with hemorrhagic shock who have not improved should receive blood and require definitive treatment for the cause of hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]. Delayed fluid resuscitation for traumatic hemorrhagic is not recommended for children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link&amp;anchor=H15#H15\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Fluid resuscitation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Delayed fluid resuscitation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypovolemic shock is uncommon in children with diabetic ketoacidosis (DKA). Patients in DKA whose perfusion does not improve with 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic fluid should be evaluated for other causes of shock. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link&amp;anchor=H30197583#H30197583\">",
"     \"Treatment and complications of diabetic ketoacidosis in children\", section on 'Fluid repletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Septic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management according to the American Critical Care Medicine guidelines for neonates and children with septic shock is suggested (",
"    <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"     algorithm 5",
"    </a>",
"    ). Clinical manifestations, rapid recognition, resuscitation, and initial management after resuscitation for pediatric septic shock are discussed in detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=see_link\">",
"       \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"       \"Septic shock: Ongoing management after resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anaphylactic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of allergies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of stridor, wheezing, urticaria, or facial edema suggest anaphylaxis. Children with possible anaphylaxis should receive intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"     epinephrine",
"    </a>",
"    , intravenous or intramuscular",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and steroids, in addition to rapid infusions of normal saline. Wheezing should be treated with nebulized",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/54/39782?source=see_link\">",
"     albuterol",
"    </a>",
"    . Patients with cardiovascular collapse or those that respond poorly to intramuscular epinephrine may require epinephrine intravenously (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56049 \" href=\"UTD.htm?2/18/2350\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66791 \" href=\"UTD.htm?39/39/40573\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Goal-directed algorithm'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Immediate management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cardiogenic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of heart disease, an abnormal cardiac examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening clinical condition with fluid resuscitation are suggestive of cardiogenic shock. Additional findings include tachycardia out of proportion to fever or respiratory distress, cyanosis unresponsive to oxygen, raised jugular venous pulsations, and absent femoral pulses. Cardiogenic shock is less common than other forms of shock in children. Early consultation with a pediatric cardiologist or intensivist is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=see_link&amp;anchor=H16#H16\">",
"     \"Initial evaluation of shock in children\", section on 'Clinical classification of shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management issues include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic shock (as from myocarditis or a toxic ingestion) should be considered for any child without a readily apparent cause for shock whose condition worsens with fluid therapy (",
"      <a class=\"graphic graphic_table graphicRef51200 \" href=\"UTD.htm?29/8/29838\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical manifestations and diagnosis of myocarditis in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some children with poor cardiac function may also be volume depleted. Fluid should be administered slowly and in boluses of 5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg.",
"      </span>",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"       dobutamine",
"      </a>",
"      or phosphodiesterase enzyme inhibitors can improve myocardial contractility and reduce systemic vascular resistance (afterload). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=see_link&amp;anchor=H21#H21\">",
"       \"Use of vasopressors and inotropes\", section on 'Dobutamine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Causes of obstructive shock (eg, tension pneumothorax, cardiac tamponade, or hemothorax) require specific interventions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link&amp;anchor=H7#H7\">",
"       \"Placement and management of thoracostomy tubes\", section on 'Pneumothorax'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link&amp;anchor=H24600630#H24600630\">",
"       \"Emergency pericardiocentesis\", section on 'Technique overview'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infants under 28 days of age in whom ductal-dependent congenital heart defects are likely should receive prostaglandin E1 (also known as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/57/23445?source=see_link\">",
"       alprostadil",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=see_link&amp;anchor=H19#H19\">",
"       \"Approach to the septic-appearing infant\", section on 'Prostaglandin E1 (alprostadil)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac arrhythmias (eg, supraventricular or ventricular tachycardia) should be addressed prior to fluid resuscitation (",
"      <a class=\"graphic graphic_algorithm graphicRef67438 \" href=\"UTD.htm?11/37/11860\">",
"       algorithm 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Treatment for massive pulmonary embolism consists of supportive care and antithrombotic therapy (unless otherwise contraindicated, as with patients who have had recent surgery). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=see_link&amp;anchor=H16#H16\">",
"       \"Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children\", section on 'Treatment recommendations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective management of children with shock requires frequent adjustment of therapeutic interventions based upon continuous hemodynamic monitoring and assessment of end organ perfusion (brain, kidneys, and skin).",
"   </p>",
"   <p>",
"    Monitoring should include continuous noninvasive measurement of heart rate and pulse oximetry with frequent measurement of blood pressure. In addition to these parameters, the following clinical features should also be observed before and after each fluid bolus (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Physiologic indicators and target goals'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Quality of central and peripheral pulses",
"     </li>",
"     <li>",
"      Skin perfusion (as indicated by temperature and capillary refill)",
"     </li>",
"     <li>",
"      Mental status",
"     </li>",
"     <li>",
"      Auscultation of lung and heart sounds",
"     </li>",
"     <li>",
"      Palpation of liver edge (to identify hepatomegaly as a sign of heart failure)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More aggressive monitoring may be necessary for children who do not improve with fluid resuscitation. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Goal-directed algorithm'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Interventions to consider include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A urinary catheter should be placed to monitor urine output.",
"     </li>",
"     <li>",
"      Children receiving vasoactive infusions should generally have arterial pressure monitoring after initial resuscitation. Placement of intraarterial catheters may occur in the emergency department or intensive care unit, depending upon resources. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2009?source=see_link&amp;anchor=H10#H10\">",
"       \"Arterial puncture and cannulation in children\", section on 'Arterial cannulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with fluid and catecholamine-resistant shock should be expeditiously transferred to intensive care units where central venous pressure (CVP) and central venous oxygen saturation (ScvO2) can be monitored. CVP is an indication of preload. A measurement of &lt;8 mmHg suggests that fluid resuscitation has been inadequate.",
"     </li>",
"     <li>",
"      ScvO2 measurements provide information regarding oxygen supply and consumption at the tissue level as an indication of perfusion. Experts recommend a target ScvO2 of &gt;70 percent as an indication of adequate perfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/2\">",
"       2",
"      </a>",
"      ]. In adults, lactate clearance is considered a reasonable alternative to measurement of ScvO2, but data in children are limited. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Assess perfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with shock whose symptoms resolve with treatment should be admitted to the hospital for observation. The cause of shock may persist (as with an infant with severe diarrhea), may reoccur (as with a biphasic anaphylactic reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/8/26762/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]), or may not be apparent.",
"   </p>",
"   <p>",
"    Children who have not improved with initial management and those whose conditions may worsen (ie, with septic or cardiogenic shock) should be admitted to an intensive care unit. Early consultation with a pediatric intensivist is suggested. Patients with hemorrhagic shock from trauma should be evaluated by a surgeon as quickly as possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PITFALLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of children with shock is challenging. Some pitfalls include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to recognize nonspecific signs of compensated shock (ie, unexplained tachycardia, abnormal mental status, or poor skin perfusion)",
"     </li>",
"     <li>",
"      Inadequate monitoring of response to treatment",
"     </li>",
"     <li>",
"      Inappropriate volume for fluid resuscitation (usually too little for children with sepsis or hypovolemic shock, but possibly too much for those with cardiogenic shock)",
"     </li>",
"     <li>",
"      Failure to reconsider possible causes of shock for children who are getting worse or not improving",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a dynamic and unstable pathophysiologic state characterized by inadequate tissue perfusion that must be identified promptly. Aggressive treatment within the first few hours after presentation can prevent the invariable progression and poor outcome that characterize the natural clinical course of shock. The ideal timeline for the initial management of shock in children is uncertain and is not usually achievable in practice in the emergency department. However, clinicians should work rapidly to reverse shock utilizing all resources at their disposal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the initial management of children with shock who are cared for in a setting with critical care capability, we suggest early goal-directed therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef77079 \" href=\"UTD.htm?41/12/42178\">",
"       algorithm 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Physiologic indicators that should be targeted include central and peripheral pulses, skin perfusion, mental status, blood pressure, and urine output (once effective circulating volume is restored). Physiologic indicators should be frequently assessed. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Goal-directed algorithm'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology and degree of shock determines the volume and rate of initial fluid resuscitation (",
"      <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid administration'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that children with",
"      <strong>",
"       decompensated",
"      </strong>",
"      hypovolemic or distributive shock (as from gastrointestinal losses, traumatic hemorrhage, sepsis, or anaphylaxis), receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per bolus of isotonic crystalloid, such as normal saline or Ringer's lactate solution, infused over 5 to 10 minutes and repeated, as needed, up to four times in patients without improvement and",
"      <strong>",
"       no",
"      </strong>",
"      signs of fluid overload (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with",
"      <strong>",
"       compensated",
"      </strong>",
"      hypovolemic or distributive shock, other than those with diabetic ketoacidosis, syndrome of inappropriate antidiuretic hormone secretion, severe malnutrition, or, in resource limited settings, severe febrile illness without dehydration or hemorrhage, receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per bolus of isotonic crystalloid, such as normal saline or Ringer's lactate solution over 5 to 20 minutes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients should be closely monitored during fluid administration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fluid administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1783323\">",
"       'Risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For suspected cardiogenic shock, children who are also hypovolemic should receive a smaller isotonic crystalloid fluid bolus of 5 to 10",
"      <span class=\"nowrap\">",
"       mL/kg,",
"      </span>",
"      infused over 10 to 20 minutes. This approach decreases the likelihood of exacerbating heart failure.",
"     </li>",
"     <li>",
"      Children with diabetic ketoacidosis (DKA) should receive careful fluid resuscitation (one bolus of 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      infused over one hour) in order to avoid cerebral edema, a rare complication of DKA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment and complications of diabetic ketoacidosis in children\", section on 'Cerebral edema'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that children with signs of shock cared for in resource limited settings that do not have critical care capability with respect to monitoring, mechanical ventilation, and administration of vasopressors receive fluid resuscitation according to the emergency triage assessment and treatment guidelines developed by the World Health Organization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We recommend that children in resource limited settings who have severe febrile illnesses without dehydration or hemorrhage and with normal blood pressures",
"      <strong>",
"       not",
"      </strong>",
"      receive boluses of isotonic fluid (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12495758\">",
"       'Resource limited settings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that children with shock receive isotonic crystalloid rather than colloid as the initial fluid therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Crystalloid versus colloid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional care includes establishing a secure airway and assessing for and treating life-threatening conditions (ie, upper airway obstruction, tension pneumothorax, cardiac tamponade, and unstable tachycardia). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Additional management decisions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of severe malnutrition, fluid resuscitation and preventing ongoing fluid loss are the treatments for hypovolemic shock. Children who have not improved following the rapid infusion of 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of crystalloid should be carefully reevaluated. We suggest that those with nontraumatic hypovolemic shock who have capillary leak or hypoalbuminemia and do not respond to 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of crystalloid receive colloid therapy or blood products (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Children with hemorrhagic shock who do not respond to 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of crystalloid should receive blood. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Hypovolemic shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management according to the American Critical Care Medicine guidelines for neonates and children with septic shock is suggested (",
"      <a class=\"graphic graphic_algorithm graphicRef80923 \" href=\"UTD.htm?28/36/29255\">",
"       algorithm 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=see_link\">",
"       \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link\">",
"       \"Septic shock: Ongoing management after resuscitation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with anaphylaxis require prompt treatment with intramuscular",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/19/37168?source=see_link\">",
"       epinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , and steroids (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"UTD.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Anaphylactic shock'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most children with cardiogenic shock require cautious fluid resuscitation in addition to vasoactive therapy. Obstructive causes of cardiogenic shock (ie, ductal-dependent congenital heart defects, pneumothorax, and pulmonary embolism) require specific therapies. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Cardiogenic shock'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All children who have been treated for shock should be admitted to the hospital. Those who do not improve with initial treatment should be admitted to an intensive care unit. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Recognition of shock. In: Pediatric Advanced Life Support Provider Manual, Chameides L, Samson RA, Schexnayder SM, Hazinski MF.  (Eds), American Heart Association, 2011. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/2\">",
"      Carcillo JA, Fields AI, American College of Critical Care Medicine Task Force Committee Members. Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 2002; 30:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/3\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/4\">",
"      Jansen TC, van Bommel J, Mulder PG, et al. The prognostic value of blood lactate levels relative to that of vital signs in the pre-hospital setting: a pilot study. Crit Care 2008; 12:R160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/5\">",
"      Levy B, Perez P, Gibot S, Gerard A. Increased muscle-to-serum lactate gradient predicts progression towards septic shock in septic patients. Intensive Care Med 2010; 36:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/6\">",
"      Cattermole GN, Leung PY, Mak PS, et al. The normal ranges of cardiovascular parameters in children measured using the Ultrasonic Cardiac Output Monitor. Crit Care Med 2010; 38:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/7\">",
"      Brierley J, Peters MJ. Distinct hemodynamic patterns of septic shock at presentation to pediatric intensive care. Pediatrics 2008; 122:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/8\">",
"      Raimer PL, Han YY, Weber MS, et al. A normal capillary refill time of &le; 2 seconds is associated with superior vena cava oxygen saturations of &ge; 70%. J Pediatr 2011; 158:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/9\">",
"      Carcillo JA, Davis AL, Zaritsky A. Role of early fluid resuscitation in pediatric septic shock. JAMA 1991; 266:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/10\">",
"      Boluyt N, Bollen CW, Bos AP, et al. Fluid resuscitation in neonatal and pediatric hypovolemic shock: a Dutch Pediatric Society evidence-based clinical practice guideline. Intensive Care Med 2006; 32:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/11\">",
"      Stoner MJ, Goodman DG, Cohen DM, et al. Rapid fluid resuscitation in pediatrics: testing the American College of Critical Care Medicine guideline. Ann Emerg Med 2007; 50:601.",
"     </a>",
"    </li>",
"    <li>",
"     Pocket Book Of Hospital Care For Children: Guidelines For The Management Of Common Illnesses With Limited Resources, World Health Organization, Geneva, Switzerland 2005. p.12.",
"    </li>",
"    <li>",
"     Emergency triage assessment and treatment (ETAT): Manual for participants. World Health Organization, Geneva, Switzerland, 2005. file://whqlibdoc.who.int/publications/2005/9241546875_eng.pdf (Accessed on January 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/14\">",
"      So KW, Fok TF, Ng PC, et al. Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 76:F43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/15\">",
"      Oca MJ, Nelson M, Donn SM. Randomized trial of normal saline versus 5% albumin for the treatment of neonatal hypotension. J Perinatol 2003; 23:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/16\">",
"      Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/17\">",
"      Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/18\">",
"      Tobias JD. Shock in children: the first 60 minutes. Pediatr Ann 1996; 25:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/19\">",
"      Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/20\">",
"      Arnold RC, Shapiro NI, Jones AE, et al. Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis. Shock 2009; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/21\">",
"      Bilkovski RN, Rivers EP, Horst HM. Targeted resuscitation strategies after injury. Curr Opin Crit Care 2004; 10:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/22\">",
"      Carcillo JA, Kuch BA, Han YY, et al. Mortality and functional morbidity after use of PALS/APLS by community physicians. Pediatrics 2009; 124:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/23\">",
"      Inwald DP, Tasker RC, Peters MJ, et al. Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit. Arch Dis Child 2009; 94:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/24\">",
"      Booy R, Habibi P, Nadel S, et al. Reduction in case fatality rate from meningococcal disease associated with improved healthcare delivery. Arch Dis Child 2001; 85:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/25\">",
"      Maat M, Buysse CM, Emonts M, et al. Improved survival of children with sepsis and purpura: effects of age, gender, and era. Crit Care 2007; 11:R112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/26\">",
"      Odetola FO, Gebremariam A, Freed GL. Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics 2007; 119:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/27\">",
"      Watson RS, Carcillo JA, Linde-Zwirble WT, et al. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/28\">",
"      Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/29\">",
"      Myburgh JA. Fluid resuscitation in acute illness--time to reappraise the basics. N Engl J Med 2011; 364:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/30\">",
"      Maitland K, George EC, Evans JA, et al. Exploring mechanisms of excess mortality with early fluid resuscitation: insights from the FEAST trial. BMC Med 2013; 11:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/31\">",
"      Myburgh J, Finfer S. Causes of death after fluid bolus resuscitation: new insights from FEAST. BMC Med 2013; 11:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/32\">",
"      Duke T. What the African fluid-bolus trial means. Lancet 2011; 378:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/33\">",
"      Maitland K, Pamba A, English M, et al. Pre-transfusion management of children with severe malarial anaemia: a randomised controlled trial of intravascular volume expansion. Br J Haematol 2005; 128:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/34\">",
"      Akech SO, Karisa J, Nakamya P, et al. Phase II trial of isotonic fluid resuscitation in Kenyan children with severe malnutrition and hypovolaemia. BMC Pediatr 2010; 10:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/35\">",
"      Wharton BA, Balmer SE, Somers K, Templeton AC. The myocardium in kwashiorkor. Q J Med 1969; 38:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/36\">",
"      Viart P. Hemodynamic findings in servere protein-calorie malnutrition. Am J Clin Nutr 1977; 30:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/37\">",
"      Viart P. Hemodynamic findings during treatment of protein-calorie malnutrition. Am J Clin Nutr 1978; 31:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/38\">",
"      Alam NH, Islam S, Sattar S, et al. Safety of rapid intravenous rehydration and comparative efficacy of 3 oral rehydration solutions in the treatment of severely malnourished children with dehydrating cholera. J Pediatr Gastroenterol Nutr 2009; 48:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/39\">",
"      Stark BJ, Sullivan TJ. Biphasic and protracted anaphylaxis. J Allergy Clin Immunol 1986; 78:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/8/26762/abstract/40\">",
"      Lee JM, Greenes DS. Biphasic anaphylactic reactions in pediatrics. Pediatrics 2000; 106:762.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6397 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26762=[""].join("\n");
var outline_f26_8_26762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15712116\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EARLY GOAL-DIRECTED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physiologic indicators and target goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fluid administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12495758\">",
"      - Resource limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Crystalloid versus colloid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GOAL-DIRECTED ALGORITHM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1783287\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1783323\">",
"      Risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADDITIONAL MANAGEMENT DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SPECIFIC MANAGEMENT DECISIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypovolemic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anaphylactic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cardiogenic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PITFALLS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6397|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?1/61/2000\" title=\"algorithm 1\">",
"      Undifferentiated pediatric shock algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/45/31440\" title=\"algorithm 2\">",
"      Management algorithm for dengue fever with hypotensive shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?41/12/42178\" title=\"algorithm 3\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/4/20545\" title=\"algorithm 4\">",
"      Pediatric bradycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/36/29255\" title=\"algorithm 5\">",
"      Pediatric sepsis management guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?11/37/11860\" title=\"algorithm 6\">",
"      Pediatric tachycardia algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6397|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/34/17963\" title=\"table 1\">",
"      Types of shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/33/17947\" title=\"table 2\">",
"      Heart rates in normal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/5/32860\" title=\"table 3\">",
"      Vasoactive receptor activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/50/18221\" title=\"table 4\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/26/17837\" title=\"table 5\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/42/22189\" title=\"table 6\">",
"      Pediatric supraventricular tachycardia rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/18/2350\" title=\"table 7\">",
"      Example of epinephrine infusion - pediatric 10 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/39/40573\" title=\"table 8\">",
"      Example of epinephrine infusion - pediatric 20 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/8/29838\" title=\"table 9\">",
"      Drug and toxin related pulse changes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17018?source=related_link\">",
"      Approach to the septic-appearing infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/61/2009?source=related_link\">",
"      Arterial puncture and cannulation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16281?source=related_link\">",
"      Corticosteroid therapy in septic shock",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14234?source=related_link\">",
"      Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/16/20746?source=related_link\">",
"      Guidelines for pediatric advanced life support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17482?source=related_link\">",
"      Prehospital care of the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/808?source=related_link\">",
"      Prevention and treatment of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/30/11754?source=related_link\">",
"      Sedation or induction agents for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=related_link\">",
"      Septic shock: Ongoing management after resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/28/7626?source=related_link\">",
"      Treatment and complications of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44632?source=related_link\">",
"      Treatment of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/1/13338?source=related_link\">",
"      Treatment of severe falciparum malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_8_26763="OTC fiber supplements";
var content_f26_8_26763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64009&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Over the counter fiber supplements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Product",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amount",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Metamucil",
"       </td>",
"       <td>",
"        12 years and over: 1 teaspoon or 1 tablespoon, depending on concentration and formulation",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        1-3 times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 12 years: 1/2 to 1 teaspoon or 1/2 tablespoon depending on concentration and formulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Under age 6: 1/4 to 1/2 teaspoon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Benefiber",
"       </td>",
"       <td>",
"        12 years and over: 1 to 2 tablespoons",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        1-3 times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7 to 11 years: 1/2 to 1 tablespoon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Under age 7: 1/4 to 1/2 tablespoon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Citrucel",
"       </td>",
"       <td>",
"        12 year and over: 1 rounded tablespoon",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        1-3 times daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 to 12 years: 1/2 tablespoon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Under age 6: 1/4 to 1/2 tablespoon",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26763=[""].join("\n");
var outline_f26_8_26763=null;
var title_f26_8_26764="Proposed criteria for PMF";
var content_f26_8_26764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66012&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proposed revised WHO criteria for primary myelofibrosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Proposed criteria for PMF",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Major criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Presence of megakaryocyte proliferation and atypia,* usually accompanied by either reticulin and/or collagen fibrosis, or, in the absence of significant reticulin fibrosis, the megakaryocyte changes must be accompanied by an increased bone marrow cellularity characterized by granulocytic proliferation and often decreased erythropoiesis (ie, prefibrotic cellular-phase disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Not meeting WHO criteria for PV&bull;, CML&Delta;, MDS&loz;, or other myeloid neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Demonstration of JAK2 617V&gt;F or other clonal marker (eg, MPL 515W&gt;L/K), or in the absence of a clonal marker, no evidence of bone marrow fibrosis due to underlying inflammatory or other neoplastic diseases&sect;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukoerythroblastosis&yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Increase in serum lactate dehydrogenase level&yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anemia&yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Palpable splenomegaly&yen;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagnosis requires meeting all 3 major criteria and 2 minor criteria.",
"    <div class=\"footnotes\">",
"     * Small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering.",
"     <br>",
"      &bull; Requires the failure of iron replacement therapy to increase hemoglobin level to the polycythemia vera range in the presence of decreased serum ferritin. Exclusion of polycythemia vera is based on hemoglobin and hematocrit levels. Red cell mass measurement is not required.",
"      <br>",
"       &Delta; Requires the absence of BCR-ABL.",
"       <br>",
"        &loz; Requires the absence of dyserythropoiesis and dysgranulopoiesis.",
"        <br>",
"         &sect; Secondary to infection, autoimmune disorder or other chronic inflammatory condition, hairy cell leukemia or other lymphoid neoplasm, metastatic malignancy, or toxic (chronic) myelopathies. It should be noted that patients with conditions associated with reactive myelofibrosis are not immune to primary myelofibrosis and the diagnosis should be considered in such cases if other criteria are met.",
"         <br>",
"          &yen; Degree of abnormality could be borderline or marked.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tefferi, Ayalew, Thiele, Juergen, Orazi, Attilio, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110:1092. Copyright &copy;2007 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26764=[""].join("\n");
var outline_f26_8_26764=null;
var title_f26_8_26765="Acute wrist injury children and adolescents";
var content_f26_8_26765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of acute wrist injury in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated activities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple sprain",
"       </td>",
"       <td>",
"        Dorsal",
"       </td>",
"       <td>",
"        Mild pain or stiffness at full wrist flexion or extension or both, normal range of motion; resolves in two weeks",
"       </td>",
"       <td>",
"        Wrist series is normal",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal radius fracture",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Common during adolescent growth spurt; point tenderness, swelling, ecchymosis, decreased grip strength",
"       </td>",
"       <td>",
"        Fracture on standard wrist series",
"       </td>",
"       <td>",
"        Impact sports; fall on extended wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scapholunate instability",
"       </td>",
"       <td>",
"        Radial",
"       </td>",
"       <td>",
"        Swelling, focal pain and tenderness, decreased range of motion, decreased grip strength, positive scaphoid stability test (but may not be able to tolerate)",
"       </td>",
"       <td>",
"        Increased scapholunate distance on AP view; increased scapholunate angle on lateral view; but may be normal",
"       </td>",
"       <td>",
"        Impact sports; racquet, stick, and club sports; fall on extended wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scaphoid (navicular) fracture",
"       </td>",
"       <td>",
"        Radial, dorsal",
"       </td>",
"       <td>",
"        Tenderness in anatomic snuffbox; decreased range of motion in flexion and extension; positive scaphoid compression test",
"       </td>",
"       <td>",
"        Fracture may be seen on AP view with ulnar deviation; may need scaphoid series.&nbsp;Initial radiographs may not demonstrate fracture.&nbsp;When suspected, thumb spica splinting and repeat radiographs in 7 to 10 days&nbsp;should be performed. Bone scan or MRI&nbsp;can demonstrate fracture sooner when earlier diagnosis is necessary (eg, elite athletes).",
"       </td>",
"       <td>",
"        Impact sports, particularly football; fall on extended wrist",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midcarpal instability",
"       </td>",
"       <td>",
"        Ulnar",
"       </td>",
"       <td>",
"        Sulcus in the dorsal ulnar wrist border; painful clunk with active ulnar deviation",
"       </td>",
"       <td>",
"        Dislocaton on standard wrist series",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal ulnar fracture",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Usually occurs with distal radius fracture; associated with TFCC injury",
"       </td>",
"       <td>",
"        Fracture on standard wrist series",
"       </td>",
"       <td>",
"        Impact sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triquetral fracture",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Point tenderness over the triquetrum or on the ulnar border, distal to the ulnar styloid",
"       </td>",
"       <td>",
"        Fracture on standard wrist series",
"       </td>",
"       <td>",
"        Impact sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lunotriquetral ligament instability",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Tenderness of the lunotriquetral ligament in the ulnar snuff box; positive lunotriquetral shear test",
"       </td>",
"       <td>",
"        Usually normal; may be step-off along proximal carpal row; associated with positive ulnar variance",
"       </td>",
"       <td>",
"        Impact sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Triangular fibrocartilage complex (TFCC) tears",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Point tenderness over the lateral wrist just distal to the ulnar styloid; pain with forced ulnar deviation or TFCC compression test",
"       </td>",
"       <td>",
"        Associated (but not diagnostic) findings: widening of DRUJ space, positive ulnar variance, fracture of ulnar styloid on AP; dislocation or subluxation on lateral. MRI with intra-articular contrast is most sensitive means of identifying TFCC injury",
"       </td>",
"       <td>",
"        Impact sports; racquet, stick, and club sports; gymnastics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal radioulnar joint (DRUJ) injury",
"       </td>",
"       <td>",
"        Ulnar, dorsal",
"       </td>",
"       <td>",
"        Pain with supination and pronation; positive DRUJ compression or piano key tests",
"       </td>",
"       <td>",
"        Dislocation can be seen on plain radiographs and these should include AP and lateral views of the forearm to assess for an associated radial fracture (Galeazzi fracture); MRI may be necessary&nbsp;to identify&nbsp;instability",
"       </td>",
"       <td>",
"        Impact sports; racquet, stick, and club sports; gymnastics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hamate hook fracture",
"       </td>",
"       <td>",
"        Ulnar, palmar",
"       </td>",
"       <td>",
"        Pain with sports but not daily activities; point tenderness over the hook of the hamate",
"       </td>",
"       <td>",
"        Fracture best seen on 45&deg; supination oblique or carpal tunnel view or with CT",
"       </td>",
"       <td>",
"        Racquet, stick, and club sports",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pisiform fracture",
"       </td>",
"       <td>",
"        Ulnar, palmar",
"       </td>",
"       <td>",
"        Pain with palpation of the pisiform and hypothenar eminence",
"       </td>",
"       <td>",
"        Fracture on standard wrist series",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CT: computed tomography; MRI: magnetic resonance imaging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26765=[""].join("\n");
var outline_f26_8_26765=null;
var title_f26_8_26766="ICS reduction with Anti-IgE";
var content_f26_8_26766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Significant reduction in BDP dose with omalizumab therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 468px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percent reduction in inhaled beclomethasone (BDP) dose, and percentage of patients with complete BDP reduction at the end of the treatment period (week 28). The beneficial of omalizumab was the same when data were limited to Unites States site (top panel) or included both United States and international sites (bottom panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Busse, WJ. Anti-immunoglobulin E (Omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12. Copyright &copy; 2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26766=[""].join("\n");
var outline_f26_8_26766=null;
var title_f26_8_26767="Chem composition PA and PRM";
var content_f26_8_26767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F80074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F80074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Chemical composition PA and SPRMs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 557px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_8_26767=[""].join("\n");
var outline_f26_8_26767=null;
